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The involvement of basophils in IgE mediated allergic disease is
well recognized, but their exact role is still unclear. The release
of histamine from the secretory granules has been extensively used
in the study of basophils in allergy: since histamine is complexed
with glycosaminoglycans (GAGs) in the secretory granules, the
release of granule-derived GAG from basophils was studied in
relation to that of histamine to examine further the mechanisms and
involvement of basophils in anaphylactic type hypersensitivity.
A competitive binding assay was developed for the detection of
naturally occurring GAGs, which were found to be contained only in
the basophil fraction of whole blood. GAG release from basophil
enriched fractions of whole blood of both atopic and non-atopic
individuals was Ca++ and dose dependent after challenge with
Dermatophagoides pteronyssinus, and differed markedly from
histamine release both in time course and allergen concentration
required for optimum release. The major highly sulphated GAGs
contained in human basophils and rat mucosal mast cells were
identified as heparan sulphate and chondroitin sulphate E; these
were released, together with histamine and rat mast cell protease
II during systemic anaphylaxis of Nippostrongylus brasiliensis
-primed rats challenged intravenously with worm antigen.
Basophil counts in atopic individuals were significantly elevated
above those of non-atopic individuals, as were eosinophil counts,
which paralleled those of basophils in both populations. Basophil
counts did not fluctuate over short or long time intervals, and did
not correlate with plasma GAG levels in either population.
Individual plasma GAG levels fluctuated considerably, and did not
(ii)
differ significantly between the two populations. However, in a
group of patients with chronic myelogenous leukaemia, with very
high basophil counts, plasma GAG levels were raised and there was
significant correlation of plasma GAG and circulating basophil
numbers.
GAG content of mast cells in nasal turbinates of atopic patients
was less than that of non-atopic controls, indicating mast cell GAG
involvement associated with granule release in atopic disease.
Thus, the release of highly sulphated GAG from normal human
basophils has been characterized, and used to study their
involvement in type 1-anaphylactic hypersensitivity reactions. It
should prove valuable in further investigation of the physiology
and pathophysiology of basophils.
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Allergy is a complicated subject, and an immunological enigma. The
term was originally coined by von Pirquet in 1906 to describe an
altered immune reactivity of an animal, following exposure to a
foreign antigen, and included both immunity and hypersensitivity.
In Britain, allergy and hypersensitivity are used synonymously,
whereas in some parts of the world such as Scandanavia, allergy
refers only to IgE mediated hypersensitivity. Four main types of
hypersensitivity reactions are recognized, as classified by Coombs
and Gell in 1963: Type 1 - anaphylactic hypersensitivity, type 2 -
cytotoxic (cytolytic) hypersensitivity, type 3 - immune complex
mediated hypersensitivity, and type 4 - delayed type
hypersensitivity. The subject of this thesis is related to
anaphylactic type hypersensitivity.
The role of type 1 hypersensitivity from a teleological point of
view is hard to define. It seems likely that IgE forms part of the
immune protection against helminths; it must be remembered that
more than half the world population suffers from helminthic
disease, and such people have high concentrations of IgE in their
blood (Ezeoke et al 1973). Helminthic infestation is not a problem
in the Western world, but despite this 15-20% of the population of
Western countries produce significant amounts of IgE to inhalant
and food allergens, and such people are termed "atopic" (Coca and
Cooke 1923); clinically they may suffer from allergic asthma,
allergic rhinitis, allergic conjunctivitis, IgE mediated food
allergy, and atopic eczema. Though atopic individuals are prone to
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developing generalized anaphylactic reactions in certain
circumstances, it is probable that everyone can develop anaphylaxis
to antigens such as drugs or Hymenoptera venoms.
Anaphylaxis is one of the most important medical emergencies, and
inadequate therapy may result in the death of the patient from
profound hypotension, glottal oedema or severe bronchospasm. The
term anaphylaxis was introduced by Portier and Richet (1902) who
noted that repeated injections of foreign protein might induce not
protection, but injury and even death. They injected Actinaria
(marine creatures) into dogs and noted that the animals, instead of
becoming increasingly immune to repeated doses, developed
progressive illness, that is, loss of "phylaxis" or anaphylaxis.
Subsequently, Prausnitz (Prausnitz and Kustner 1921) showed that a
humoral factor in allergic serum could be passively transferred to
a second non-allergic individual, with resultant reaction to that
allergen (in this case to fish protein). It was not until the 1960s
that the exact nature of the underlying immunological events of
type 1 hypersensitivity reactions were further elucidated by the
work of the Ishizakas and that of Johannson and Bennich. The
Ishizakas demonstrated from studies on ragweed allergic rhinitis
that there was a heat—labile immunoglobulin present in patients'
serum which was not IgG, IgA, IgM or IgD, and they named it IgE
(Ishizaka and Ishizaka 1966; Ishizaka et al 1966; Ishizaka and
Ishizaka 1967). Their findings were complemented by those of
Johannson and Bennich who recognized that one of their patient's
myeloma was not IgG, IgA, IgM or IgD (Johansson and Bennich 1967)
and named the immunoglobulin IgND: they also recognized that
patients with asthma had raised levels of this immunoglobulin in
their serum (Johansson 1967). Collaborative studies between the
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Ishizakas and the Scandanavian work confirmed finally that IgE and
IgND were one and the same antibody (Bennich et al 1969).
IgE is a monomeric divalent immunoglobulin with two light and two
heavy (e ) polypeptide chains and does not fix complement via the
classical pathway, but may activate and later components of the
complement sequence by means of the alternative pathway (Ishizaka
and Ishizaka 1973). Like all other immunoglobulins, IgE is produced
by plasma cells, and has a molecular weight of 188,000, 12% of
which is carbohydrate. In the Western world it is a minor component
of circulating immunoglobulins, present in concentrations of
0-400ng/ml, although atopic individuals may have up to 1000 times
this amount. It has a half life in human serum of 2-3 days
(Waldmann 1969; Waldmann et al 1976), which is relatively short
compared with other immunoglobulins, such as IgG (which has a half
life of 25 days).
A feature of fundamental importance to IgE function is its ability
to bind avidly and exclusively to the surface of two cell types:
basophils and mast cells. Binding is reversible and does not
involve a covalent bond (Ishizaka et al 1973; Ishizaka and Ishizaka
1974). These cells contain specific membrane receptors with high
binding affinities for the portion (Ishizaka et al 1973;
-8 -9
Ishizaka et al 1979) of IgE molecules (10 to 10 M for human
basophils). A normal human basophil is estimated to have 30-100 x
3
10 receptor sites, most of which are filled in an atopic
3
individual, and is thought to bind 10-40 x 10 IgE molecules, which
may be increased by 3-7 times, with exposure to high concentrations
of IgE. Cross-linking of adjacent IgE receptors on mast cell and
basophil surfaces by whatever means, results in the release of
various mediators stored within the cytoplasmic granules, which is
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a highly complex sequence of events (simplified in Figure 1), and
produces the symptoms typical of immediate hypersensitivity or
allergic reactions.
The elevated serum levels of IgE which initiate allergic reactions
in sensitised individuals also occur in response to various
intestinal parasitic infections (Ezeoke et al 1973). In all its
forms, allergy is regarded as a disease state, but the mast
cell/basophil/IgE antibody system can be beneficial as in
establishment of immunity to certain parasitic infections,
particularly intestinal helminths. IgE antibodies produced in
response to exposure to helminth antigen activate the mast
cell/basophil system, with massive local release of pharmacological
mediators at the site of infection, resulting in the expulsion of
the parasite from the body. It is still not known why a certain
number of people synthesize the large quantities of IgE which cause
allergic reactions, but may be elicited as an immune response to
foreign antigens and persist because they are normally biologically
advantageous. The allergic reactions caused by this IgE may
therefore be an unfortunate consequence of maintaining this level
of immunity.
The role of IgG in allergic reactions remains controversial.
Studies in the human have suggested that IgG antibodies may act as
short term sensitizing anaphylactic antibodies (Parish 1970; Bryant
et al 1973), and certainly there are IgG receptors on human
basophils (Ishizaka et al 1972). Work by Stanworth and Smith (1973)
has suggested that this IgG is of the subclass IgG^, but this is
far from proven. The role of IgG as a second anaphylactic antibody
thus remains to be elucidated. It has also been suggested that IgG
(particularly IgG^) may act as a blocking antibody, thus preventing
-5-







Infiltration of Immune-reactive Cells.
Acute Inflammatory Response, and
Tissue Damage.
Figure 1: The Mechanisms of Type 1 Hypersensitivity.
Primary sensitising exposure to the antigen stimulates the
production of IgE-specific antibody. This binds to the F
c
receptors on the surface of mast cells or basophils.
Secondary and subsequent exposure to the same antigen will
cross-link the cell-bound IgE, resulting in the release of
the secretory granule contents to produce the effects listed.
Modified from Staines et al 1985.
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anaphylactic reactions; this may well be the case in certain
circumstances, though final proof of this is lacking.
(I). Mast Cells and Basophils.
Mast cells and basophils are central participants in a variety of
inflammatory and immunological disorders, particularly in diseases
involving immediate hypersensitivity, and share several notable
properties:
a. Both have surface receptors with high binding affinity for IgE
antibody (Ishizaka et al 1979).
b. Both contain prominent cytoplasmic granules with affinity for
certain basic dyes, which appear electron dense by electron
microscopy. These granules are the source of potent chemical
mediators implicated in "a wide spectrum of inflammatory and
immunological processes.
c. Exposure of IgE-sensitized mast cells or basophils to
appropriate antigen results in the non-cytolytic release of
preformed and newly generated chemical mediators from the granule
matrix.
d. Exocytotic degranulation of basophils and mast cells may be
induced by many immunologically specific and non-specific agents.
Despite these prominent similarities, there are many features which
distinguish the two cell types:
a. The nucleus of mast cells is generally large and round. The
nuclear chromatin is often aggregated beneath the nuclear membrane,
not densely clumped as in basophils and other granulocytes, which
causes the irregular lobed characteristic appearance of the nucleus
in these cells.
-7-
b. Basophils have a short half life of 2-5 days, with only 12 hours
in the circulation (Mitchell and Askenase 1983), whereas mast cells
are long lived, with a half life of 3-4 months (Padawer 1974).
c. Mast cells are usually larger (10-30p m diameter) than basophils,
which are the smallest of the human granulocytes with a diameter of
10-14p m (Ackerman and Bellios 1955). The cytoplasmic granules of
human basophils display marked size heterogeneity (up to 1.2pm
diameter, over twice the size of human mast cell granules), but are
generally fewer and more widely separated than those of mast cells
(Parwaresch 1976).
d. The cytoplasmic granules of mast cells stain with greater
intensity than those of basophils. This is due to the granular
proteoglycan content. Mast "cell granules contain heparin, whereas
basophil cytoplasmic granules contain a proteoglycan which is less
sulphated than heparin, the exact nature of which has yet to be
determined.
e. Human mast cells contain more histamine (l-15p g of histamine per
0
10 cells; Patterson et al 1976), than basophils (l-3p g of
0
histamine per 10 cells; Ishizaka et al 1973).
f. Although both cell types originate in the bone marrow, they are
thought not to have a common precursor cell. Basophils, like other
polymorphonuclear granulocytes differentiate and mature in the bone
marrow, circulate in the blood, and do not normally occur in
extravascular sites other than the bone marrow (Dvorak 1978). Mast
cells in contrast, are normally distributed throughout the
connective tissue, often situated adjacent to blood and lymphatic
vessels, and near to or within peripheral nerves. They may be
especially abundant near epithelial surfaces such as those of
respiratory and gastrointestinal systems and the skin, that are
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exposed- to environmental antigens (Riley 1959; Brinkman 1968;
Trotter and Orr 1974; Feltkamp-Vroom et al 1975; Padawer 1978).
Mast cells do not usually circulate in the blood, but are a normal
component of the bone marrow and lymph node connective tissues
(Spicer et al 1975), and in some species are also abundant in the
fibrous capsules of internal organs and in physiological
transudates such as peritoneal fluid (Padawer 1978).
(i). Mast Cells.
Both mast cells and basophils are bone marrow derived, but while
basophils differentiate and mature in the bone marrow, mast cells
are thought to mature outside the bone marrow or circulation,
generally at local sites 'in the connective tissue or serous
cavities, from mitotically active precursor cells. Recent studies
in mice suggest that the proliferation and differentiation of these
precursors are thymus dependent, and are under the influence of
local factors including interleukin 3 (Guy-Grand et al 1984).
Studies of rodent mast cells have revealed that these precursor
cells, which may circulate in the blood (Zuker-Franklin et al
1981), contain few cytoplasmic granules with little or no heparin
(Combs et al 1965). As the cells mature, their proliferative
capacity is markedly reduced and the number of cytoplasmic granules
increases (Combs et al 1965). This is complicated further by recent
reports indicating that rodents possess clearly distinguishable
populations of mast cells in the connective tissue and in the
intestinal mucosa (Enerback 1981; Barrett and Metcalfe 1984).
Morphology.
In humans, as in experimental animals, mature mast cell morphology
and size vary somewhat depending on the organ or site of origin,
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but in general they appear in tissue sections as round, oval or
elongated cells, 10-30p m in diameter (Trotter and Orr 1974). The
nucleus is usually round to oval, with chromatin that becomes
progressively more clumped and densely stained with cell
maturation. Cytoplasmic granules are round and closely packed,
0.1-0.4p m in diameter and may have a complex substructure with a
unique spiral or crystalline appearance (Trotter and Orr 1974;
Padawar 1978). Unlike human basophils, mature human mast cells do
not contain electron-dense aggregates of cytoplasmic glycogen, but
they do frequently exhibit centrioles and a complex system of




Basophils are derived from the same bone marrow precursors as
eosinophils and neutrophils. They normally comprise approximately
0.3% of nucleated cells in the bone marrow, and 0.5-1.0% (20-45
3
cells/mm ) of the circulating leucocytes, and are thus the least
common human granulocyte. The human basophil has a segmented
multilobed nucleus with dense irregular condensations of chromatin
along a thin nuclear membrane. The nucleus is quite similar to that
of the neutrophil and eosinophil, although the segmentation of the
nuclear lobes is less pronounced. The characteristic cytoplasmic
granules of the basophil are round to angular, membrane-bound
structures. The granule substructure has a distinct crystalline
appearance (Parwaresch 1976), and is composed of dense particles in
a less dense matrix with occasionally complex membrane structures
(Dvorak 1978). A subpopulation of smaller cytoplasmic granules has
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been reported in human basophils (Ackerman and Clark 1971; Nichols
and Bainton 1973; Hastie 1974). These differ both ultrastructurally
and histochemically, and are usually situated between the nuclear
lobes. After degranulation, intact electron-dense granules are
depleted, and appear as large membrane-bound vacuoles. Numerous
cytoplasmic aggregates of glycogen particles are also present with
an inconspicuous Golgi apparatus, a few mitochondria, ribosomes,
several strands of rough endoplasmic reticulum, and numerous
electron-lucent 50-70nm cytoplasmic vesicles. These form a complex
vesicular system, which plays a critical role during the
degranulation process.
Occurrence.
The involvement of the basophil has been implicated in a wide
variety of immune-inflammatory disease states; the most important
and relevant to the present study being its involvement in
immediate hypersensitivity reactions.
Immediate Hypersensitivity Reactions.
In humans, basophils contain virtually all of the histamine present
in blood (Graham et al 1955; Sampson and Archer 1967), and its
release in conjunction with a variety of low-molecular-weight
mediators in response to antigenic stimuli is clearly established,
and is strong evidence for their involvement in immediate
hypersensitivity reactions. Allergic atopic diseases have a major
immediate hypersensitivity component, and thus the early symptoms
of allergic disorders such as allergic rhinitis, asthma, urticaria,
anaphylaxis, food and drug allergies, after exposure to allergen,
are IgE-mediated events.
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The clinical symptoms of allergic disease are diverse, and are
determined by various host factors, including:
(i) The organ affected.
(ii) Properties of the allergen involved, previous exposure to the
allergen, and its dose and route of administration.
(iii) Class and concentration of circulating tissue-fixed IgE
(homocytotropic) antibody.
(iv) Presence and concentration of antigen-specific blocking
(non-homocytotrophic) antibody.
Interaction of the allergen with specific IgE antibody causes
aggregation of receptors on the cell surface, and results in
anaphylactic degranulation with the secretion of granule contents.
Immediate hypersensitivity- responses involving basophils are
systemic in nature, since 'basophils are normally present only in
the circulation or bone marrow. Massive basophil degranulation
occurs with generalized systemic release of both preformed and
newly synthesized mediators (James and Austen 1964). These
orchestrate the inflammatory response that develops, and cause
smooth muscle contraction, vascular dilation, vessel permeability,
and the recruitment of infiltrating leucocytes. Symptoms include
vascular collapse and changes in target organs which frequently
include skin, larynx, trachea, oesophagus, eyes and periorbital
region.
Delayed-type Hypersensitivity Responses.
Basophils are also thought to play a role in certain delayed
hypersensitivity reactions. Most observations of delayed-type
immune reactions, in which basophils are actively recruited to
leave the circulation and enter the site of an inflammatory-
reaction, have been made in the skin of experimental animals; the
lesions that develop in such reactions are termed cutaneous
basophil hypersensitivity (CBH), (Dvorak et al 1970). Sensitized
guinea pigs (immunised by injection of protein antigens without
mycobacterial adjuvants) develop a systemic, though tenuous form of
delayed-type hypersensitivity (DTH); one of the principle
characteristics of these reactions is the striking infiltration of
basophils to tissues.
Like classic tuberculin-type DTH, CBH reactions have a delayed time
course, becoming apparent at 4-6h, maximal at 18-24h, after skin
test. CBH reactions also contain a large mononuclear cell
infiltrate, and are in part lymphocyte dependent (Dvorak et al
1970). They are typically-flat, non-indurated lesions with little
fibrin deposition, whereas classical DTH reactions are
characterized by local activation of clotting mechanisms with
extensive dermal fibrin deposition, leading to induration, and
contain very few basophils.
In addition to cutaneous reactions, basophils also participate to
varying extents in delayed-onset immunological reactions elicited
in the eye (Friedlander and Dvorak 1977), gut (Askenase et al
1978), subcutis (Dvorak et al 1979a) and peritoneal cavity (Dvorak
and Dvorak 1972).
Similar reactions to those of CBH, induced after sensitization by
repeated intradermal injections of small quantities of rabbit serum
proteins, were found in the skin of human volunteers by Jones and
Mote (1934), leading to the name "Jones-Mote" reaction. The
relation of these human responses to those of the guinea pig is
uncertain, although they differ from classic, tuberculin DTH
responses in the same way as CBH, and one of their principal
characteristics is the striking infiltration of basophils (Askenase
and Atwood 1976). Nevertheless, basophil accumulation can occur in
tuberculin lesions of purified protein derivative (PPD), and other
immune reactions of the skin (Dvorak et al 1974; Askenase and
Atwood 1976). These include lesions of allergic contact dermatitis
(Dvorak and Mihm 1972), and delayed time course late phase
responses (DeShazo et al 1979). In humans, basophils are a
significant component (up to 5%) of the cells infiltrating sites of
skin allograft rejection responses (Dvorak et al 1979b) and
detailed study* of bullous pemphigoid lesions in various stages of
development have revealed infiltration of basophils at these sites
(Dvorak et al 1982). —
It appears therefore, that in humans, basophil involvement in DTH
represents only a part of the complex spectrum of DTH responses,
rather than a distinct form of response.
Studies of immune reactions in humans at various sites other than
the skin, have resulted in the identification of a role for the
basophil in various immune inflammatory -reactions in different
organ systems.
Nose ■ Basophils have been demonstrated in nasal secretions
(Hastie et al 1979), presumably having migrated through the lamina
propria and epithelium. The emigration of basophils into the nasal
tissues and secretions occurs after nasal provocation with
allergen, or during the appropriate pollen seasons.
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Conjunctiva of the eye. One of the morphologic changes evident in
vernal conjunctivitis, is the infiltration of basophils to the
epithelium of substantia propria (Collin and Allansmith 1977).
Lung. The appearance of basophils in the sputum of patients,
during the various phases of bronchial asthma has been reported,
and suggests that basophils move from the bloodstream into
bronchial tissue during the acute phase of an asthma attack (Kimura
et al 1975). It has also been reported that in vitro histamine
release can be induced by nuclear components in leucocytes of
patients with both chronic bronchitis and non-atopic asthma (Juhl
et al 1981), but the relevance of this finding to and the
involvement of the basophil'in the pathogenesis of this disease is
unclear.
Intestine. Examination of diseased tissue from the bowel wall of
patients with Crohn's disease has revealed the presence of
basophils, which show varying degrees of degranulation (Dvorak et
al 1980). The peripheral blood basophils also degranulate in vivo
in these patients when the disease is active (Dvorak and Monahan
1982).
Kidney. Basophil involvement has been demonstrated in the
inflammatory responses of a variety of different forms of renal
disease, including penicillin-induced allergic interstitial
nephritis (Colvin et al 1974), and renal allograft rejection
(Colvin and Dvorak 1974).
Blood. Elevated levels of circulating peripheral blood basophils
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occur in patients with chronic myelogenous leukaemia (CML) (Juhlin
1963a; Juhlin 1963b), and in patients with systemic lupus
erythematosus in vivo degranulation of peripheral blood basophils
occurs during the acute phase of this disease (Camussi et al 1981).
Cancer. Basophil infiltration has been demonstrated in cancerous
tissue as part of the cellular response (Black and Leis 1973), and
increased numbers of peripheral blood basophils occur in patients
with lung cancer (Anthony 1982). It seems likely therefore that a
role for the basophil in the immune response to malignancy exists.
Both basophils and mast cells exhibit phagocytic capability under
certain circumstances (Dvorak et al 1972; Padawar 1969), but its
importance in the normal function of these cells is unclear. The
frequency of basophils in most mammalian species is similar to that
in man, although rabbits may have up to 10 times as many. There is
a striking inverse relationship between the frequency of basophils
and mast cells within different animal species. For example, in
animals in which basophils are normally rare or absent, such as
rats and mice, tissue mast cells are numerous, and vice versa. In
some lower vertebrates, only a single type of metachromatic
granule-bearing cell is present, which exists in both the
connective tissue, and in the circulation (Stadecker et al 1977).
These considerations, together with the biochemical similarities of
the two cell types supports the widespread presumption that these
cells supplement each other, and have similar or even identical
functions.
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II. Stimuli for Basophil/Mast Cell Activation.
The process of basophil or mast cell degranulation is a secretory
event, and may occur in response to a long and growing list of
immunologically specific and non-specific agents. Sensitivity to
many of these stimuli varies strikingly according to species and
cell type, but only the immunologic stimuli are relevant to the
study of human allergic reactions.
(i). Immunological Stimuli.
IgE Receptor Mediated.
The activation of mast cells and basophils depends on the cross
bridging of the receptors, to which IgE antibodies are bound,
with the F , portion of the molecules available for interactionab
with specific antigen (Figure 1). Thus activation of the cell is
dependent on the antigenic specificity of the IgE antibody. This
process requires bridging of very few (1%) of the IgE molecules on
the cell surface.
In addition to specific antigen, cross-linking of cell bound IgE
may also be induced by heterologous (for example, rabbit or goat)
antisera to IgE or to immunoglobulin light chain (k or \ )
Anti-IgE-receptor mediated antibody may also cause this event.
Protein A from Staphylococcus aureus, and mitogens such as
Concanavalin A also activate cells by cross-linking the
carbohydrates of the IgE molecules (Siraganian 1976).
IgG Receptor Mediated.
Mast cells and basophils have F^ receptors distinct from the IgE
receptor, that bind IgG molecules (Ishizaka et al 1970). Since the
binding of IgG molecules is of much lower affinity, this is a less




Mast cells and basophils may be activated by two major
complement-derived anaphylatoxins C5 and C3 , via distinct
S. Si
receptors which are different from the immunoglobulin receptors
(Siraganian and Hook 1976a). C5 is a more potent anaphylatoxin
a
than C3 , and C4 may weakly interact with C3 receptors. C3
Si Si Si D
receptors have been demonstrated on human basophils (Thomas and
Lichtenstein 1979) and may induce cell activation, but these are
not present on mast cells.
Lymphokines.
These lymphocyte-derived mediators activate basophils directly
(Thueson et al 1979) or indirectly by modulating the cell
activation process induced by other secretogogues, such as viral
and immune interferon (Ida et al 1977).
Basic peptides.
Formyl methionine tripeptides activate human basophils via specific
receptors, but have no effect on rat mast cells. These basic
peptides are chemotactic for a number of cell types, and simulate
various bacterial chemotactic factors (Siraganian and Hook 1977).
Eosinophil granule major basic protein.
This basic protein, which is rich in arginine, is the main
constituent of eosinophil granules, and causes activation of human
basophils and mast cells (O'Donnell et al 1983).
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Other compounds.
An ever increasing list of other compounds can activate mast cells
and basophils by various mechanisms. For example, ionophores are
lipophilic molecules that insert themselves into cell membranes and
transport Ca++ and Mg++ ions across the membrane, thereby
increasing intracellular calcium and magnesium concentrations
(Foreman et al 1973). Mast cells are activated by various
polycationic substances such as compound 48/80, polymyxin B,
polylysine and polyarginine. Other compounds which cause activation
include morphine, tubocurarine, protamine, ATP, dextran (between
5 6
4x10 and 2x1-0 molecular weight), chymotrypsin, mellitin, mast
cell degranulating peptide from cobra venom, and a cationic
lysozymal granule protein from neutrophils (Siraganian 1985).
(III). Mechanisms of Mediator Release.
The activation of basophils and mast cells is initiated by
interaction of antigen with specific IgE on the cell surface, and
leads to a complex series of biochemical events which culminate in
the secretion of mediators from the cell (Levine 1966). This
process is generally termed anaphylactic degranulation. The
association between degranulation and the release of histamine in
rat mast cells was first described by Riley in 1953. Later, Fawcett
(1955) confirmed this, and demonstrated the non-cytolytic nature of
the degranulation process. Thon and Uvnas (1967) proposed a two
stage process for degranulation. This involves exposure of the
cytoplasmic granules to the cell exterior, followed by release of
histamine by a process of cationic exchange upon contact of the
granule matrix with the extracellular fluid. Classic experiments of
Rohlich et al (1971) provided conclusive evidence that
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degranulation is a secretory (or exocytotic) event that is
non-cytotoxic, in which the membranes surrounding individual
secretory granules fuse with the plasma membrane of the cell, and
in some cases, also with each other.
Most of the events associated with IgE-mediated degranulation are
common to both basophils and mast cells, although certain
differences have been noted (Lichtenstein 1968; Lichtenstein et al
1973). A general outline of these events is therefore presented,
highlighting any differences between basophils and mast cells where
appropriate.
A speculative scheme of the events leading to mediator release has
been proposed (Siraganian 1983), and these are summarized in Figure
2.
(i). Biochemical Events of Mediator Release.
One of the earliest events of cell activation is thought to involve
the activation of a membrane-associated proteolytic enzyme, which
is likely to be a serine esterase closely associated with the
receptor for IgE (Becker and Henson 1973). IgE receptor aggregation
is thought to activate methyl transferase enzymes, resulting in
membrane phospholipid methylation, and the formation of
phosphatidylcholine. This in turn causes local changes in
transmembrane potential, and opens up Ca++ channels. The increased
intracellular Ca++ concentration activates the enzyme phospholipase
A^, resulting in the formation of arachidonic acid and lysolecithin
by cleaving phosphatidylcholine or phosphatidylinositol. The
lysolecithin is thought to promote membrane fusion, and arachidonic
acid is metabolized by either the cyclooxygenase or lipooxygenase

























Figure 2: Proposed Scheme of Events Leading to the Release of
Mediators from Mast Cells and Basophils.
Abbreviations are as follows:
R = Receptor
MTase = Methyl transferase
SAM = S-adenosyImethionine
PE = Phosphatidyl ethanolamine
PMME = Phosphatidyl-N-monomethyl ethanolamine
PC = Phosphatidylcholine
Modified from Siraganian 1985.
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FGD^ in mast cells) and leucotrienes (such as SRS-A) which are
discussed later, in section (IV) of this Chapter. These early
events also cause the characteristic alterations in intracellular
levels of cyclic 351-adenosine monophosphate (cAMP) by activation
of adenylate cyclase. Increased concentrations of intracellular
cAMP result, and together with the increased intracellular Ca++ and
cGMP levels, they regulate the events that follow. During this
step, phosphorylation of proteins is thought to occur, leading to
microtubular aggregation, exposing granules to the extracellular
space, and resulting in the release of mediators.
The process of mediator release is rapid, has an absolute
requirement for the presence of Ca++ in the medium and is
temperature-dependent with optimal release occurring at 37°C
(Siraganian 1985). Metabolic energy is also an essential
requirement at multiple steps in the release process, and is
thought to be obtained from either aerobic or anaerobic glycolysis,
although experiments using a number of cell systems have shown that
other cells may utilize oxidative phosphorylation (Johansen 1980).
Calcium Requirement.
In normal cell systems, the low intracellular Ca + concentrations
(O.ly m in cytoplasm) compared with the extracellular Ca++ (2mM),
are maintained by an energy-dependent pump which moves Ca++ out of
the cell. Calcium influx into the cell is thought to be the
intracellular signal for the initiation of cellular activation, and
is therefore essential for mediator release (Rubin 1974). This
hypothesis is based on the following observations:
"f + + +
a. Increasing intracellular Ca levels by Ca ionophore A23187
which transports Ca++ into the cell, microinjection, fusion with
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Ca++-containing vesicles, or permeabilization of the cell membrane,
all activate the release process (Foreman et al 1973).
b. The release process is inhibited by the removal of Ca++ stores,
with for example Ca++ chelators such as EDTA.
45 ++
c. It has been demonstrated that the movement of Ca into the
cell occurs prior to the release of mediators (Foreman et al 1973;
Ishizaka et al 1983).
Intracellular Ca++ is thought to regulate a large number of enzyme
systems, including phospholipase and microtubule assembly, by
binding to calmodulin. This is a ubiquitous protein, with a
molecular weight of 17,000 and four binding sites for Ca++. The
binding of Ca++ to any one of the four binding sites mediates a
conformational change, whfeh results in the association of this
complex with enzymes. w
Phospholipid Methylation.
The process of phospholipid methylation in the early events of
degranulation is thought to function in signal transduction across
the cell surface (Hirata and Alexrod 1980). There are two
methyltransferases in the cell membrane.
a. Methyltransferase I, which faces the cytoplasmic surface, and
transfers one methyl group from S-adenosylmethionine (SAM), a
high-energy methyl donor, to phosphatidyl ethanolamine (PE) (Figure
3), resulting in the formation of phosphatidyl-N-monomethyl
ethanolamine (PMME).
b. Methyltransferase II, which faces the extracellular space, then
adds a further two methyl groups resulting in the formation of
phosphatidylcholine (Figure 3).
Only IgE-mediated cell activation requires this phospholipid
-23-



















Figure 3: Biochemical Pathway for Phospholipid Methylation.
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methylation, since inhibitors of methylation prevent IgE receptor-
mediated cell activation, but have no effect on the activation of
cells by, for example, compound 48/80, the calcium ionophore
A23187, formyl methionine tripeptides, or complement fragments
(Morita et al 1981; Morita and Siraganian 1981). The activation of
cAMP and methylation enzymes affect each other, and have a complex
relationship. Inhibitors which elevate intracellular cAMP, also
inhibit methylation, though specific inhibitors of methylation
suppress the early increase in cAMP levels (Ishizaka et al 1981).
Nevertheless, the initial IgE-mediated activation sequence appears
to require activation of a membrane enzyme to facilitate
phospholipid methylation, and increase intracellular levels of cAMP
and Ca++ (Ishizaka et al 1984).
Cyclic Nucleotides.
Activation of cells by IgE-mediated mechanisms results in an
increase in intracellular (cAMP) levels, which is a very rapid
process, and parallels phospholipid methylation (Ishizaka et al
1981). A large number of substances may alter intracellular levels
of cAMP, including 6 -adrenergic agents, some prostaglandins (for
example PGE^), histamine via H receptors, cholera toxin and
adenosine. The interaction of these ligands with specific
cell-surface receptors results in the activation of the
membrane-associated enzyme adenylate cyclase, and therefore the
formation of cAMP. The exact role of cAMP in mediator release is
not known; a transient monophasic rise in intracellular cAMP is
necessary for cellular activation, although high levels of
intracellular cAMP inhibit mediator release. The intracellular
effects of cAMP are mediated by the cytoplasmic cAMP-dependent
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protein kinases, which are involved in the phosphorylation of
contractile or cytoskeletal proteins, such as myosin light-chain
subunits, microtubule-associated protein, or tubulin subunits. This
process is thought to modulate the triggering of mediator release,
and inhibit secretion (Winslow and Austen 1982). Phosphorylation of
myosin light-chain kinase inhibits contraction and movement of
granules to the cell surface, and mobilization of Ca++ from
intracellular pools may be inhibited by phosphorylation of a
protein which binds Ca++ (Winslow and Austen 1984). Increased
levels of intracellular cGMP consequent on exposure to cholinergic
agents such as acetylcholine or carbachol, also enhance
IgE-mediated secretion in mast cells. These agents however, have no
effect on human basophils.
(IV). Pharmacological Mediators of Mast Cells and Basophils.
The mediators that are secreted from mast cells and basophils when
activated in immediate type hypersensitivity reactions are either
preformed or are newly generated on cellular activation. The
content of these substances in human basophils and mast cells is
slightly different, and a further level of complexity exists in the
content of the two mast cell subsets in rodents. The major
differences are outlined in Table 1, and the substances involved
are described below.
(i). Preformed mediators of secretory granules.
Biogenic Amines.
Histamine.
Histamine (8 -imidazolylethylamine) is common to mast cells and
basophils of most animal species, with the exception of fish and
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Tablel: Mediators of Mast Cells and Basophils.
MEDIATOR RAT HUMAN
Preformed Connective tissue Mucosal Mast cell Basophil
Mediators mast cell mast cell
Biogenic amine Histamine Histamine Histamine Histamine
Major Heparin Not Heparin Not
proteoglycan determined determined
Predominant Chymase (RMCPI) RMCP II Tryptase Kallikrein








activating - - +
factor
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amphibians (Chiu and Lagunoff 1972). The major source of tissue
histamine was found to be the mast cell (Riley and West 1953), and
the major source of humoral histamine was attributed to the
basophil fraction by Graham et al (1955). In rabbits however,
although basophils are relatively frequent, they contain only about
25% of blood histamine, the remainder being associated with the
platelets (Benveniste et al 1973). Rodent connective tissue mast
cells contain 10-30p g, and human mast cells l-15p g of histamine per
10^ cells (Schwartz and Austen 1981), whereas normal human
basophils contain only l-3p g of histamine per 10^ cells (Ishizaka
et al 1983; MacGlashan and Lichtenstein 1980).
The histamine present within basophils and mast cells is thought to
be confined largely to their specific cytoplasmic granules, as
revealed by cell disruption studies (Pruzansky and Patterson 1967),
and is released by immunological reactions that result in
degranulation of the cell (Lichtenstein 1968). These considerations
have allowed for the use of histamine release from these cells as
the major biochemical marker for cellular activation and
degranulation.
The synthesis and metabolism of histamine in these cells is
described and discussed in detail in Chapter 2:2.
Serotonin.
5-hydroxytryptamine [ 3-(8 -aminoethyl)-5-hydroxyindole] or serotonin
is formed from tryptophan, by the sequential action of
tryptophan-5- hydroxylase and aromatic L-amino acid decarboxylase,
producing 5-hydroxytryptophan and 5-hydroxytryptamine respectively
(Lagunoff and Benditt 1959). Serotonin was first purified and
crystallized from human serum by Rapport in 1949, and chemically
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synthesized by Hamlin and Fischer in 1951. In humans, serotonin is
absent from both basophils and mast cells, but is contained in
platelets and tissue of the central nervous system. It is
concentrated in the hypothalamic region of the brain, where it is
localized in granular synaptic vesicles in nerve endings. In
rodents, serotonin is absent from mucosal mast cells and basophils,
but is contained in connective tissue mast cells at concentrations
0
of about lp g of serotonin per 10 cells (Moran et al 1962). It is
packaged in the secretory granules, associated with serotonin
binding proteins, and is released in parallel with histamine, when
it is sequentially degraded to 5-hydroxyindoleacetaldehyde and
5-hydroxyindoleacetic acid by monoamine oxidase and aldehyde
dehydrogenase respectively (Udenfriends et al 1956).
In rats, serotonin enhances peripheral vasopermeability, and in
mice is involved in delayed hypersensitivity reactions. In humans,
serotonin raises body temperature by a hypothalamic mechanism,
enhances vasopermeability and causes contraction of many smooth
muscle systems.
Dopamine.
Dopamine is a catecholamine intermediate in the synthesis of
noradrenaline and adrenaline, and is normally found in mammals
concentrated in the corpus striatum region of the brain, where it
functions as an inhibitory neurotransmitter. Dopamine is a further
biogenic amine found in bovine mast cells (Jenkinson et al 1970).
Proteoglycan,
Proteoglycans are complex macromolecules composed of
glycosaminoglycans (GAGs) associated with a protein core by means
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of covalent bonds, and are responsible for the characteristic
granule metachromatic staining of basophils and mast cells with
basic dyes. The structural differences and properties of the
different types of proteoglycan are detailed in Chapter 2:1.
The predominant proteoglycan in secretory granules varies with cell
type and species. Human mast cells, rat and mouse connective tissue
mast cells and rat mast cells grown from embryonic fibroblast
monolayers contain heparin (Metcalfe et al 1979; Metcalfe et al
1980; Bland et al 1982), whereas bone marrow-derived mouse mast
cells have been shown to contain chondroitin sulphate E (Razin et
al 1982). The GAGs of bone marrow-derived rat mast cells and normal
human basophils are less sulphated than heparin, and have yet to be
identified unequivocally. The nature and content of GAG in the
various cell types is discussed in Chapters 3 and 4.
Intracellularly, the highly ionic proteoglycans form the matrix of
the secretory granule, ionically bound to cationic proteins
including some proteases. These proteoglycan-protein complexes are
in turn attached by ionic linkages to many of the preformed
mediators such as histamine (and where present, serotonin), Zn++
and other pharmacologically active granule constituents such as
eosinophil chemotactic factor (ECF-A) (Thon and Uvnas 1966; Uvnas
et al 1970). These complexes are packed into a small nuclear volume
to allow the formation of the macromolecular complex of the
secretory granule (Schwartz et al 1981a). On degranulation, ion
exchange mechanisms result in the release of these loosely bound
small molecules from the secretory granules (Aborg and Uvnas 1968),
and it has also been shown that basophil and mast cell
proteoglycans are themselves released from the cell during this
process (Yurt et al 1977). Heparin is tightly bound to tryptase in
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human mast cells (Schwartz et al 1981a), and chymase and
carboxypeptidase A in rat mast cells (Schwartz et al 1981b;
Schwartz et al 1982). These complexes are thought to regulate
various secretory granule enzyme systems and facilitate the uptake
of histamine into the secretory granule against a concentration
gradient (Uvnas et al 1970).
Neutral Proteases.
Neutral proteases are the third major component of human and rat
serosal mast cell secretory granules. Gomori (1953) demonstrated
neutral protease activity in rat mast cells, and later Benditt and
Arase (1959) showed its chymotrypsin rather than trypsin substrate
specificity, by cleavage of the acetylethyl esters of aromatic and
not basic amino acids. By ■contrast, neutral proteases of human mast
cells have trypsin-like activity and cleave N-a -benzoyl-DL-arginine
-0 -naphthylamide hydrochloride (Glenner and Cohen 1960). Mast cell
proteases are strongly positively charged which has important
implications for interaction of these enzymes with intragranular
proteoglycans.
Rodent Mast Cell Neutral Proteases.
Chymase (RMCP I) and carboxypeptidase A are present in the
secretory granules of rat serosal mast cells; chymase has been
localized to the granules of mast cells from rat skin, muscle, lung
parenchyma and serosal cavities, and carboxypeptidase A is found in
peritoneal mast cells and in skeletal muscle where the mast cell is
the most likely source (Woodbury et al 1978a; Everitt and Neurath
1980; Bodwell and Meyer 1981). By contrast, mast cells from
gastrointestinal and bronchial mucosa contain a chymotrypsin-like
protease referred to as rat mast cell protease II (RMCP II)
(Woodbury et al 1978b). These neutral proteases are complexed with
proteoglycan in the secretory granules, and are released along with
histamine and B -hexosaminidase during IgE-mediated degranulation.
Human Mast Cell Neutral Proteases.
Tryptase is an endopeptidase that cleaves peptide and ester bonds
on the carboxyl side of basic amino acids (Schwartz et al 1981a).
Like the rat mast cell neutral proteases, tryptase is the principal
protease of the secretory granules of human pulmonary mast cells,
where it resides as a complex with proteoglycan. It is released in
parallel with IgE-mediated release of histamine and can also serve
as a marker for mast cell activation (Schwartz et al 1987).
Tryptase accounts for about 23% of total mast cell protein, a
similar level to that of neutral protease in rat mast cells, and is
0
present in concentrations of about 12y g per 10 cells (Schwartz
1986).
A second protease, a serine esterase is found in the secretory
granules of human mast cells of the skin and interstitial
submucosa, exhibits a cleavage pattern similar to that of
pancreatic chymotrypsin (Irani et al 1986). Calculations of
potential amounts of this enzyme in cutaneous mast cells range from
0
0.1-1.0y g per 10 mast cells, approximately 1-10% of the amount of
tryptase present in human pulmonary mast cells.
Human Basophil Neutral Proteases.
A bradykinin-generating enzyme (BK-A) has been found in human
basophils, and is a kallikrein-like endopeptidase which generates
bradykinin from high molecular weight kininogen, and it is released
along with histamine by IgE-mediated activation (Newball et al
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1979).
The exact role of the neutral proteases of mast cells and basophils
is difficult to define, since their natural protein substrates have
yet to be determined. The possible biological effects of these
enzymes may be as follows:
a. Degradation of blood-vessel basement membrane, with resultant
increased vascular permeability.
b. Degradation of connective tissue components, such as the peptide
core of proteoglycans, allowing the influx of secondary
inflammatory cells.
c. Degradation of debris and activation of growth factors to
promote wound healing.
Although plasma proteins, including angiotensin I and have been
shown to be substrates • for these proteases in vitro, the
physiological relevance of these observations remain to be
demonstrated.
Preformed Chemotactic Factors.
Mast cell degranulation in vivo results in the influx of secondary
cells such as eosinophils, neutrophils and lymphocytes, recruited
to the sites of immediate hypersensitivity reactions by mast
cell-derived chemotactic factors. Studies to identify factors
selective for eosinophils revealed a group of preformed
intragranular peptides that were collectively termed 'eosinophil
chemotactic factors of anaphylaxis' (ECF-A) and were first
described by Kay et al (1971). These exist in low and intermediate
molecular weight forms (Goetzl and Austen 1976). Two acidic
tetrapeptides, Val-Gly-Ser-Glu and Ala-Gly-Ser-Glu augment the
number of functional C receptors on human eosinophils, thereby
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facilitating immune adherence and phagocytosis, and are active in
—8
concentrations as low as 10 M (Goetzl and Austen 1976). Exposure
to these tetrapeptides causes subsequent deactivation of any
further eosinophil chemotactic response.
Two other chemotactic peptides of presumptive mast cell origin are
termed eosinophil chemotactic oligopeptide, with a molecular weight
of 1200-2500 which preferentially attracts eosinophils in vitro
(Austen et al 1976), and high molecular weight neutrophil
chemotactic factor of anaphylaxis (HMW-NCF), which has also been
described in human basophils (Lewis et al 1974), human lung
fragments (Austen et al 1976), and human serum (Atkins et al 1977).
Acid Hydrolases,
A number of acid hydrolases (listed below) have been identified in
human and rat mast cell secretory granules, which perhaps defines
this organelle as a modified primary lysosome. These enzymes are
thought to have mainly extracellular functions, but may also be
involved in the degradation of ingested GAGs, glycoproteins and
complex glycolipids.
8 -Hexosaminidase: This is an acid exoglycosidase found in both rat
and human mast cells, most of which is localized
to the secretory granules.
8 -Glucuronidase: This is also an acid exoglycosidase, localized to
both rat and human mast cell secretory granules.
6 -D-Galactosidase: This enzyme has been detected in the secretory
granules of purified rat serosal mast cells.
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Arylsulphatases: Lysosomal arylsulphatases A and B catalyse the
hydrolysis of aromatic sulphate esters. Rat mast
cells contain approximately equal quantities of
arylsulphatases A and B, although only the A
subtype is localized to the secretory granule.
Human pulmonary mast cells contain these enzymes,
although the distribution of the subtypes has not
yet been determined.
Oxidative enzymes.
Superoxide dismutase and peroxidase enzymes have been detected in
the secretory granules of rat mast cells. Peroxidase is required in
the conversion of PGG^ to PGH^ in arachidonic acid metabolism, it
is capable of destroying le-ukotriene C , and activity, and
may provide mast cells with cytotoxic capabilities (Henderson et al
1981).
(ii) Newly Generated Mediators of Mast Cells and Basophils.
Whereas the preformed mediators are stored in the secretory
granules and can be extracted from quiescent mast cells or
basophils, membrane-derived lipid mediators are not formed until
after the cells have been activated. The lipid mediators that have
been identified include metabolites from the oxidative metabolism
of arachidonic acid, and the phospholipid derivative platelet
activating factor (PAF).
Arachidonic Acid Metabolism.
After mast cell and basophil activation, arachidonic acid is made
available from membrane phospholipids by phospholipase A^, or by
the sequential action of phospholipase C and diacylglycerol lipase
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(Figure 4). Arachidonic acid is then processed by one of two
separate enzymatic pathways: the cyclooxygenase (prostaglandin
synthetase) pathway, which leads to the production of
prostaglandins and thromboxanes, or one of the lipooxygenase
pathways leading to the production of n-hydroxylipids and dihydroxy
fatty acids, and to the sulphidopeptide leucotrienes C , and
(which collectively constitute the substance formerly known as the
slow reacting substance of anaphylaxis or SRS-A) (Figure 4).
Different cell types generate distinct arachidonic acid
metabolites. In vitro activation experiments have revealed that
purified rat and human lung mast cells generate PGD^ as the
predominant arachidonic acid metabolite, whereas only human mast
cells generate products of 5-lipooxygenase, including 5-HETE, and
the sulphidopeptide leukotrienes (Patterson et al 1976; Lewis et al
1981). Basophils synthesize only the sulphidopeptide leukotrienes
(MacGlashan et al 1983).
Prostaglandins.
Arachidonic acid metabolism by the cyclooxygenase pathway leads
predominantly to the formation of prostaglandin by a series of
membrane-associated enzyme events (Figure 4). A membrane-associated
cyclooxygenase converts arachidonic acid to prostaglandin G^ (PGG^)
which in turn is converted to PGH^ by a peroxidase enzyme. Both
PGG^ and PGH^ are unstable intermediate molecules and are rapidly
converted to PGD^ by endoperoxide-D-isomerase, thromboxane A^,
heptadecatrienoic acid (HHT) or another prostaglandin (Figure 4),
which varies with cell type according to the availability of
specific enzymes. For example, both rat and human mast cell





















Figure 4: Biochemical Pathway for the Metabolism of Arachidonic
Acid.
Modified from Schwartz and Austen 1984.
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thromboxane and PGF^, which is a reduction product of PGH^
(Lewis et al 1982), whereas human basophils do not synthesize this
mediator, although rat basophilic leukaemia cells produce some PGD^
(MacGlashan et al 1983).
The addition of PGD^ or inhibitors of the cyclooxygenase pathway
(for example, indomethacin) to human mast cells has little or no
effect on histamine release (Lewis et al 1982; Lichtenstein 1982),
although PGD^ is thought to enhance immunological release of
histamine from human basophils (Lichtenstein 1982). Nevertheless,
it is generally believed that the products of this pathway are not
involved in the secretory process.
PGD^ is an important potent mediator of anaphylaxis, and its
biological effects in tissues are extensive. Very small amounts of
PGD^ injected into human -skin causes increased vasodilation and
vasopermeability resulting in an erythematous wheal-and-flare
reaction similar to that seen with histamine, which persists for as
long as 2h, accompanied by leucocyte infiltration. Inhaled PGD^
produces bronchoconstriction with a potency about 10 times greater
than that of histamine (Smith et al 1980).
Leukotrienes.
The products of the 5-lipooxygenase pathway are the leukotrienes
(Figure 4). The 5-lipooxygenase enzyme forms 5-L-hydroperoxy-
6-trans-8,11,14- cis-eicosatetraenoic acid (5-HPETE), which is
either spontaneously hydrolysed to 5—L-hydroxy-6-trans-8,11,14-cis-
eicosatetraenoic acid (5-HETE) or converted enzymatically to the
unstable epoxide 5,6-oxide-7, 9-trans-ll,14-cis-eicosatetraenoic
acid (LTA^). The LTA^ either forms LTB^ or is conjugated with
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glutathione to form LTC^, the first of the SRS-As. Subsequently,
two additional SRS-As are generated by the sequential removal of
glutathione to yield LTD^ and of glycine to yield LTE^ (Figure 4).
Inhibitors of arachidonic acid metabolism block histamine release,
whereas diverting arachidonic acid to the lipooxygenase pathway (by
selective inhibition of the cyclooxygenase pathway, with
indomethacin or aspirin) enhances histamine release (Marone et al
1979). These considerations suggest a possible role of a product
from the lipooxygenase pathway in cell secretion.
Leukotriene C „, D„ and E„ all elicit erythema and wheal formation4' 4 4 J
when injected 'into human skin, and inhalation causes bronchospasm
and contraction of airway smooth muscle in vivo and in vitro.
Antihistamines have no effect on this activity, and a role for
these substances as mediators of bronchial asthma is therefore
unlikely. These sulphidopeptide leukotrienes are about 30 (LTE^) to
1000 (LTC^ and LTD^) times more potent contractile factors than
histamine (Adelroth et al 1986), and are known to cause
constriction of coronary arteries. These considerations suggest
that these substances contribute to the hypotensive as well as the
peripheral airway manifestations of systemic anaphylaxis, but the
true relevance of the leukotrienes in immediate hypersensitivity
has yet to be defined.
Platelet Activating Factor (PAF).
PAF (l-alkyl-2-acetyl-glyceryl-3-phosphorylchlorine) is produced by
mast cells, neutrophils, monocytes and platelets, but not human
basophils (Schleimer et al 1986). Although initially PAF was
recognized because of its ability to aggregate platelets, it is now
known to have potent effects on many other cells including mast
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cells, where IgE-mediated release of PAF implicates it as an
important mediator of immediate hypersensitivity reactions. The
bronchoconstricting properties of PAF have not been tested in
humans, although it causes a wheal-and-flare response when injected
into the skin, and is about 1000 times more potent than histamine.
PAF is a powerful chemotactic agent for polymorphonuclear
leucocytes, and thus may be involved in the recruitment of
secondary cells to sites of mast cell activation (Schwartz and
Austen 1984).
(V). Possible Role for the Basophil.
Despite the vast amount of research on mast cells and basophils in
recent years, the exact physiological function or functions of
these cells remain poorly Understood. It is generally accepted that
their role is related to their ability to bind IgE molecules and
release mediators contained within their cytoplasmic granules, and
is not restricted to hypersensitivity reactions. The functions of
mast cells and basophils are thought to be complementary due to
their close association with IgE antibody, the most obvious being
in the immune defence reaction to parasitic infection (Ogilvie and
Jones 1971). During parasitic infection, mast cells or basophils
could be activated by parasite-specific IgE, and mediators released
leading to eventual parasite expulsion. The majority of parasitic
infections are coupled with increased IgE synthesis. These
parasites are often large organisms compared to other infectious
agents, and therefore defences offered by macrophage and
lymphocytes are somewhat inadequate. The IgE sensitized mast cells
and basophils may therefore serve to back up these primary defence
mechanisms.
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Mast cells play a defensive role in local inflammatory reactions,
which lead to heightened accessibility of antibodies and complement
within the inflamed area. Infiltration and accumulation of various
types of immunologically reactive cells (including basophils)
results in the activated tissue. Together, these humoral factors
and cells form a system of far superior defence power than could
have been achieved without inflammatory reactions. Padawer (1978)
suggested that basophil attraction to sites of mast cell
activation, to release mediators upon interaction with
extracellular antigen, causes oedema, vasodilation and increased
vascular permeability, accompanied by the influx of IgG, IgM and
unbound IgE. This unbound IgE may serve to initiate a second
response, interacting with'mast cells and leading to the further
involvement of antibody ahd inflammatory reactive cells.
In most parts of the industrialized world, parasitic diseases are
rare, yet 10-15% of the population have elevated IgE antibodies
directed against various antigens such as pollen, house dust mite,
drugs, foods or insect venoms. The participation of the IgE/mast
cell/basophil system in these individuals may be due to a failure
to limit their proper immune response, coincidentally leading to
anaphylactic reactions and the symptoms of allergic disease.
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Aims of Study.
The aims of the present major study were as follows:
a. To develop further and refine the sensitive competitive binding
assay of Dawes and Pepper (1982), for the measurement of highly
sulphated GAGs.
b. To determine the source and exact biochemical nature of the GAG
in whole blood, plasma and tissue extracts.
c. To study the conditions of release of this GAG from human
basophils in response to antigenic challenge in vitro, using
basophil enriched fractions of whole blood from both atopic and
non-atopic individuals. Since the release of histamine from
basophils is widely used in the study of allergy, and histamine is
associated with GAG within the secretory granules, release of the
GAG during this response was studied in relation to that of
histamine.
d. To study the involvement of GAG in the process of systemic
anaphylaxis in vivo, using both human and animal models; patients
receiving platelet transfusions and preparations of intravenous
immunoglobulin, and Nippostrongylus brasiliensis-infected rats
challenged intravenously with worm antigen.
e. To measure numbers of circulating basophils in healthy and
atopic individuals, using a new and highly sensitive method of cell
counting- the Technicon H-6000, in an attempt to confirm that the
basophil has an important role to play in allergic disease.
f. To study the circulating levels of GAG in human plasma and
tissues, to answer a number of fundamental questions with regard to
its physiological importance. For example, does this circulating
plasma GAG level vary with time in individuals, and is plasma GAG
concentration related to individual basophil count.
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Chapter 2.
(2:1). Measurement of Glycosaminoglycans.
(1). Introduction.
Glycosaminoglycans (GAGs) constitute a class of polysaccharides
often associated with protein by means of covalent bonds, to form
proteoglycans. GAG side chains attach to a peptide core via the
linkage region:
(Disaccharide repeats)-GlucUA 8 1-3 Gal 8 1-3 Gal 8 1-4 Xyl-Serine,
-common to most O-linked GAGs (Grebner et al 1966). There are no
formal criteria for identifying GAGs, but are all negatively
charged polymers made up almost entirely from repeating
disaccharide units; they' consist of a carbohydrate backbone
containing alternating sequences of uronic acid and hexosamine
residues, the only exception being keratan sulphate in which
galactose replaces the uronose residue. The hexosamine residues can
be:
a. N—acetylglucosamine, in heparin, heparan sulphate
and hyaluronate.
or b. N—acetylgalactosamine, in chondroitin sulphates
and dermatan sulphate.
All GAGs (with the exception of hyaluronate) contain ester sulphate
groups at the C„ or C_ position of the acetyl hexosamine residues.4 b
The residues of heparin and heparan sulphate may be N—acetylated or




In heparin the disaccharide units are composed of D-glucuronic or
L-iduronic acid in 8 1-4 linkage to glucosamine (Helting and Lindahl
1972). Figure A shows three forms which may exist; an N-acetylated
type (i), and two N-sulphated types (ii) and (iii), and in each
example R may be SO^ or H. In "full-fledged" heparin, iduronic
acid is by far the most abundant uronic acid component, and
accounts for 70-90% of the total uronic acid (Roden 1980).
Figure A.
CH20R.
1 0 (i) GlcNAc 1—4GlcUA8 1-4.
0 (ii) GlcNS03 1-4G1cUA8 1-4.
OR HV-O—\0H^ HC02H V ° (ii;L) GlcNS03 1—4GlcUA 1-4.
H NH H OR
I
S0„
One carboxyl group, and one to four sulphates may be present per
disaccharide unit. These sulphate residues are substituted at the
nitrogen of glucosamine, the C-3 and C-6 hydroxy1 groups of
glucosamine, and the C-2-hydroxyl group of iduronic acid. The
protein core of heparin isolated from rodent skin tissue (Robinson
et al 1978) and serosal mast cells (Metcalfe et al 1980) contains
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alternating serine and glycine amino acid units. Every second or
third serine is linked to a glucosaminoglycan side chain, and the
density of these side chains is thought to provide some resistance
of the protein core to protease digestion (Horner 1971).
Heparin has many known biological functions, most of which are
mediated by binding of the heparin molecule to a protein.
Antithrombin III is activated by interaction with heparin, which
mediates its anticoagulant activity by promoting inhibition of
several serine proteases involved with coagulation, namely thrombin
(Rosenberg 1977), low molecular weight fractions of factor XII
(Stead et al 1976), factors Xa, IXa (Oterud et al 1976), and XIa
(Damus et al 1973). Inhibition of kallikrein (Burrowes et al 1975)
and plasmin (Highsmith and- Rosenberg 1974) is also potentiated.
This anticoagulant activity is neutralized by other proteins with
high affinities for heparin, such as protamine (Chargaff and Olson
1937) eosinophil major basic protein (Gleich 1977) and platelet
factor 4 (Broekman et al 1975). Heparin is also involved in many
cellular and humoral activities including regulation of the
electronegative potential of vascular wall (Jaques 1967), fat
metabolism (Wollin and Jaques 1974), the ovarian cycle (Lindner et
al 1977) and a wide range of enzyme activities (Dawes 1982).
Heparin is present in mammalian connective tissue where it forms
the matrix of the mast cell secretory granule to which many of the
preformed basic mediators such as histamine bind by ionic
interaction (Uvnas et al 1970).
Heparan Sulphate.
Heparin and heparan sulphate are considered to be members of the
same family which includes a spectrum of molecules of different
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uronic acid composition and degree of sulphation, from highly
sulphated, iduronic acid - rich polysaccharides (heparin) at one
end of the spectrum and low-sulphated, glucuronic acid-rich species
at the other (Lindahl and Hook 1978). Gallagher and Walker (1985)
proposed that because of their differing patterns of sulphation,
they should be classed as separate families of N-sulphated
polysaccharides. They showed that more than 80% of glucosamine
residues in heparin are N-sulphated and even more 0-sulphated,
whereas N-sulphate and N-acetyl groups were arranged in similar
numbers and patterns along heparan sulphate molecules, while the
0-sulphate grobps varied considerably depending on the source of
heparan sulphate. These molecular distinctions between heparan
sulphate molecules have been- further defined (Dietrich et al 1983)
and a large number of different structural forms were found to
exist, depending on the proportion of four basic disaccharide
units, which vary according to tissue and species of origin.
The ability of heparan sulphate to inhibit the coagulation process
is much less than that of heparin, and its major biological
function is therefore less obvious. Heparan sulphate is abundant on
many cell surfaces (Kraemer 1971a; Kraemer 1971b; Kjellen et al
1980) and it is thought to function in cell-cell recognition and
adhesiveness (Dietrich et a.1 1977) due to its inherent molecular
variability in different cell types (Dietrich et al 1983;
Buonassisi and Colburn 1983).
Chondroitin Sulphate.
Chondroitin sulphates are GAGs with 8 1-4 linked disaccharide units
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The main subtypes of chondroitin sulphate are chondroitin
4-sulphate, chondroitin 6-sulphate, dermatan sulphate and a less
abundant subtype chondroitin-4,6-disulphate (chondroitin sulphate
E) where numbers designate the position of O-sulphation on
galactosamine. Thus chondroitin sulphates have varying degrees of
sulphation, and highly sulphated chondroitin sulphate can be
mistaken for heparin.
All cells probably contain GAGs and each cell or tissue may contain
one or more types; these also vary between species. For example rat
peritoneal mast cells have been shown to synthesise not only
heparin, but also chondroitin 4-sulphate, chondroitin 6-sulphate
and a GAG containing a disulphated disaccharide, thought to be
chondroitin sulphate E (Stevens and Austen 1982).
Methods for the measurement of heparin and related GAGs have to
date been of two types based on
Chemical methods such as the uronic acid carbazole reaction (Bitter
and Muir 1962) , and metachromatic interactions with dyes such as
Azure A (Jaques et al 1947) and toluidine blue (Jaques and Wollin
1967) can be applied to all GAGs, but do not distinguish between
them. The assay of heparin by means of its ability to catalyse the
hydrolysis of Auramine 0 (Band and Lukton 1982) is specific for
a. chemical properties and interaction with dyes
or b. anticoagulant activity.
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heparin, but is subject to interference from many components and
will not detect concentrations of heparin below lp g/ml. Analysis of
the monosaccharide constituents (Roden et al 1972; Blumenkrantz and
Asbol-Hansen 1973) defines the type of GAG, but requires large
amounts and cannot be used on a routine basis.
Methods based on the biological activity of heparin as an
anticoagulant involve either direct measurement of heparin's
inhibitory effect on in vitro blood coagulation (Marder 1970) or
more specifically, quantitation of heparin enhancement of clotting
enzyme inactivation by antithrombin III (Yin et al 1973) or factor
Xa (Yin et al 1973; Teien et al 1976). These assays are subject to
interference from clotting factors and inhibitors of coagulation
(Yin et al 1973; Godal 1975) and due to problems stemming from the
microheterogeneity of heparin preparations, there is considerable
variability in the detection of different heparin preparations with
different assay systems.
The ability of heparin-like polysaccharides to form insoluble
complexes with serum lipoproteins (Srinivasan et al 1975) has been
exploited by Wu and Cohen (1984) in the development of a
competitive binding assay. It is based on the competition of
naturally occurring GAGs (isolated from tissue digests) with
radiolabelled heparan sulphate for the formation of precipitates in
serum. The use of this method is however limited in that it will
not detect concentrations of less than 10p g/ml.
A competitive binding assay was developed by Dawes and Pepper
(1982), based on the competition of unlabelled and radiolabelled
GAGs for binding to a positively charged solid phase. The assay is
sensitive to the degree of sulphation and molecular weight of the
GAG, and will detect concentrations as low as 200ng/ml. This assay
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was developed further and refined for application in the study of
material contained in basophilic leucocytes.
(2). Materials and Methods.
Materials.
Reagents.
Tween 20, Triton X-100, trichloroacetic acid 'AnalaR' (TCA) and
dimethyl sulphoxide 'AnalaR' (DMSO) were purchased from BDH
Limited, Poole, Dorset. Opocrin (HTS/435), (heparan sulphate
standard) was supplied by Dr R Mastacchi, Alfaricerche, Corlo,
Italy. Organon'10172 was a kind gift of Dr H. Moelker, Organon,
Oss, Netherlands. Porcine mucosal heparin (sodium salt, grade 1;
Product No. H3125), bovine serum albumin (BSA),(Fraction V Powder;
Product No. A4503), Pronaae (bacterial protease Type IV; Product
No. P0384), chondroitinase ABC (Product No. C2905), lipoprotein
lipase (Product No. L8634) and phospholipase C (Type V, Product No
4014) were all purchased from Sigma Chemical Company Ltd, Dorset,
England. Heparan sulphate used for iodination was a gift from Dr
E.A.Johnson (National Institution of Biological Standards and
Control; London, UK). Polybrene [ poly (N,N,N',N'-tetramethyl-
N-trimethylenehexamethylene) diammonium bromide] was purchased from
Aldrich Chemical Company Limited, Dorset, England. Sepharose 4B,
Sephadex G-50 Superfine, Sephadex G-25 and Epoxy-Sepharose were
purchased from Pharmacia (G.B. Ltd), Milton Keynes, England.
125 125





To make a stock solution of 0.25M phosphate buffer, lOOg of sodium
dihydrogen orthophosphate (NaH^PO^.H^O) was dissolved in 1 litre,
and added to 16 litres of deionised water. 570g of di-sodium
hydrogen orthophosphate (NaHPO^), was dissolved in 2 litres of
heated deionised water, and added slowly with mixing to previous 17
litres. This solution was then made up to 20 litres and adjusted to
pH 7.4. This was then diluted 1:5 with deionised water for use at
0.05M.
Tween/phosphate buffer.
Phosphate buffer (0.05M) was made as required from the stock
solution of 0.25M stored at'room temperature. Tween 20 was added at
1% (weight/volume), and stored at 4°C for up to one week.
BSA buffer.
Bovine serum albumin (BSA) was added to Tween/phosphate buffer at a
concentration of lOmg/ml. This buffer was susceptible to bacterial
contamination, and was made fresh when required.
Sepharose 4B.
Sepharose 4B was filtered on a sintered glass funnel and washed
thoroughly with phosphate buffer (0.05M, pH 7.4). The solid phase
was then resuspended to original volume using phosphate buffer, and
used at a dilution of 1:150 vol/vol to determine non-specific
binding in the assay.
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Polybrene—Sepharose 4B.
Polybrene was used as the binding reagent in place of the protamine
described in the original method of Dawes and Pepper (1982), since
it was more stable and not susceptible to protease digestion. This
reagent was prepared by Dr DS Pepper. Polybrene was mixed with
epoxy-Sepharose at pH 12 for 16h at 37°C. The loading was optimised
at 12m g Polybrene/ml of slurry. The product was thoroughly washed




Heparan sulphate 1 (NIBSC)7 the heparan sulphate Org 10172 and
commercial sodium hepahin (Sigma) were conjugated with
3-(4-hydroxyphenyl) propionic acid N-hydroxysuccinimide ester
(SHPP) by reacting the heparan sulphate or heparin (lOmg) with an
excess (lOmg) of non-iodinated SHPP in 5ml of 0.05M sodium borate
(pH 9.2) at 4°C for 20h. Unreacted ester, at this stage hydrolysed
to the acid, was removed by gel filtration in water on Sephadex
G-25. The material eluted at the void volume was chromatographed on
a column of Polybrene-agarose (MacGregor et al 1984) to isolate the
biologically active derivatives. These were desalted, lyophilised
125
and iodinated with I by the method of Greenwood et al (1963) as
follows.
The reaction tube contained
10m 1 of Na125I (lmCi)
10m 1 of derivatised heparan sulphate or heparin (containing at
least 500m g/ml)
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10y 1 of Chloramine T (at 5mg/ml dissolved in 0.25M phosphate
buffer immediately before use).
The mixture was allowed to react for approximately 10 seconds and
then stopped by adding 0.86ml of Na^S^O^ (160m g/ml in 0.05M
phosphate), followed by 100m 1 of KI carrier (lOmg/ml in 0.05M
phosphate buffer).
The reaction tube was immediately counted on a NE
Scaler-Ratemeter(SR3) y -counter, and the contents transferred to a
lxlOcm Sephadex G-50 column. The reaction tube was rinsed twice and
finally counted. The column was run in Tween/phosphate buffer, and
20xlml fractions were collected and counted. The stock tracer was
stored in liquid nitrogen at -170°C in 20m 1 aliquots, and was
stable for approximately 3-4 months. Aliquots were thawed as
required for assay, and diluted with Tween/phosphate buffer to a
concentration of lOng/ml.
Assay of Glycosaminoglycans.
The assay mixture contained
50(i 1 of biological sample or standard.
50m 1 of Polybrene-Sepharose 4B.
125
50m 1 of I heparan sulphate I or heparin.
150m 1 of BSA buffer or DMSO.
The concentration of Polybrene-Sepharose 4B used was predetermined
by testing serial dilutions in the assay. The concentration chosen
for use bound 50-60% of tracer in the absence of unlabelled
material, and gave reproducible results with biological samples.
The starting concentration for the heparin standard was 1m g/ml, and
eight doubling dilutions of this formed the standard curve. The
starting concentration for heparan sulphate assay was 20m g/ml, and
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eight doubling dilutions were made. All standards and samples were
assayed in duplicate. For each assay, standard curves were included
both before and after all samples, to detect drift in the assay.
Maximum binding of the tracer was determined for each assay by
including quadruplicate zero standard tubes, which contained 50p 1
of Tween/phosphate buffer instead of 50p 1 of standard or sample.
Non-specific binding of the tracer was determined for each assay by
including duplicate samples where 50p 1 of Tween/phosphate buffer
replaced sample or standard, and 50p 1 of Sepharose 4B replaced
Polybrene-Sepharose 4B.
Four counting standard tubes containing only 50p 1 of tracer were
used to determine the time required to detect 10,000 counts.
All tubes were shaken at room temperature for 3h or 18h, and
Sepharose-bound material was separated from that remaining in the
liquid phase, by the method described by Hunter (1977). This
involved sedimentation of the assay mixture through a solution of
Tween/phosphate buffer containing 10% sucrose, which was dispensed
using a multi-channel pump dispenser and manifold. Supernatants
were removed after 20 minutes by aspiration. Tracer bound to
Sepharose was then counted on a NE 1600 y -counter (Nuclear
Enterprises, Sighthill, Scotland), for the time determined from the
counting standards.
Collection of Biological Samples.
Serum.
Whole blood samples were collected in 10ml volumes, and allowed to
clot at room temperature. These were then centrifuged (llOg; 15min;
4°C) and supernatant serum retained.
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Plasma.
Whole blood samples were collected into a variety of anticoagulants
at a dilution of 1:9 (vol anticoagulant/vol blood). These were ETP-
[ EDTA (78mM), theophylline (lOmM) and prostaglandin E^
(0.33ji g/ml), pH 7.4] , EDTA (50mM), or citrate (3.12% trisodium
citrate in 5% HEPES buffer, w/v). The samples were then centrifuged
(llOg; 15mins; 4°C) and supernatant plasma retained.
Preparation of Biological Samples.
Biological samples were prepared for assay by incubating with
Pronase (a non-specific protease isolated from Streptomyces
griseus), at a final enzyme concentration of 5mg/ml at 37°C for
18-24h. The treated samples were then frozen to -20°C before assay.
Determination of Total Cell Heparan Sulphate.
Triton X-100.
A stock solution of 1% Triton X-100 (w/v) was made using 0.05M
phosphate buffer. Whole blood samples were diluted 1:10 with this
stock solution and treated with Pronase before assay.
Freeze/thaw x 6.
Whole blood samples were frozen to -20°C and thawed six times to
ensure complete cell lysis. Samples were then centrifuged (800g;
4°C; 30min) to obtain supernatant and a cell pellet containing cell
membranes and debris. Supernatants were removed and cell pellets
resuspended to the original sample volume using Tween/phosphate
buffer. Both supernatants and resuspended pellet solutions were




Chondroitinase ABC (5 units) was reconstituted to 1ml using 0.05M
phosphate buffer. This was stored at -20°C in lOOy 1 aliquots.
Chondroitinase ABC was added to samples at a final concentration of
0.2 units/ml. A control sample of chondroitin 4-sulphate in plasma
(lOOp g/ml) was used to test the activity of chondroitinase ABC in
this system.
Lipoprotein lipase.
Lipoprotein lipase (100 units) was reconstituted to 2ml using 0.05M
phosphate buffer to give a stock solution of 50 units/ml. This was
added to samples at a final concentration of 1 unit/ml, and
incubated for 24h at 37°C.
Phospholipase C
Phospholipase C was supplied as a stock solution containing 250
units/160p 1. This was diluted in 0.05M phosphate buffer, and added
to samples at a final concentration of 1 unit/ml. Samples were then
incubated at 37°C for 24h.
(3). Results.
Calculation of % yield and specific activity of radioiodinated
tracer.
Specific activity and concentration of tracer were determined by
the following method, (based on Greenwood et al 1963) illustrated
with an example in Table 1. The elution profile of this
radioiodination is shown in Figure 1. There were two peaks of
radioactivity, a first peak containing iodinated GAG (Peak I), and
125
a second peak (Peak II), containing unbound I.
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Table 1: Calculation of the Percentage Yield and Specific Activity
of Tracer following Chloramine T Radioiodination.


















Total radioactivity added = 107639c/10sec (1000 p Ci or 37000 kBq).
Total GAG added = 68p g of derivatised heparan sulphate I
125
Total free I eluted from column = 26896 counts.
Total counts associated with antigen = Total counts added-total
eluted.
= 107693 - 26896
= 80824 counts.
% Yield = 80824 x 100
107693 = 75.05%
Specific activity = 0.7505 x 1000
68 = 11.04 p Ci/p g
Of 80824 counts associated with antigen, 71943 are in fractions 4,5
and 6. Thus fractions 4,5 and 6 contained 71943 x 68
80824 = 60.53 ug/3ml
Thus stock tracer contained = 20.18 p g/ml.
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Figure!: Elution Profile of Radioiodination.
Elution profile of iodinated GAG following reaction of
125
I with derivatised GAG, when purified on a Sephadex
G-50 column. Two peaks of radioactivity were observed:
125 125
I-GAG (Peak I), and free I (Peak II).
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a. The total I used for radioiodination was determined by
counting the reaction tube before fractionation on the
Sephadex G-50 column.
b. The radioactivity associated with GAG was calculated as being
125
that in a, minus the counts eluted as free I (Table 1) from
the Sephadex G-50 column. This figure was then used to calculate
125
the % yield of I-labelled material, and its specific
activity.
125
c. The counts in each fraction containing I-labelled material
were then expressed as a percentage of b, and used to calculate
the concentration of radiolabelled GAG. This method assumes that
125
all radioactivity that is not eluted as free I is antigen
associated, and may result in an overestimation. However, the
125
error is likely to be small, as free I (as iodide) does not
readily adsorb to the reaction tube or the Sephadex G-50 column.
Measurement of standard and exogenous heparin.
125
The original assay used heparin as the standard and I-labelled
heparin as the tracer, in a buffer of 1% Tween/phosphate. A typical
standard curve is shown in Figure 2. Various conditions were
sequentially altered to optimise this system for use with
biological samples. A variety of substances were tested in the
standard assay to replace the 150p 1 of 1% Tween/phosphate buffer in
an attempt to improve reproducibility and stability of samples in
the assay. These were
a. Urea: This was tested at 5M and 1M concentrations. A standard
curve was obtained for both, but there was a considerable
reduction in total binding.





Figure 2: Heparin Assay Standard Curve.
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with the standard when 0.5M NaOH or 1M NaOH and 1M NaCl
were used. However, non-specific binding was increased to
35-40%, when it should have been less than 5%.
c. DMSO: Binding curves comparable to the standard were obtained
when DMSO was included in the assay at 50% by volume.
d. BSA buffer: Binding curves obtained when BSA buffer was used at
lOmg/ml gave low non-specific binding levels, but
overall maximum binding was reduced, producing a
curve with a less steep gradient than the standard.
BSA buffer and DMSO were tested using serial dilutions of fresh
plasma spiked with heparin at lOmg/ml. They were equally suitable,
and no interference from plasma constituents was detected in either
system.
Four samples of plasma obtained from patients receiving heparin for
therapeutic purposes were tested in this assay. All samples had
high detectable levels of heparin, and assay of serial dilutions of
each sample produced a curve parallel to that of standard heparin.
This indicated that the material was similar to heparin, and was
therefore directly comparable to the standard (Figure 3).
Measurement of endogenous material.
Human Serum.
Serum samples were obtained from 30 normal healthy controls,
Pronase treated and assayed. Levels obtained ranged from
860-3850ng/ml (mean value = 1895.6ng/ml; SD=713.9ng/ml;
SEM=130.3ng/ml).
Human Plasma.
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Figure 3: Assay of Exogenous Heparin.
Serial dilutions of plasma from a patient receiving
heparin for therapeutic purposes were assayed, and
compared with the standard heparin curve. Parallel curves
were obtained.
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anticoagulants (Table 2). Spontaneous release of material into
plasma during sampling and handling of samples was minimal using
citrate anticoagulant. Citrate anticoagulant was therefore chosen
as the most appropriate anticoagulant to obtain plasma samples in
this study. Plasma samples from 30 normal healthy controls were
Pronase treated and assayed. Levels obtained ranged from 200 to 873
ng/ml (mean value = 443.8 ng/ml; SD=195.3ng/ml; SEM=35.6ng/ml).
Assay of endogenous material.
Plasma samples with and without Pronase treatment were serially
diluted and assayed, using both BSA buffer and DMSO heparin assay
systems. Detectable levels were obtained from Pronase treated
samples only, but when serially diluted, did not produce a curve
parallel to the heparin standard (Figure 4). Various combinations
of standard and tracer were then screened for an appropriate system
for assay of the naturally occurring material in plasma.
Heparan sulphate I tracer was used in place of heparin tracer, and
Opocrin (heparan sulphate I) replaced heparin as the standard
(Figures 5a and 5b).
DMSO caused interference and reduced binding considerably in the
heparan sulphate assay. The curve was very flat and could not be
used as a standard curve (Figure 5b).
The BSA buffer system detected the heparan sulphate standard, and
produced a satisfactory standard curve which was less steep than
that of the heparin standard. This system also detected material in
Pronase treated biological samples, with reproducible results
(Figure 5a).
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Table 2: Collection of Plasma Samples using Different
Anticoagulants.
Control 1 Control 2 Control 3
ETP 900 860 732
EDTA 676 585 738
Trisodium citrate 599 554 599
Serum
, 2815 1915 2288
Samples were collected from three healthy controls, and assayed for
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Figure 4: Measurement of Endogenous Material in Heparin Assay.
Fresh human plasma samples with and without Pronase
digestion were serially diluted, assayed and compared
with the standard heparin curve. Material was detected in
Pronase treated plasma only, and its dilution curve was
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Figure 5: Assay of Endogenous Material in Heparan Sulphate Assay.
The assay of heparan sulphate standard, using heparan
sulphate I tracer, was compared with the standard
heparin assay in the presence of a. BSA buffer, and b.
50% DMS0. Serial dilutions of Pronase treated plasma
were also included, to test the activity of naturally
occurring endogenous GAGs with heparan sulphate I
tracer. Heparan sulphate-like material was detected in
the presence of BSA buffer, and DMS0 clearly interfered
with its assay.
pocrin + HSI tracer.
Pronase treated plasma +
HS I tracer.
100
Heparin- or Opocrin ng.
, Heparin standard +
1000 heparin tracer.
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Organon 10172 (Org 10172) was tested as the standard, and iodinated
Org 10172 was used as tracer. The graphs produced were parallel to
those using heparan sulphate I and Opocrin. A correlation curve of
the Opocrin/Org 10172 standards was drawn (Figure 6), and revealed
limited scattering of points, especially on the middle "working
area" of the curves. There was less correlation at lower
concentrations, due to differing degrees of sulphation of the two
materials. Having established the most appropriate combination,
that of heparan sulphate I tracer and Opocrin standard, a range of
specific GAG standards were tested (as dilution curves) to
determine those detectable with this system (Figure 7). Heparan
sulphate I, dermatan sulphate and chondroitin sulphate E were all
measurable at (approximate concentration range) l-10y g/ml, and
produced dilution curves parallel to the Opocrin standard. Heparin
was also detected, but was distinguished from the other GAGs tested
by its characteristic steep curve. Chondroitin 4-sulphate, and
chondroitin 6-sulphate were also detected, but only when present at
concentrations of greater than Img/ml.
Effect of freezing on Pronase treated samples.
Doubling dilutions of biological samples treated with Pronase gave
a curve parallel to the heparan sulphate I standard curve, although
reproducibility was poor at lower concentrations, reducing the
sensitivity of the assay. Pretreated samples were frozen to -20°C
before assay, which eliminated this problem.(Figure 8)
Freezing samples after digestion with Pronase may remove
interfering components (possibly by precipitation), and therefore
background disturbance. The intra-assay and inter-assay CV's for
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Figure 6: Correlation Curve of Opocrin and Organon 10172 Standards.
Both heparan sulphate standards, Opocrin and Organon
10172 were assayed over the same concentration range,
using heparan sulphate I tracer and BSA buffer in the
assay. The graph shows there was good correlation between












Figure 7: Glycosaminoglycans in Heparan Sulphate Assay.
Serial dilutions of a range of different GAGs were
assayed using heparan sulphate I tracer, and BSA buffer.
These were Opocrin, standard heparin, heparan sulphate I
(HSI), dermatan sulphate (DS), chondroitin sulphate E
(CS-E), chondroitin 4-sulphate (C-4-S), and chondroitin
6-sulphate (C-6-S).
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Figure 8: Effect of Freezing on Pronase Treated Samples.
Serial dilutions of Pronase treated plasma, before and
after freezing and thawing once were assayed, and
compared with the standard Opocrin. Both dilution curves
were parallel with standard Opocrin; the frozen/thaw
sample had greater reproducibility and stability at lower
concentrations.
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respectively. However, repeated freeze/thaw of samples tended to
decrease their stability in the assay, and reproducibility became
poor. Samples frozen and thawed more than twice were discarded.
Variation of shaking time.
Two standard curves and nine pretreated plasma samples were
prepared for assay in duplicate. One set was shaken at room
temperature for 3h, and the other for 18h before separation of the
solid phase.
Standard curves were similar for each assay, but results obtained
from plasma samples were very different (Table 3).
Biological samples were therefore not stable at room temperature
overnight. Three hours of shaking appeared to be sufficient to
allow the assay mixture to equilibrate, but not to allow incubation
interference.
Determination of total cellular material.
To measure levels of total GAG contained in whole blood samples,
cells were initially lysed by the following method.
Triton X-100.
Triton X-100 was added to whole blood samples at a final
concentration of 1% to cause complete cell lysis by dissolving the
membrane, and thus allow detection of total GAG contained in all
blood cellular fractions. A high concentration of material was
detected in whole blood treated in this way, but doubling dilutions
of these samples did not produce a curve parallel to doubling
dilutions of Pronase treated plasma, or heparan sulphate in the
assay (Figure 9). The heparan sulphate standard was set up in
-70-
Table 3: Variation of Shaking Time in Assay.
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Figure 9: Assay of Pronase Treated Plasma and Triton X—100 lysate.
Serial dilutions of Triton X-100 lysates were assayed and
compared with those of frozen/thawed, Pronase treated
plasma, and standard Opocrin. The dilution curve of
Triton X-100 lysate sample was more horizontal than those
of the plasma and standard Opocrin curves, which were
parallel to each other.
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duplicate: one diluted with Triton X-100, and the other set up as
normal. Both curves were identical when assayed, which ruled out
interference from Triton X-100.
The lack of parallelism of the Triton X-100 lysate indicates that
the material being detected in the assay was not directly
comparable to the standard used. Alternative methods were therefore
tested to release total GAG contained in whole blood samples.
Methods tested were as follows.
Freeze/thaw x 6.
Cells were lysed by freezing (to -20°C) and thawing (to room
temperature) untreated whole blood samples six times. Since
membrane material was not dissolved by this method, samples were
centrifuged to remove membranes and cellular debris.
Serial dilutions of Pronase treated supernatants and resuspended
membrane pellets were assayed, and it was found that interfering
components were contained in the membrane fraction. Material
released into the supernatant fraction produced a dilution curve
parallel, and was therefore directly comparable with those of both
plasma and heparan sulphate I standard. However the absolute values
of GAG contained in these supernatant samples were all < lOOOng/ml,
much less than was released into serum. Thus this method did not
successfully measure total content of GAG in whole blood.
Since the material detected from the resuspended cell pellet
produced the same pattern as that of the Triton X-100 lysate
(Figure 10), it was assumed that the interfering components were
confined to the membrane fraction. To determine the nature of the
material or interfering component of the membrane fraction, the
Triton X-100 lysate was treated with a variety of enzymes before
Pronase treatment as follows.
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Figure 10: Assay of Freeze/Thaw Supernatant and Resuspended,
Membrane—Containing Cell Pellets.
A sample of whole blood was frozen and thawed six times,
centrifuged and serial dilutions of both supernatant and
resuspended cell pellet were assayed. These were
compared with serial dilutions of Triton X-100 lysates
and standard Opocrin. Supernatant sample dilution curve
was parallel, and directly comparable with standard
Opocrin, whereas the resuspended cell pellet produced a
dilution curve with a more horizontal slope, parallel
with the Triton X-100 lysate sample.
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a. Chondroitinase ABC
To test if the material being detected in the membrane fraction was
chondroitin sulphate, the effect of chondroitinase ABC on a sample
of Triton X-100 lysate was tested. Control samples of lysate
contained commercial chondroitin 4-sulphate at a final
concentration of 100p g/ml. Overnight incubation with chondroitinase
ABC degraded the chondroitin 4-sulphate in the control sample, and
at the lowest dilutions of Triton X-100 lysates, binding was
reduced by 55.6% with chondroitinase ABC digestion, although
detectable material was still present after this treatment (Figure
11). The interference detected in the lysate samples could
therefore have been partly due to the presence of a chondroitin
sulphate component in the membrane fraction.
b. Lipoprotein lipase.
Lipoprotein lipase treatment did not affect the response of the
Triton X-100 lysate in the assay, since dilution curves of the
lysate samples were similar before and after treatment (Figure 12).
c. Phospholipase C.
Digestion of a Triton X-100 lysate samples with phospholipase C
yielded material which was readily assayed, and doubling dilutions
of the treated lysate gave a curve parallel to the standard (Figure
13). Interference detected with the lysate (possibly by
phospholipids in the membrane fraction) had been effectively
removed by predigestion of the sample with phospholipase C.
Having established that the interference in the lysate samples was
due to components confined to the membrane fraction, further
methods for release were tested.
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Figure lib.
Figure 11: Digestion with Chondroitinase ABC.
Chondroitin 4-sulphate was diluted in Triton X-TOO, and
treated with chondroitinase ABC. Serial dilutions of
these chondroitinase digested and untreated samples were
prepared in Triton X-100, and assayed. Chondroitin
4-sulphate was detected and produced a relatively
horizontal dilution curve, which was degraded in the
presence of chondroitinase ABC (Figure 11a). A Triton
X-100 lysate sample was treated with chondroitinase in
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Figure 12: Digestion with Lipoprotein Lipase.
Serial dilutions of Triton X-100 lysate samples, with
and without digestion with lipoprotein lipase, were
assayed and compared with standard Opocrin. Incubation
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Figure 13: Digestion with Phospholipase C.
Serial dilutions of Triton X-100 lysate samples with and
without digestion with phospholipase C, were assayed and
compared with standard Opocrin. Increased levels of
material were detected after digestion with
phospholipase C, and the dilution curve became more
parallel with that of standard Opocrin.
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Tween 20.
A 2% Tween 20 solution was used as an alternative lysing agent to
Triton X-100, as it was thought to dissolve only certain membrane
components (possibly leaving those causing assay interference which
could be removed by centrifugation). Centrifugation was necessary
to remove undissolved membranes, which were retained and
resuspended to the original sample volume with 0.05M phosphate
buffer. Both supernatants and resuspended cell pellet samples were
serially diluted and assayed as before (Figure 14).
The dilution curves of these samples showed that material released
by cell lysis with Tween 20 was directly comparable with heparan
sulphate standard. Material associated with interfering membrane
components were removed from each sample by centrifugation.
However, the absolute values of GAG detected in the supernatant
samples were again < lOOOng/ml and clearly did not reflect the total
content of GAG in these whole blood samples. Increasing the
concentration of Tween 20 to 4% slightly increased the 'releasable'
material detected (by approximately 2.5%). These levels of material
detected were however still too low to be defined as total cellular
content.
Release Without Membrane Solubilisation.
Methods to release total cellular material which did not involve
the solubilisation of membranes were tested as follows,
a. Deionised water (Hypotonic lysis).
Whole blood samples were diluted 1:2-1:10 with deionised water,
Pronase treated and assayed without centrifugation. No detectable
material (< 200ng/ml) was present in any of the samples, and this
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Figure 14: Cell Lysis with Tween 20.
Whole blood was diluted with 2% Tween 20, centrifuged,
and serial dilutions of both supernatant and resuspended
cell pellet were assayed. These were compared with
serial dilutions of Triton X-100 lysate and standard
Opocrin. The supernatant sample dilution curve was
parallel and directly comparable with the standard
Opocrin, whereas the resuspended cell pellet produced a
dilution curve with a more horizontal slope, parallel
with the Triton X-100 lysate sample.
b. Trichloroacetic acid (TCA).
This was added to samples at a final concentration of 0.5%, but
interfered with the standard curve, and was therefore unsuitable.
c. Magnesium chloride (MgCl^)
Free Ca++, required for both the release mechanism and the clotting
mechanism was chelated by diluting whole blood samples 1:10 with
citrate anticoagulant, and MgCl^ was added to at a final
concentration of 0.2M. At this concentration, Mg++ is thought to
mimic Ca++ ions in such a way that leucocyte release occurs,
whereas the clotting mechanism remains inactive. These whole blood
samples were centrifuged and supernatants Pronase treated and
assayed as before. All samples produced levels of < 200ng/ml, and
clearly GAG release from cells had not occurred.
d. Variation of citrate concentration.
Citrate was normally used at 3.12% (w/v) to chelate existing
sources of Ca++ in whole blood samples, and inhibit the clotting
mechanism. It was tested at half strength (1.56%) and also 1.25%,
and 1% (w/v), in an attempt to prevent coagulation, but allow
sufficient Ca++ to remain in solution, and allow release of GAG.
Two whole blood samples were tested in this way, centrifuged, and
supernatants were Pronase treated and assayed. (Table 4)
These levels were not much higher than would be expected of plasma
samples (in full strength citrate levels of 200-873ng/ml can
normally be expected), and release of total GAG had clearly not
occurred. Citrate could not be tested at a concentration less than
1%, since clotting occurred in the samples. A combination of 1.56%
citrate and 0.2M MgCl^ added to the two whole blood samples, was
also tested. Levels of 450 and 622 were obtained and again were
levels similar to plasma, rather than total levels released from
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Table 4: Variation of Concentration of Citrate Anticoagulant.
Concentration of Citrate
Anticoagulant.
Control 1. Control 2.
Full Strength (3.12%). 393 256
Half Strength (1.56%) 972 266
Citrate only at 1.25%. 690 392
Citrate only at 1%. 650 495
Citrate at 1.56% and
0.2M MgCl^.
622 450
Samples were collected from two healthy controls, and results are
expressed as ng/ml.
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basophils contained in the samples,
e. Recalcification.
Whole blood was taken into full strength citrate as before, plasma
was removed, and the cell fraction resuspended to its original
volume with 0.1M calcium chloride (CaCl ). These were incubated at
37°C for either 4h or 24h and then centrifuged. Supernatant samples
were Pronase treated and assayed, giving levels of 200 and 240
ng/ml. Again it was clear that release had not occurred.
(4). Discussion.
The purpose of. the studies described in this section was to develop
further the assay of Dawes and Pepper (1982), and validate its use
in the detection and characterization of GAGs associated with human
basophilic leucocytes.
The assay was first improved by replacing protamine (used in the
original assay system) with Polybrene. This, covalently linked to
solid phase (Sepharose) bound the highly negatively charged
heparin-related GAG molecules with high affinity. Moreover, this
reagent, unlike protamine-Sepharose, was extremely stable which
greatly increased its shelf life (up to 9 months in aqueous
suspension at 4°C); in addition, it was not susceptible to
digestion with Pronase, which obviated the need for inactivation of
the Pronase used in sample pre-treatment. Standard heparin was
iodinated as described, and an example of the curve obtained with
the assay of standard heparin is shown in Figure 2. The stability
and reproducibility of the assay was increased by including BSA
buffer or DMSO (50% by volume) in all tubes. The addition of fresh
plasma to standard heparin caused no interference in the assay,
even with 24h incubation at 37°C before assay. Similar dilution
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curves were obtained from plasma samples of patients receiving
commercial heparin for therapeutic purposes (Figure 3), and
predigestion with Pronase was not required for its detection. This
could be regarded as 'in vivo' addition of heparin to plasma, and
the detection of this added exogenous material was in no way
altered by its incubation in plasma.
The assay of naturally occurring endogenous GAG was less straight
forward. Firstly predigestion of samples with Pronase was
essential, since naturally occurring GAGs were bound to a variety
of proteins in vivo, and the assay was subject to interference from
these proteins. It was not possible to measure material from
untreated biological samples, but predigestion with Pronase yielded
material which was readily assayed. However, the levels of GAG
detected were low, and dilution curves, where measureable, were not
parallel with that of standard heparin (Figure 4).
The most important factor influencing the binding affinity of a GAG
to Polybrene is its degree of sulphation. The greater the degree of
sulphation of a GAG, the greater its capacity to compete for
binding sites. Since heparin is very highly sulphated, it had the
greatest affinity for Polybrene of the GAGs tested. Less sulphated
GAGs will compete less effectively with standard radiolabelled
heparin, and will therefore appear to be present in lower
concentrations than they actually are. It was therefore necessary
to develop a system using a standard GAG and tracer as similar as
possible to the GAG naturally occurring in biological samples. The
appropriate assay system was achieved by replacing the heparin
125standard in the original assay with Opocrin and I-heparin tracer
125
with I-heparan sulphate tracer. Dilution curves of Pronase
treated plasma were parallel to the standard curve obtained using
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this new system (Figure 5a), although in the presence of DMSO
binding was severely reduced (Figure 5b). DMSO is thought to affect
hydrophobic interactions. The structure of heparin is such that
hydrophobic bonding is much less important than in less sulphated
structures such as heparan sulphate molecules. The use of DMSO in
the assay system will therefore discriminate between these GAGs and
will not allow the detection of less sulphated GAGs (such as
heparan sulphate), which have lower binding affinities to begin
with. Using BSA buffer in place of DMSO, heparan sulphate-like
material was detected in biological samples. Dilution curves of
Pronase treated plasma were parallel with the standard curves of
two available heparan sulphate standards, Opocrin and Org 10172.
These two standards were compared, and correlation (Figure 6) was
good at high concentrations of the standards, to well after the mid
point (that is, the working area) of the curve. At lower
concentrations however, the correlation was slightly reduced,
probably due to slight differences in their degrees of sulphation.
Thus the use of either standard should produce similar results at
concentrations greater than 200ng/ml, and samples with levels below
this were not read. Opocrin was chosen as the heparan sulphate
standard for this study, and used consistently throughout.
The properties of this assay system were such that larger, highly
sulphated GAG molecules should be more readily assayed than smaller
molecules of low charge density. The various GAGs tested in this
assay behaved accordingly (Figure 7). The GAGs tested with a
similar degree of sulphation were heparan sulphate I, Opocrin,
dermatan sulphate, and an oversulphated chondroitin sulphate -
chondroitin sulphate E. The dilution curves of these GAGs were more
or less parallel to each other, and were measurable over a similar
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concentration range (approximately l-10u g/ml). The highly sulphated
heparin standard was assayed more readily than these, and its high
affinity for Polybrene and effective competition with the heparan
sulphate tracer produced a very steep dilution curve, measurable
over a much lower concentration range (approximately O.l-l^i g/ml).
At the other end of the scale, chondroitin 4-sulphate and
chondroitin 6-sulphate (differing only by the position of sulphate
substitution on galactosamine) gave a dilution curve with a shallow
slope, and were measurable only at concentrations of greater than
lmg/ml. On this basis therefore, the material detected in
biological samples could be heparan sulphate, chondroitin sulphate
E or dermatan sulphate. However, dermatan sulphate is mainly
restricted to connective tissue and is thought not to circulate in
peripheral blood in appreciable amounts; it therefore probably does
not constitute the GAG measured in this study. Studies to further
characterize the endogenous GAG detected are discussed in Chapter
3.
Doubling dilutions of human plasma, human serum and supernatants of
freeze/thaw preparations (that is, lysed whole blood with the
membrane fraction removed) all produced curves parallel to standard
Opocrin. However, at the lower concentrations stability was reduced
and reproducibility was poor. Factors contributing to this
interference were removed by precipitation, since reassay of
samples after freezing to -20°C increased the sensitivity, and was
a useful step to ensure minimal background interference.
Repeat assays of aliquoted samples frozen/thawed only once produced
reproducible results (r=0.98), but repeated freeze/thaw of
individual samples increased the levels detected. Moreover, the
levels increased more with each freeze/thaw. This was probably due
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to the structural characteristics of the molecules assayed. GAGs
are found in covalent association with proteins to form
proteoglycans (Lindahl and Hook, 1978).
Pronase digestion releases the individual side chains, each
representing 1 heparan sulphate equivalent in the assay. Repeated
freeze/thaw of the Pronase digests may have caused, further
breakdown of the chains, resulting in many smaller GAG units, each
with the capacity to bind to Polybrene, and thus increasing the
apparent content of GAG in the sample. This view is supported by
the finding that overnight incubation of the Pronase treated
samples at room temperature produced the same effect as this
freeze/thaw process (Table 3). Endoglycosidases contained in the
sample may act during this long incubation period and cleave the
carbohydrate backbone in the same way as the freeze/thaw procedure,
increasing the apparent GAG content. Care was therefore needed to
ensure that all biological samples were frozen/thawed as
infrequently as possible, and the incubation period of the assay
was minimal (3h).
GAGs are present in the connective tissue of mammals (Comper and
Laurent 1978; Mathews 1975), on cell surfaces (Kraemer 1971a;
Kraemer 1971b; Kjellen et al 1980) and in circulating basophilic
leucocytes (Hakomori 1965; Olsson et al 1970). In an attempt to
measure the total content of endogenous GAG in peripheral whole
peptide core. Pronase Repeated Freeze/thaw
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blood (that is, plasma content plus GAG within circulating blood
cells), whole blood lysates were prepared and assayed. A solution
containing the detergent Triton X-100 was used to dissolve
membranes and release GAG molecules contained in blood cells. The
material detected in these lysates was not directly comparable with
the material measured in plasma, or with standard Opocrin (Figure
9). Since large amounts of protein as well as membrane fractions
were present in these samples, it was not altogether surprising
that some interference in this sensitive assay system occurred.
Removal of the membrane fractions after cell lysis (with the
freeze/thaw method) eliminated this interference (Figure 10), and
confirmed that the interfering factors were contained in the
membranes. Freeze/thaw supernatants contained material with a
similar degree of sulphation to that contained in plasma, serum and
standard Opocrin, and may therefore be classed as heparan sulphate
or chondroitin sulphate E as before. The material detected in the
resuspended cell pellet fraction however, behaved in the same way
as Triton X-100 lysates in the assay, and was therefore not
comparable with standard Opocrin. The amount of GAG detected in the
supernatants from such preparations was relatively low
(125-800ng/ml), and did not exceed that in serum (860-3850ng/ml).
Moreover, there was high variation with different preparations, and
between preparations obtained from the same donor. This method was
therefore not appropriate for the determination of total GAG
contained in whole blood samples. It was however useful in
identifying the exact location of the interfering components in
Triton X-100 lysates.
Most chondroitin sulphate molecules (with the exception of
chondroitin sulphate E and other variants found in non-mammalian
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species), have relatively low degrees of sulphation, and therefore
produce a dilution curve with a more horizontal slope in the assay
(Figure 7). Since Triton X-100 lysate dilution curves are also
relatively horizontal, the possibility that chondroitin sulphate
was being detected in these samples was tested (Figure 11). The
digestion of chondroitin 4-sulphate by chondroitinase ABC was not
impaired in the presence of Triton X-100 (Figure 11a), and
chondroitin sulphates naturally occurring in Triton X-100 lysates
would therefore have been readily degraded with this treatment.
Chondroitinase ABC reduced the apparent concentration of GAG in the
lysate samples to some extent, but dilution curves of lysate
digests remained non-parallel with standard Opocrin (Figure lib).
This partial loss of assayed material indicates that chondroitin
sulphates contained in Triton X-100 lysate samples may have caused
some, but not all, the interference detected from these samples in
the assay. The majority of the interference was still present after
chondroitinase ABC digestion.
Membranes consist mainly of proteins and lipids, and these
components were abundant in Triton X-100 lysate samples.
Heparin-like polysaccharides have been found to bind directly with
lipoproteins contained in whole blood, to form insoluble complexes
(Srinivasan et al 1970; Srinivasan et al 1975). Moreover, heparan
sulphate is thought to be an essential component of the
lipoprotein-lipase binding site of endothelial cell surfaces
(Shimada et al 1981; Cheng et al 1981). Lipoproteins bound to GAGs
may alter their response in the assay, and this possibility was
tested by the removal of lipoprotein from samples by digestion with
lipoprotein lipase. Triton X-100 lysate samples treated with this
enzyme did not differ from untreated lysate samples when assayed
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(Figure 12). Membrane lipids include glycolipids, cholesterol and
most abundant are phospholipids. Removal of the phospholipid
component in Triton X-100 lysate samples was obtained by digestion
with phospholipase C (Figure 13). GAG detected in the lysate
samples treated in this way was readily assayed with dilution
curves parallel to standard Opocrin; a strong indication that the
material detected was similar to that of other biological samples
tested. Predigestion of Triton X-100 samples with phospholipase C
eliminated much of the interference in the assay. The interfering
nature of the phospholipids dissolved in the lysate samples may be
explained by their direct binding with GAGs, reducing their
Polybrene binding affinity. Moreover, the structure of
phospholipids is such ,tbat direct competition with free GAG





Basic structure of phospholipids.
Predigestion of lysate samples with phospholipase C introduced a
further pretreatment stage, and reproducibility of individual
samples in the assay was poor. It was also an expensive
pretreatment and therefore was not appropriate for routine use;
methods were tested which allowed the total release of GAG from
cells, and also removed the interfering components.
The dilution of whole blood samples with Tween 20 followed by
centrifugation effectively removed the interfering components
(Figure 14), but did not allow the detection of total GAG. This
problem was encountered with all methods involving removal of
membrane fractions before assay, and attempts to resolve it were
the subject of much time and effort, though ultimately ineffective.
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Much of the cellular GAG must therefore be contained in, or bound
to the membrane component, and some of this is apparently released
on clotting. Alternative methods were unsuccessful for similar
reasons, and due to lack of time, this problem remained unresolved.
Nevertheless, the importance of such values was not ignored, and
where necessary, alternative values were used to demonstrate the
magnitude of a response. This is discussed in greater detail, and
is applied mostly to Chapter 6.
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Chapter 2.
(2:2). Measurement of Histamine.
(1). Introduction.
Histamine (6 -imidazolylethylamine) is a low molecular weight
(111.11) biogenic amine, commonly present in the tissues of mammals
and other animals. It is synthesised in mast cells and basophils
from L-histidine by the action of L-histidine decarboxylase (Figure
A), (Schayer 1963; Galli and Dvorak 1975; Galli et al 1976). This
reaction requires pyridoxal-5-phosphate as a cofactor.
FigureA.
H-C=C-CH -C-COOH Histidine decarboxylase H-C=C-CH0-CH0-NH0
I I 2| > I I 2 2 2




After synthesis, histamine is thought to be largely confined to the
secretory granules of mast cells (Anderson and Uvnas 1975) and
basophils (Pruzansky and Patterson 1967), where it associates by
ionic interaction with acidic groups of glycosaminoglycans and/or
proteins (Uvnas et al 1970). Normal mast cells generally contain
0
more histamine (l-15(i g/10 cells), (Patterson et al 1976; Schwartz
0
and Austen 1981), than basophils (l-3u g/10 cells),(Ishizaka et al
1983; MacGlashan and Lichtenstein 1980), although this varies
considerably depending on the maturation, nutrition and activation
history of the cells.
Nearly all tissues can catabolise histamine (Schayer and Reilly,
1974) and under normal conditions it is metabolised slowly with an
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intracellular half-life of approximately 50 days (Schayer 1952). In
man, the catabolic route usually involves methylation by
histamine-N-methyltransferase to form l-methyl-4-(6 -aminoethyl)
-imidazole (methylhistamine), which is then deaminated to























Alternatively, (Figure C), histamine is oxidized to imidazole-4,
5-acetic acid by diamine oxidase (histaminase), which is then




HC==C-CH -CH_-NH„ (histaminase) HC=C-CHo-C00H
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The biologic response to histamine in the body is mediated by its
binding to, and activation of, two different types of tissue or
cell receptor, designated (Ash and Schild 1966) and (Black et
al 1972). The ratio of distribution of these receptors in various
organs in the body is not constant (Black et al 1972; Chand and
Eyre 1975), but in general contraction of bronchial and
gastrointestinal smooth muscle and enhancement of the inflammatory
reaction occur via H receptors, whereas stimulation of gastric
acid secretion by parietal cells and inhibition of the inflammatory
reaction are receptor mediated (Lichtenstein 1976). Moreover,
the stimulation of the two receptor types generally causes
antagonistic effects (Brimble and Wallis 1973; Turker 1973).
Histamine can regulate the IgE-mediated release of materials from
human basophils (Lichtenstein and Gillespie 1973; Lichtenstein and
Gillespie 1975; Lichtenstein 1976) and lung tissue (Chakravarty
1959), as well as lysosomal enzyme release from neutrophils (Zurier
et al 1974). It also modulates the function of certain
thymus-derived lymphocytes (Lichtenstein 1976; Plaut et al 1974;
Roszkowski et al 1977), via receptors contained on the surface
of these cell types. Both and receptors on the surface of
eosinophils and neutrophils are under the control of histamine, and
this regulates migration of the cells in tissues (Clark et al
1975). Thus histamine is essential to the regulation of the
inflammatory process.
Histamine may be measured by several techniques. These include:
a. Biological assays, using isolated organs such as the cat or
guinea pig terminal ileum in organ bath (Austen 1976), which are
very laborious and non-specific, but are however very sensitive.
b. Colorimetric assays following treatment with a diazonium salt
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(Rosenthal and Tabor 1948) or dinitrofluorobenzene (Mclntire et al
1950; Lowry et al 1954), which are very insensitive.
c. Radioenzymatic assay (Snyder and Taylor 1976), which is specific
and sensitive, but requires a very demanding and difficult pig
brain enzyme extraction.
d. Fluorometric method (Shore 1976), which requires the separation
or extraction of the histamine from samples, but is sensitive and
precise.
This fluorometric method was originally described by Shore et al
(1959), and has since been improved to increase both specificity
and sensitivity (Redlich and Ulick 1969; Hakanson et al 1972; Shore
1976). The method is based on the coupling of histamine to
o-phthalaldehyde (OPT) .at a highly alkaline pH to form a




CHO HC HC CH„
/ A / \ /
HC-CH HC=C-CH -CH„—NH„ HC C C=C
I \ I I 2 2 2 > I II I I
HC C-CHO + HN N HC C N N
\ / \//
HC=CH HC HC HC HC
o-phthalaldehyde Histamine OPT-histamine fluorophore
Some compounds are known to contribute to the fluorescence observed
in the final o-phthalaldehyde reaction (Shore 1971; Siraganian
1974), resulting in falsely elevated values for histamine
concentrations. These interfering substances include spermidine,
spermine, histidine, arginine, histidyl-histidine, agmatine,
reduced glutathione and ammonia at concentrations of greater than
4y g/ml (Lorenz et al 1970; Shore et al 1959). This problem is
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eliminated by the extraction procedure, since approximately 85-92%
of available histamine was extracted into the n-butanol (Shore et
al 1959) while all other amines remained in the aqueous phase. The
histamine was then returned to the aqueous phase, and condensed
with OPT in a strongly alkaline solution. The resulting fluorescent
product was rather labile, but stability was increased (for up to 1
hour) upon acidification. The formation of the histamine-OPT
fluorophore has very specific structural requirements, since
alkylation of either of the nitrogen atoms of the imidazole ring or
side chain of the histamine molecule inhibits the reaction. The
fluorescence intensity of the fluorophore is directly proportional
to the histamine concentration over the range 5.0-500ng/ml (Shore
et al 1959).
The fluorescence of the histamine-o-phthalaldehyde complex has
greater stability and intensity than the complex formed by some
other amines. The extraction and assay of histamine by this method
is precise, sensitive to concentrations as low as 5ng/ml, and is
specific for the quantitative estimation of histamine in body
fluids and tissues.
(2). Materials and Methods.
Materials.
Reagents.
Methanol 'AnalaR'(Product code 101586B), n-butanol 'AnalaR'(Product
code 100616J), n-heptane 'AnalaR'(Product code 103636C), and
perchloric acid 60% 'AnalaR'(Product code 101754W) were all
purchased from BDH Chemicals Ltd, Poole, Dorset, England. Histamine
dihydrochloride, (crystalline; Product No H7250), o-phthalaldehyde
(Product No P0657) and phosphoric acid (Product No P7891) were
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purchased from Sigma Chemical Co Ltd, Dorset, England.
OPT Reagent.
lOmg of recrystallised o-phthalaldehyde was dissolved in 5ml of
methanol, to obtain a solution of 0.2% (w/v). This methanolic
solution was stable for approximately two weeks when kept
refrigerated in a dark bottle. However, to ensure maximum accuracy,
this reagent was made as required.
Methods.
Preparation of Biological Samples.
Protein was removed from samples by perchloric acid precipitation
prior to the extraction steps. To 1ml volumes of sample, 0.2ml of
8% perchloric acid was added. These samples were thoroughly mixed,
incubated at 37°C for 30 min and then centrifuged (250g; 4°C;
15min), and supernatants retained. The dilution factor introduced
at this stage was accounted for when calculating histamine content
in each sample.
Extraction of Histamine from Biological Samples.
lml volumes of perchloric acid treated samples were transferred
into 15ml screw-cap glass culture tubes (13 x 100mm with
Teflon-lined cap), containing 300mg of NaCl and 1.25ml of
n-butanol. To each of these tubes, 0.1ml of 3N NaOH was quickly
added and thoroughly mixed for at least 1 min to extract the
histamine into the butanol. The tubes were then centrifuged (llOg;
4°C; lOmin). lml of the butanol (top) layer was removed from each
tube, and transferred to a 15ml screw cap glass tube containing
1.9ml of n-heptane, and 0.6ml of 0.12N HC1 before shaking for at
least Imin, and leaving to stand for approximately lOmin to allow
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for the clear separation of the two phases. 0.5ml of the aqueous
phase (bottom layer) was carefully removed from each tube, ensuring
that none of the organic phase was transferred at the same time.
These samples were then assayed fluorometrically as described
below.
Histamine Standards.
A stock solution containing 10p g/ml of histamine dihydrochloride
was prepared, using 0.12N HC1 as the diluent, and stored in 0.5ml
aliquots at -20°C. Standards containing 1, 0.5, 0.25, 0.1, 0.05,
0.025 and O.Olu g/ml in 0.12N HC1 formed the standard curve. Blank
control samples (containing 0.12N HC1 only) and quality control
samples (containing 40 and 80 ng/ml of histamine dihydrochloride
were included in each assay.
All standards and samples were prepared for assay in duplicate.
Fluorometric Assay.
To all tubes, containing 0.5ml of standard or sample, 0.1ml of IN
NaOH was added to provide the strongly alkaline conditions required
for the condensation of histamine with OPT. This was followed by
the addition of 25y 1 of OPT, thorough mixing, and transfer to an
ice bath (approximately 4°C). The reaction was allowed to proceed
for 40min and was stopped by adding 50ul of 2M phosphoric acid
(H^PO^) to each tube. The tubes were thoroughly mixed and allowed
to equilibrate to room temperature for approximately 15min before
reading on a Perkin Elmer Fluorescence Spectrometer with an
activation wavelength of 363nm and a fluorescence wavelength of
468nm.
Reversed blanks were used to ensure there was no non specific
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binding of histamine with OPT under less alkaline conditions. These
were prepared by adding 25p 1 of 2M H^PO^ to control tubes, before
the fluorescent label.
(3). Results.
Measurement of histamine standard.
Histamine dihydrochloride was diluted in 0.12N HC1, and a typical
standard curve is shown in Figure 1. Histamine dihydrochloride
standards were assayed, diluted in plasma and Tris ACM buffer
(diluent for cell suspensions in release studies; Chapter 6), and
compared with the normal standard diluent of HC1, to determine any
interference they may cause in the assay. All standard curves
produced were identical.
Effect of perchloric acid on histamine standard.
Histamine dihydrochloride standards were assayed, diluted in 1.5%
and 3% perchloric acid solutions. Using 1.5% perchloric acid as the
assay diluent produced a curve similar to that of the standard,
whereas 3% perchloric acid significantly reduced the fluorescence
of the OPT-histamine complex (Figure 2).
Measurement of Histamine in Biological Samples.
The histamine content in each of the biological test and control
samples, was determined by direct comparison with the standard
curve to give mass histamine (values of histamine
dihydrochloride/ml). This value was then converted to true
















Figure 2: Effect of Perchloric Acid on Histamine Standard Curve.
Using 1.5% perchloric acid as assay diluent did not affect
the standard histamine, whereas 3% perchloric acid
significantly reduced the fluoresence of the OPT-histamine
fluorophore.
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Molecular weight of histamine = 111.11.
Molecular weight of histamine dihydrochloride = 184.11.
Histamine moiety in sample = Mass histamine x 111.11 ng/ml.
184.11
= Mass histamine x 0.603 ng/ml.
The intra-assay Coefficient of Variation (CV) for quality control
samples containing 40 and 80 ng/ml of histamine dihydrochloride was
10.7% and 10.3% respectively. The inter-assay CV for samples
containing 25 and 75ng/ml of histamine dihydrochloride was 10.6%
and 12.9% respectively.
Activation and Fluorescence Spectra of the OPT Fluorophore.
The activation and fluorescence spectra of the OPT fluorophore were
determined by testing its'fluorescence on variable activation and
excitation wavelengths, using a scanning fluorometer (Figures 3a
and 3b).
a. Activation of fluorophore.
The exitation or fluorescence monochromator of the scanning
fluorometer was set at 450nm, and the spectrum from the activating
monochromator was scanned between 300 and 400nm. Figure 3a shows
the spectrum obtained; maximum activation of this fluorophore
occurs at 350nm.
b. Fluorescence (or exitation) of fluorophore.
The activating monochromator was set at 350nm, and the spectrum
from the excitation monochromator was scanned between 300 and
600nm. Figure 3b shows the spectrum obtained, with maximum
fluorescence at 450nm.
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Figure 3a: Spectrum of Activation of Fluorophore.
The maximum activation of the OPT—histamine fluorophore
occurred at 350nm.
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Figure__3b: Spectrum of Fluorescence (or Excitation) of Fluorophore.
The maximum fluorescence or excitation of the OPT-histamine
fluorophore occurred at 450nm.
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Th is procedure was repeated using a sample containing a large
concentration of histamine (95ng/ml). The peaks obtained for both
spectra occurred at the same wavelength as those of the standard
histamine-OPT fluorophore. The activation and fluorescence spectra
of the OPT fluorophore used in this assay (Figures 3a and 3b)
produced the same pattern as those originally obtained by Bowman et
al (1955).
% Efficiency at Filter Wavelengths.
The Perkin Elmer Fluorescence Spectrometer used to determine
fluorescence routinely had fixed wavelength filters of 363nm
(activation), and 468nm (fluorescence). Since these were not the
wavelengths at which maximum emission of the fluorophore occurred,
the efficiency of these filters (expressed as % maximum) was
determined, using the activation and fluorescence spectra as
follows:-
a. Activation wavelength efficiency.
Activation wavelength efficiency = Emission at 363nm x 100
Emission at 350nm
= 215.1 x 100
225.0
= 95.6% of maximum.
b. Fluorescence wavelength efficiency.
Fluorescence wavelength efficiency = Emission at 468nm x 100
Emission at 450nm
= 82.8 x 100
86.5
= 95.7% of maximum.
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(4). Discussion.
It is generally accepted that in humans all blood histamine is
associated with basophils (Erlich 1953; Graham et al 1955;
Valentine et al 1955) and is confined largely to their specific
cytoplasmic granules. Studies on basophil degranulation have
revealed that nearly all this histamine is released on
immunological stimulation (Lichtenstein 1968). Using the
fluorometric method for the detection of histamine, the total
histamine content of whole blood was found to be 83ng/ml
(SD=2.45ng/ml; range=32.4-173.5ng/ml), and histamine release from
whole blood correlates with its release from washed leucocyte
preparations (r=0.93) (Siraganian and Brodsky 1976). On the basis
of these observations, the fluorometric assay was utilised for the
study of histamine release from basophil enriched fractions of
whole blood (Chapter 6). Although the sensitivity of this assay is
not sufficient to detect plasma histamine levels, it is
nevertheless adequate for the requirements of this study. Using a
more sensitive enzymatic method for histamine determination in
human plasma, the average normal concentration was found to be
0.69ng/ml, SD=0.26ng/ml (Lorenz et al 1972). However, widely
discrepant results were revealed by a survey of 19 laboratories,
using similar methods for the detection of histamine in human
plasma (Gleich and Hull 1980). The levels of histamine in plasma
are very low, and therefore difficult to determine accurately.
Moreover, there may be rapid fluctuation due to the influence of
many external factors including cold, and physical stimuli such as
exercise. As the interpretation of plasma levels is open to
question, no attempt was made to increase the sensitivity of this
assay for the detection of histamine in plasma.
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The manual extraction and assay of histamine by the fluorometric
method is accurate and sensitive for the determination of this
biologically active molecule over the range 5.0-500ng/ml (Shore
1959). It was necessary to remove protein from samples, and the
standard method of perchloric acid precipitation (Siraganian and
Hook 1976b) was used. Samples were therefore pretreated by diluting
5:1 (vol sample/vol acid) with a solution of 8% perchloric acid,
and centrifuging to remove precipitates. Histamine standards did
not contain significant amounts of protein to warrant this
pretreatment, but any interference it may cause was tested on the
standard curve. Final concentrations of 1.5% perchloric acid or
less did not interfere with fluorescence of the fluorophore formed
by standard histamine. This was important, since the final
concentration of perchloric acid used to treat the biological
samples was 1.33%, and it was therefore concluded that this
pretreatment did not interfere with measurement of the histamine
contained in samples.
Since the OPT reagent is itself fluorescent, its contribution to
the final fluorescence obtained from samples after assay was
determined in each assay, by using reversed blanks as controls. In
these control samples, the condensation step was inhibited by
introducing acid conditions before the addition of OPT. Reagent
blanks were used as a second internal control for each assay, and
if values obtained from these tubes were more than 10% higher than
the reversed blanks, the assay was considered invalid.
The fluorescent and exitation ability of the fluorophore produced
by the biologically occurring histamine was studied and compared
with that of standard histamine. The fluorescence and exitation
spectra obtained from both samples were identical, validating the
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use of this standard, for quantitation of the histamine naturally
occurring in biological samples. The filters used to determine the
fluorescence of standards and samples in each assay were not of the
wavelengths at which maximum fluorescence and emission of the
fluorophore occurred. They were nevertheless able to detect
significant fluorescence with sufficient accuracy for this method,





Glycosaminoglycans (GAGs) are a ubiquitous component of mammalian
cells, mostly occurring as cell surface-associated proteoglycans
(Kraemer 1971a; Kraemer 1971b). GAGs are widely distributed in
animal tissues; different cell types and species synthesize and
contain different classes of GAG, and this has been the subject of
much research in recent years. Heparin is a possible constituent of
blood vessels (Haruki and Kirk 1964; Stevens et al 1977; Castellot
et al 1981), and has been reported to be present in circulating
blood (Eiber and Danishefsfty 1957; Horner 1974), and in plasma, but
is not freely available (Staprans and Felts 1985). However the
majority is associated with mast cells (Jorpes et al 1937; Straus
et al 1982). Heparin has been isolated from rat skin (Horner 1971)
and from rat peritoneum (Yurt et al 1977), and human tissue
(Metcalfe et al 1979; Metcalfe et al 1980), and it has been
proposed that all physiologically available heparin occurs
exclusively in the granules of these mast cells (Scully et al
1986). However, some mast cells contain other GAGs; cultured
purified rat peritoneal mast cells have been found to synthesize
proteoglycan with chondroitin sulphate side chains posessing large
amounts of N-acetylgalactosamine-4,6-disulphate (Czarnetzki and
Behrendt 1981; Stevens and Austen 1982;) rather than heparin.
Studies revealed that in these rodent mast cells, the chemical
composition of proteoglycan synthesized changes as the cells go
through a transition during maturation, from having GAGs of
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relatively low sulphation, comparable with chondroitin sulphate, to
highly sulphated GAGs, corresponding to heparin or chondroitin
sulphate E. Typically, mature mast cells grown from primary mouse
embryonic fibroblast monolayers were found to contain 20-40%
chondroitin sulphates, and 60-70% heparin (Bland et al 1982),
whereas cultured bone marrow-derived mucosal mouse mast cells
contained chondroitin sulphate E, but not heparin (Razin et al
1982).
The synthesis of GAG in mature serosal mast cells was found to be
influenced by the presence of p-nitrophenyl-B -D-xyloside (Stevens
and Austen 1982), which stimulated the production of chondroitin
sulphates A, C and E, as well as heparin. Moreover, preferential
synthesis of chondroitin sulphate in mouse mastocytoma cells,
normally synthesising both* chondroitin sulphate and heparin (Lewis
et al 1973) occurs in the presence of this xyloside (Robinson and
Lindahl 1981). In general the composition of GAG in serosal and
mucosal mast cells follow specific patterns, which may be altered
during cell maturation and chemical stimulation. The chemical
composition of the GAG synthesised in a particular mast cell is one
feature that has been used to define mast cell heterogeneity, and
various other differences observed between mast cells from the
mucosal surface and those present in the peritoneal cavity have
been well documented (Enerback 1981; Bienenstock et al 1982; Pearce
1983). The existence of these two mast cell subsets in rodents
highlight the similarities between mucosal mast cells and basophils
(Gleich et al 1986; Schwartz 1986), and has been discussed in
Chapter 1.
Differences between human intestinal mucosa and lung parenchyma
mast cells have not been detected by either morphologic or electron
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microscopic studies (Fox et al 1985), and Lichtenstein et al (1986)
have been unable to identify these two mast cell subsets in humans,
although human mast cells are heterogeneous (Schulman et al 1983;
Shanahan et al 1987). Mast cells in general have many biochemical
and morphological similarities with basophilic leucocytes, and are
thought to arise from the same progenitor (Zuker-Franklin 1980).
One common feature is in their staining properties, and it was
assumed that the GAG responsible for taking up the stain was the
same as in mast cells; heparin. However on the basis of
cytochemical studies, Hakomori (1965) studied this further and
suggested that hyaluronic acid, heparin or heparan sulphate is
present in granules of these cells. Later Olsson et al (1970)
demonstrated the presence of a heparin-like substance in human
basophilic leucocytes. * Material was classed as being
'heparin-like', as it contained both sulphate and glucosamine
residues, and was resistant to degradation by hyaluronidase, but
sensitive to heparinase. A second class of GAG was also detected
which contained galactosamine residues, and was classed as
chondroitin sulphate. However, density gradient centrifugation
revealed that only the heparin-like substance followed the
distribution of basophils. These data, and earlier reports of the
presence of chondroitin sulphate in neutrophilic granulocytes
(Olsson and Gardell 1967), indicated that chondroitin sulphate may
be present in various blood cell types, but that heparin-like GAG
was exclusively contained in basophilic leucocytes.
Recent reports of GAG isolated from basophils, have been of
chondroitin monosulphates or oversulphated chondroitin sulphate E
(Metcalfe et al 1984; Seldin et al 1986; Rothenberg et al 1987),
and the glucosamine/sulphate rich moiety isolated by Olsson et al
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(1970) seems to have been ignored. The aim of the studies described
in this chapter was to determine the cellular location and
biochemical nature of GAG contained in whole blood.
(3:2). Materials and Methods.
Materials.
Reagents.
Human serum albumin was purchased from KabiVitrum Ltd, London, UK,
and hydroxychloroquine sulphate from Sterling-Winthrop,
Surbiton-upon -Thames, Surrey, UK. Lymphoprep and Ficoll-metrizoate
were purchased from Nyegaard, Oslo, Norway, and Dextran T-500 from
Pharmacia (GB Ltd), Milton Keynes, England. Fractogel TSK HW 55(F)
was purchased from Merck, Darmstadt. Benzamidine hydrochloride
(Product no B6506), 6-aminohexanoic acid (E-amino-n-caproic acid;
Product no A2504), heparitinase (Product no H6512) and
chondroitinase ABC (Product no C2905) were all purchased from Sigma
Chemical Company Ltd, Dorset, England.
Buffers.
Tris A.
This buffer was first used in studies with leucocytes by




0.3mg/ml human serum albumin.
This was adjusted to pH 7.6 at room temperature with IN HC1.
Washing buffer.
This consisted of Tris A buffer with hydroxychloroquine added to a
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concentration of 5mM.
Moore and James Counting Stain.
This consisted of:
40ml 0.05% Toluidine blue in 0.85% NaCl.
11ml 95% Ethyl alcohol.
lml Saturated solution of saponin in 50% ethyl alcohol.
Fractogel buffer.
This consisted of:
0.05M Phosphate buffer (pH 7.4).
0.2M NaCl.




3mM Sodium azide, (NaN^).
This was adjusted to pH 6.7 at room temperature with IN HC1.
Methods.
Blood Fractionation Methods
Cellular fractions from whole blood were obtained by density
gradient centrifugation, and these were performed by Dr IR
MacGregor. The methods used were as follows.
Basophils.
Basophils were separated from peripheral blood based on the method
of Day (1972). Whole blood was taken into ETP anticoagulant
(described in Chapter 2), in an ice bath, and 10ml of
anticoagulated blood mixed with 10ml of 0.9% w/v NaCl, and layered
over 10ml Lymphoprep in a polycarbonate centrifuge tube. After
centrifugation with a swing out head (400g at the interface; 30
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min; room temperature), supernatant down to 2mm from the red cell
pellet was removed, mixed gently, and layered over cold buffered
Ficoll-metrizoate solution with a density (d) of 1.065g/ml.
Hydroxychloroquine was added to all density solutions at a final
concentration of 5mM to stabilise cell membranes, and thereby
reduce release reactions during fractionation. The tube was
centrifuged (400g; 15min; room temperature) and the platelet-plasma
layer and the separating fluid (down to the cell pellet) was
removed and discarded. The basophil-enriched cell pellet was
resuspended in washing buffer, and after centrifugation (lOOg;
5min; room temperature) the supernatant was removed, and the cell
pellet resuspended in 2.5ml of Ficoll-metrizoate with d=1.085. A
gradient was formed using this and an equal volume of buffer with
d=1.065 in an 8ml centrifuge tube, and centrifuged at 3800g for
30min. Acceleration and deceleration were controlled manually over
5min periods. The supernatant was removed and the pellet was washed
twice in washing buffer at lOOg for 5min, before final resuspension
in 1ml washing buffer. Cell counts were performed using the stain
of Moore and James and counted in a Neubauer haemocytometer
counting chamber.
Platelets and Erythrocytes.
A 6ml sample of ETP anticoagulated whole blood was centrifuged at
120g for 15min at 4°C. Supernatant platelet-rich plasma (PRP) was
removed and centrifuged at 4800g for 15min at 4°C; this pellet was
resuspended in 6ml of washing buffer and centrifuged at 2000g for
15min at 4°C. The platelet pellet was finally resuspended in 2ml
washing buffer.
The red blood cell pellet retained from the initial centrifugation
stage, plus trapped plasma, was resuspended in washing buffer, and
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centrifuged (4800g; 15min; 4°C). Plasma supernatant was removed,
and the red cell pellet resuspended in 6ml of washing buffer and
centrifuged (2000g; 15min; 4°C). The cell pellet was finally
resuspended in 10ml of washing buffer.
Lymphocytes.
A 9ml sample of ETP anticoagulated blood was diluted with an equal
volume of 0.9% (w/v) NaCl solution at room temperature, and layered
on 9ml of Lymphoprep and centrifuged (800g; 15min; room
temperature). Cells at the interface were carefully removed with a
Pasteur pipette, without removing the upper layer. 7ml of cell
suspension was carefully mixed with 21ml of washing buffer and then
centrifuged at 80g for lOmin at room temperature. Supernatant was
removed and the pellet resuspended in 20ml of washing buffer,
centrifuged (80g; lOmin; room temperature) and the pellet finally
resuspended in 1ml of washing buffer.
Eosinophils and Neutrophils.
The residual red cell-granulocyte pellet from the lymphocyte
preparation procedure was resuspended in 1ml EDTA (0.01M) plasma,
with 0.4ml of 4.5% (w/v) Dextran T500 in 0.9% (w/v) NaCl solution
and kept at 4°C for 3h. Supernatant fluid was removed (0.75ml), and
half was layered over 4ml of Ficoll-metrizoate (in distilled water)
with a density of 1.195. The remaining supernatant was layered over
4ml of Ficoll-metrizoate with density of 1.148. Both tubes were
centrifuged at 400g for 40min at room temperature. The cell
pellets, eosinophils for light solvent and neutrophils for dense
solvent, were resuspended in 5ml of washing buffer and centrifuged
(lOOg; lOmin; room temperature), then resuspended in 1ml of washing
buffer. Since a good pellet of neutrophils at d=1.195 was not
obtained, the supernatant of d=1.148 was diluted, centrifuged, and
this pellet used.
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Basophil enriched fractions from peripheral blood.
Basophil enriched fractions from whole blood samples were prepared
essentially as described by Siraganian and Hook (1976b). From each
individual studied, 40ml of whole blood was taken into 7ml of 2.14%
clinical grade Dextran/4.29% dextrose,(w/v)/0.025M EDTA. This was
divided equally between two 50ml plastic tubes, which were then
placed at an angle of 45°, and allowed to settle for 90min. All
subsequent steps were performed at 4°C. Supernatant leucocyte-rich
plasma from both samples were carefully withdrawn using a Pasteur
pipette, and pooled in a 50ml plastic centrifuge tube. Since
basophils were contained in the sediment just above the red cell
layer, some of the red cell layer was removed with the plasma, to
ensure maximum recovery of basophils. The supernatant plasma was
then centrifuged (llOg; 15min; 4°C), supernatant removed and the
cell pellet resuspended in 0.01M phosphate buffer (pH 7.4)
containing 0.9% (w/v) NaCl. This was then centrifuged (llOg; 15min;
4°C). The supernatant was removed and the cell pellet resuspended






The cellular suspension was frozen to -20°C and thawed six times,
and then dialysed overnight to remove NaCl, with two 1 litre





The dialysate was then centrifuged to remove cell debris (10,000g;
30min; 4°C). The supernatant was carefully removed and prepared for
loading onto columns. An internal marker was added to each sample,
in the form of control heparin tracer (at lOng/ml). Glucose was
also added (at lOmg/ml) both as an indicator of the column bed
volume, and to increase the density of the sample to allow
efficient layering on the column.
Determination of Molecular Weight of Glycosaminoglycan.
The molecular size distribution of GAG in samples was compared with
125
that of I-heparin, by gel filtration using Fractogel TSKHW-55(F)
(150mls) decanted into a 1.6cm x 100cm glass column (Column
C16/100; Pharmacia) containing a fixed porous plate. The gel was
washed thoroughly with fractogel buffer; immediately before use,
the buffer was drained to the interface in the column, carefully
ensuring that all the gel was covered. The prepared sample was then
layered over the interface without disturbing the packed gel.
Fractogel buffer was then carefully layered over the sample, until
the column was completely filled. The column was eluted with 200ml
of fractogel buffer, and 40 fractions of 5ml volume were collected
at room temperature overnight, in 13mmxl00mm glass disposable
culture tubes (Corning) using a Frac-100 fraction collector
(Pharmacia, Milton Keynes, England). Each fraction was counted on a
NE 1600 y -counter to detect the heparin tracer marker. Each
fraction was also tested for the presence of glucose using BM test
strips (BM Test-7; Cat no 290238, Boehringer Co, East Sussex,
England). A sample of each fraction was then treated with Pronase
(5mg/ml), and assayed for GAG as described in Chapter 2:1, to
determine its elution position.
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Determination of Degree of Sulphation of Glycosaminoglycan.
The relative degree of sulphation of GAG in samples was compared
125
with that of I-heparin by the elution position obtained from a
column of Polybrene immobilised on epoxy-Sepharose 6B (Pharmacia)
according to the method described by MacGregor et al (1984), using
a gradient of 0-2M NaCl in citrate buffer.
Polybrene-Sepharose (25ml) was decanted into a 25mmxl50mm glass
column containing a fixed porous plate, and washed thoroughly with
citrate buffer. Prepared samples were layered onto the interface,
carefully ensuring the Polybrene-Sepharose was not disturbed.
Citrate buffer was then carefully layered over the sample, and 20
fractions of 5ml volume were collected. All the sample was eluted
at this stage, except for GAG-containing material which remained on
the column bound to Polybrene. A 0-2M NaCl gradient in citrate was
then used to elute GAGs from the column, and 60 fractions of 5ml
volume were collected over this range. A Frac-100 fraction
collector was used to collect these fractions overnight in
13mmxl00mm glass culture tubes, and each fraction was counted on a
NE 1600 y -counter to determine elution of the heparin tracer
marker, and tested for the presence of glucose as before. The salt
concentration in every fifth sample was measured
conductimetrically. NaCl was removed from these samples by
overnight dialysis in 5 litre volume of citrate buffer at 4°C. Each
dialysate was then treated with Pronase (5mg/ml), and assayed for
GAG as before.
Effect of Protease Digestion.
To assess the effect of proteases on GAG contained in samples,
Pronase was added to prepared samples (at 5mg/ml), and incubated
overnight at 37°C, before preparing and loading onto columns as
before.
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Effect of 8 -Elimination.
Prior to addition to column, the sample was treated with an equal
volume of 1M NaOH, overnight at 37°C. The sample was then prepared
and loaded onto the column as before.
Effect of Chondroitinase ABC Digestion.
The sample was prepared as previously described; chondroitinase ABC
was added at a final concentration of 0.2 units/ml, and incubated
at 37°C overnight. The sample was then prepared and loaded onto the
column as before. In control experiments to test the activity of
chondroitinase ABC, chondroitin 4-sulphate (lOmg/ml) was diluted in
normal human plasma, and treated with chondroitinase ABC (0.2
units/ml). The elution position of chondroitin 4-sulphate was
determined by measuring metachromasia with azure A (Lam et al
1976).
Effect of Heparitinase Digestion.
The sample was prepared as previously described, and dialysed
overnight in 0.25M sodium acetate containing 0.025M calcium acetate
(pH 6.8). Heparitinase was added to this dialysate at 0.5 units/ml,
and incubated at 30°C for at least 3h. After incubation, the sample
was prepared and loaded onto the column as before. In control
experiments to test the activity of heparitinase, Organon 10172
(lOmg/ml) was diluted in normal human plasma and treated with
heparitinase as described above.
Effect of Nitrous Acid Treatment.
Samples were added to 0.24M NaNO^ (final concentration) in 1.8M
acetic acid solution and adjusted to pH7 using Tris buffer and 4M




Cell fractions were isolated by the method of Day (1972), and Table
1 shows the cell count obtained in each preparation. Purity was
> 84% in each case. Each cell fraction lysate was assayed for GAG,
which was found to be mostly contained in the basophil fraction.
The small quantity detected in the lymphocyte fraction was probably
due to basophil contamination (Table 1).
Calculation of Molecular Weight of GAG.
The relative elution positions of a number of GAGs of known
molecular weight from the Fractogel TSKHW-55(F) column, using
125
I-heparin as an internal standard, were used to produce a
calibration curve (Figure 1). The molecular size distribution of
GAG in each experimental sample was compared with that of the
125
internal marker I-heparin in each elution profile, and using the
calibration curve, its molecular weight was measured.
The elution profile of the heparan sulphate standard is shown in
Figure 2, and using the calibration curve, its molecular weight was
estimated at approximately 40,000. The smaller second peak of
125
radioactivity detected in later fractions was due to unbound I.
The elution profile in Figure 3 illustrates that the material
contained in human basophils covered a wide range of molecular
weight, from over 500,000 to 2,300. This was repeated using
basophil fractions from two different individuals, and similar
results were obtained (Table 2).
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Table 1 Concentration of GAG in Various Fractions of Whole Blood
following Density Gradient Centrifugation.
Cell count/ml GAG HS equiv.
H g/10s cells
Erythrocytes 2.3 x 109 0.2
Platelets 146 x 106 0.2
Lymphocytes 4.3 x 106 6.96
Eosinophils 0.02 x 106
(84% eosinophils; 16% neutrophils)
0.39
Neutrophils 0.12 x 10 0.39
(84% neutrophils; 16% lymphocytes)
Basophils 0.23 x 10 243.3
















Fraction position in relation
to peak of heparin marker.
Figure 1. Calibration Curve.
The relative elution positions of a number of known
molecular weight GAGs from the Fractogel TSKHW-55(F)
125
column with I-heparin were used to form a standard
calibration curve.
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Figure 2. Elution profile from Fractogel TSKHW-55(F) of heparan
125
sulphate standard (Opocrin) (• •) and I-heparin
tracer (• •). The Opocrin eluted at a position













Figure 3. Elution profile from Fractogel TSKHW-55(F) of GAG
extracted from a basophil enriched fraction of whole
1 PS
blood (• •) and I-heparin tracer (• •). The sample
material had a wide range of high molecular weight GAGs,
from 2,300 to over 500,000.
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Table 2: Size of Basophil-Derived GAG.
Molecular Weight Range.
Individual 1 2,300 - > 500,000.
Individual 2 2,000 - 220,000.
Individual 3 2,500 - 270,000.
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Determination of Degree of Sulphation of GAG.
Heparan Sulphate Standard.
The NaCl concentration at which a GAG was eluted from the
Polybrene-Sepharose column, varied according to degree of
sulphation, and the relative degree of sulphation of GAG in each
sample was therefore determined by comparing its elution pattern
125
with that of the internal marker, I-heparin. The elution profile
in Figure 4 illustrates that the heparin control was displaced from
the Polybrene-Sepharose column when the concentration gradient
reached 1M NaCl. Less sulphated GAG molecules were contained in
earlier fractions, since they had lower affinities for Polybrene,
and therefore elution occurred at lower concentrations of NaCl.
Heparan sulphate standard "was eluted from the column over the
concentration range 0.6240.80M NaCl. The peak of radioactivity
125
detected in the first 20 fractions was due to unbound I.
GAG released from human basophils.
Material released from human basophils (taken from the same
individual as in Figure 3) was also contained in earlier fractions
than the heparin standard, and was eluted from the
Polybrene-Sepharose column over the concentration range 0.53-0.73M
NaCl (Figure 5).
This supported earlier findings (Chapter 2:1) that the material
contained in basophils was of a similar degree of sulphation to
that of heparan sulphate standard. This was repeated using basophil
fractions from two different individuals, and similar results were
obtained (Table 3).
GAG contained in human plasma.
40ml of citrated plasma was tested on the Polybrene-Sepharose

















Figure 4. Elution profile from the Polybrene-Sepharose column with
0-2M NaCl gradient (o o) of heparan sulphate standard
125
(•——•) and I-heparin (• •). Opocrin eluted at a
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Figure 5. Elution profile from the Polybrene—Sepharose column with
0-2M NaCl gradient (o o) of basophi1-derived GAG
125
(•—•) and I-heparin (• • ). Cell-derived material











Table 3: Degree of Sulphation of Basophil—Derived GAG.
Concentration of NaCl,
where peak elution occurs.
Individual 1 0.53M - 0.73M
Individual 2 0.54M - 0.73M
Individual 3 ' 0.52M - 0.72M
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in keeping with the findings of Chapter 2:1, that GAG contained in
plasma was of a similar degree of sulphation to that of heparan
sulphate.
Sequential Studies.
Basophil enriched fractions of whole blood were obtained from two
individuals at weekly intervals over periods of 3 and 4 weeks, to
detect any changes that may occur in the GAG contained in
basophils. All samples were tested for both size and degree of
sulphation and the results are shown in Table 4. In general,
material obtained was similar on each occasion, with the important
exception of the first sample taken from one individual. On this
occasion, the material obtained was identical to the heparin
standard, with molecular -weight of 12,000 (Figure 6a), and its
elution from the Polybrene-Sepharose column was identical with the
heparin standard at 1.0M NaCl (Figure 6b). When serial dilutions of
fraction 17 (from Figure 6a) were assayed, the resulting curve was
not parallel with the heparan sulphate standard (Figure 7a) , but
using the heparin assay (that is, in the presence of 50% DMSO), the
material was readily assayed and produced a dilution curve parallel
with the heparin standard (Figure 7b). It was concluded that on
this occasion, the material released from the basophils of this
individual was heparin rather than the larger, less sulphated GAG
detected on all other occasions.
Effect of Pronase on Size of GAG.
Figure 8 illustrates the elution profile of the same sample as that
in Figure 3 after digestion with Pronase. The material detected was
reduced to a mean molecular weight of 40,000.
-130-
Table 4a: Sequential Studies on the Size of Basophil-Derived GAG.
Molecular Weight Range of GAG.
Individual 1. Individual 2.
Week 1. 12,000 2,500 - 270,000
Week 2. < 2,000 - 220,000 < 2,000 - 500,000
Week 3. 22,000 - 250,000 2,000 - 270,000
Week 4. 25,000 - 250,000
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Table 4b: Sequential Studies on the Degree of Sulphation of
Basophil-Derived GAG.
NaCl Cone, at which peak elution occurred.
Individual 1. Individual 2.
Week 1. 0.97M - 1.03M 0.52M - 0.72M
Week 2. 0.54M - 0.73M 0.50M - 0.88M
Week 3. 0.50M - 0.73M 0.58M - 0.75M
Week 4. 0.44M - 0.75M
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Fraction Number.
Figure 6a Elution profile from the Fractogel TSKHW-55(F) column of
GAG extracted from basophils of an individual (• •) and
125
I-heparin (• •). On this occasion sample material


















Figure 6b Elution profile from the Polybrene-Sepharose column with
0-2M NaCl gradient (o o) of GAG extracted from
125
basophils of an individual (• •) and I-heparin
(• •). On this occasion, sample material eluted at an
identical NaCl concentration as the heparin standard.
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Opocrin ng
Figure 7a Serial dilutions of fraction 17 of Figure 6a were assayed
and compared with heparan sulphate standard. The
resulting curve was steeper than the Opocrin standard
curve, indicating that the sample GAG had a higher degree
of sulphation.
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Figure 7b Serial dilutions of fraction 17 of Figure 6a were assayed
in the presence of 50% DMSO, and compared with heparin
standard. The resulting curves were parallel, indicating
that sample material had a similar degree of sulphation














Figure 8. Elution profile from the Fractogel TSKHW-55(F) column of
the same sample used for Figure 3 after digestion with
125
Pronase (•—•) and I-heparin (• •). Pronase

















Figure 9. Elution profile from Fractogel TSKHW-55(F) column of the
same sample used for Figure 4 after digestion with
125
chondroitinase ABC (• •), and I-heparin (• •).
Much of the basophil-derived GAG was digested with this
treatment, and undegraded material represented components
of approximately 20,000 molecular weight.
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Table 5: Effect of Nitrous Acid Degradation on Basophil-Derived
GAG.
GAG n g.
Before treatment. After treatment.
Per ml blood. 9.4 3.3
Per 10 basophils. 188.0 66.0
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Effect of B -Elimination on GAG.
Size.
6 -elimination of material contained in the sample (of Figure 3),
caused a similar reduction in size as that of Pronase digestion;
the mean molecular weight of material detected after this treatment
was 40,000.
Degree of Sulphation.
After B -elimination, the basophil-derived material was eluted at
0.53-0.73M NaCl, similar to that of the untreated material of the
same sample which was eluted at 0.39-0.73M NaCl. The difference in
the lower limit of elution was probably due to the increased
affinity of the free polysaccharide chains for Polybrene-Sepharose.
Effect of Chondroitinase ABC Digestion on Size of GAG.
Figure 9 shows the elution profile from the Fractogel TSKHW-55(F)
column of the same sample as that in Figure 3 after digestion with
chondroitinase ABC. The material was reduced in concentration, and
the remaining undegraded material represented components of
approximately 20,000 molecular weight.
(3:4). Discussion.
The design of the assay for GAG used throughout these studies is
such that heparan sulphate, dermatan sulphate and oversulphated
chondroitin sulphate E were all measurable at 0.2-1.0 p g/ml, but it
was insensitive to chondroitin 4-sulphate and chondroitin
6-sulphate, as described in Chapter 2:1. Although heparin could
also be quantitated by this assay, it was easily distinguished from
the less sulphated GAGs by the slope of the dilution curve, and by
including 50% DMS0 in the assay it could be made specific for
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heparin. When plasma or any basophil-derived material was assayed
under these conditions, no heparin was detected; heparin is
therefore not a component of basophil proteoglycan. As the assay
response to chondroitin 4-sulphate and chondroitin 6-su.lphate was
poor, the data presented in this Chapter do not conflict with
previous reports of chondroitin sulphate A (chondroitin 4-sulphate)
in basophilic cells (Olsson and Gardell 1967; Metcalfe et al 1984;
Seldin et al 1986). It should however be emphasized that none of
the more recent studies refers to normal circulating basophils and
there does appear to be considerable patient variation in the type
of GAGs identified (Rothenberg et al 1987). Moreover, chondroitin
4-sulphate is synthesized by a wide range of cell types, and the
more highly sulphated GAGs measured by this assay are of greater
physiological interest.
Human basophil-derived material contained GAGs which had molecular
weights in the range of 2,300 - > 500,000 (Figure 3); high molecular
weight material was probably proteoglycan in which individual GAG
side chains had not yet been cleaved from the protein core. After
Pronase digestion or 8 -elimination, which released all single
polysaccharide chains from the proteoglycan, most of the GAG had
molecular weights of the order 40,000 (Figure 8). This was
consistent with that of the heparan sulphate standard (Figure 2),
whereas heparin side chains are usually of the order 7,000 to
25,000 (Robinson et al 1978).
Further information about the structure of basophil-derived GAG was
derived from its Polybrene binding affinity and elution from the
Polybrene-Sepharose column. All basophil-derived GAG eluted at a
lower NaCl concentration than the heparin standard, and was
therefore of a lower sulphate content (Figure 5). Moreover, the
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pattern of elution of the basophil-derived material was similar to
that of the heparan sulphate standard (Figure 4), indicating once
more that basophil-derived GAG had a similar degree of sulphation
to heparan sulphate. The GAG contained in citrated human plasma
produced the same elution pattern, indistinguishable from that of
the basophil-derived material, from both Fractogel TSKHW-55(F) and
Polybrene-Sepharose columns; thus plasma GAG may originate from
circulating basophils.
Figures 6 and 7 illustrate that during the collection of weekly
sequential samples from one individual, basophil-derived GAG
extracted on one occasion was heparin-like, rather than the larger,
less sulphated material obtained from all other preparations (Table
4). This was undoubtedly a genuine observation, but could not be
repeated, since all subsequent samples from this subject contained
GAG similar to that found in all other individuals studied. These
data indicate possible variability of the biochemical nature of
GAGs contained in basophils in individuals; further evidence is
necessary to confirm this finding.
Much of the 40,000 molecular weight GAG contained in both human
plasma and normal basophilic leucocytes was degraded by digestion
with chondroitinase ABC (Figure 9), and therefore had a chondroitin
sulphate-like (rather than heparin-like) backbone. This material
was probably the highly sulphated chondroitin sulphate E, since
other chondroitin sulphates are not detectable with this assay.
Some GAG resisted the chondroitinase ABC digestion (Figure 9); this
resistant material was likely to be heparan sulphate, but enzyme
degradation studies to test this theory were largely unsuccessful,
due to the low activity of heparitinase in this experimental
system. Alternative methods were therefore sought, and nitrous acid
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treatment, which degrades material at N-acetyl glucosamine
residues, was tested on basophil-derived GAGs.
After nitrous acid degradation, 30% of the original material
remained (Table 5). Since chondroitin sulphate-like GAGs contain no
N-acetyl glucosamine residues, the nitrous acid resistant
basophil-derived GAG was probably chondroitin sulphate E. Thus,
approximately 70% of the highly sulphated GAGs contained in human
basophils, was heparan sulphate, with the remaining 30% consisting
of chondroitin sulphate E. However, it must be remembered that
these calculations were made from experiments using relatively
crude basophil-derived GAG preparations; and as they are based on
the assumption that an equivalent response of the assay to both
types of GAG was obtained exact quantitation is not possible. As
previously mentioned, there is also the possibility that variation
of basophil-derived GAGs may occur in individuals., However, it is
clear from these studies that, human basophils do contain both
heparan sulphate and highly sulphated chondroitin sulphate,
probably chondroitin sulphate E.
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Chapter 4.
GAG in Plasma During Systemic Anaphylaxis of
Nippostrongylus brasiliensis-primed Rats.
(1). Introduction.
The anaphylactic reactions of type 1 hypersensitivity in man are
systemic or local, depending on how the shocking dose of antigen is
presented in the body. The local form of anaphylaxis is likely to
develop if the appropriate antigen comes into contact with
respiratory or intestinal mucous membranes of a susceptible
individual. Local adverse respiratory reactions may cause the
symptoms of hay fever or asthma, whereas a mixed form of reaction
can develop with intestinal symptoms, including urticaria and
sometimes asthma. If the antigen is administered elsewhere than in
the respiratory or alimentary tract, for example with drugs such as
penicillin, foreign serum or perhaps an insect bite, the dramatic
and rapid systemic form of anaphylaxis will develop. The symptoms
include dyspnoea with bronchospasm and laryngeal oedema, urticaria,
reduced blood pressure, and occasionally death.
Anaphylaxis is dependent upon the presence of IgE antibodies which
have the ability to passively sensitize mast cells and basophils.
Bridging two adjacent cell-bound IgE molecules by antigen leads to
an allosteric membrane change which initiates a biochemical
sequence leading to synthesis and release of preformed
pharmacologically active mediators, detailed in Chapter 1.
Anaphylactoid reactions, which represent immediate-type systemic
responses in which basophils and/or mast cells are also
degranulating, but IgE antibodies or other immunological mechanisms
of activation are not the cause. A number of mediators are known to
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induce anaphylactiod reactions, such as the carbohydrates Dextran
and Mannitol (Hedin et al 1976; Lamb and Keogh 1979) and certain
dyes such as bromosulphothalein (Nedwicki and Roth 1960),
presumably by direct activation of basophils and/or mast cells.
A noteworthy feature of rats infected with the nematode intestinal
parasite Nippostrongylus brasiliensis, has been the appearance of
high titres of parasite specific and non-specific IgE antibodies in
blood (Jarrett and Miller 1982). Subsequent intravenous challenge
with worm antigen causes a severe adverse reaction in these
animals, producing the classic symptoms of systemic anaphylaxis.
The ability to simulate the events of systemic anaphylaxis in the
rat has provided a useful model to study the mechanisms involved in
IgE-mediated anaphylactic, shock.
The IgE and mast cell/basophil system in Nippostrongylus-infected
rats is thought to assist in the expulsion of the nematode from the
intestine (Askenase 1980), but does render the animal susceptible
to mucosal anaphylaxis. The reaction in rodents is characterized by
major changes in the small intestine, including increased secretion
of mucus (Urquhart et al 1965), mucosal permeability and systemic
secretion of a distinctive protease enzyme, rat mast cell protease
II (RMCP II), contained in the mast cells of the lamina propria
(Woodbury and Miller 1982; King and Miller 1984).
Recent evidence indicates that rodents possess distinguishable
populations of mast cells, termed "connective tissue mast cells"
(isolated from connective tissue, lung and serosal cavities) and
"mucosal mast cells" (derived from the lamina propria of the
gastrointestinal tract) (Enerback 1981; Bienenstock et al 1982;
Barrett and Metcalfe 1984). The major differences between the two
cell types are summarized in Table 1.
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Table 1: * Two Different Types of Rodent Mast Cells.
Mucosal Mast Cells. Connective Tissue Mast Cells.
Found in mucosal membranes
such as the lamina propria of
the gastrointestinal tract.
Found in serosal layers, the
peritoneal cavity and in
solid tissues, eg. skin and
tongue.
Small cells with few granules
of variable shape.
Larger cells with many
uniform granules.
Low, age-dependent








Contain the serine protease
RMCP II.








response to compound 48/80
and polymxin B.





half life approx. 40 days.
Thymus-dependency of
proliferation.
Main repository of histamine
in the gut mucosa.
Less soluble granular matrix
containing heparin.
Surface receptors for IgE.
Secretory response to compound
48/80 and polymyxin B.
Activation inhibited by disodium
cromoglycate and theophylline.
Response to nematode infections
unclear.




Main repository of histamine in
peritoneum and tongue.
* Summarized from Enerback 1981; Wingren et al. 1983;
Seldin et al 1985; Gleich et al 1986.
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There are two major hallmarks which distinguish the mucosal and
connective tissue cell that are of interest to the studies of this
Chapter:
a. Protease content.
The mucosal mast cells of rodents contain the highly soluble
neutral serine protease RMCP II, of M^ approximately 25,000
(Woodbury et al 1978a; Woodbury and Neurath 1978; Woodbury and
Miller 1982; Woodbury et al 1984), whereas connective tissue mast
cells contain a M^ 28,000 protease, typed with monospecific
antisera as RMCP I (Woodbury et al 1978b). The exclusive cellular
localization of RMCP II has been exploited, and used as a marker to
study the involvement of mucosal mast cells in the parasitised gut
of the rat, and to monitor 'its functional activity during systemic
anaphylaxis (Miller et al 1986).
b. Glycosaminoglycan content.
The predominant GAG contained in the granules of connective tissue
mast cells is heparin (Enerback et al 1974; Enerback et al 1976),
whereas mucosal mast cells contain a GAG with a lower degree of
sulphation (Stevens and Austen 1981; Enerback et al 1985) the exact
nature of which has yet to be determined. However, similarities
have been reported between rat mucosal mast cells and mast cells
derived from the bone marrow of mice, which contain chondroitin
sulphate E (Razin et al 1981; Razin et al 1982).
Homogeneous populations of mast cells resembling the mucosal mast
cell subclass have been obtained in vitro from rat bone marrow
cultured in the presence of conditioned medium from
antigen-activated immune mesenteric lymph nodes (Haig et al 1982;
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Haig et al 1983). These mast cells stain with alcian blue but not
safranin, they contain RMCP II but no RMCP I (McMenamin et al
1987), have a low histamine content, and proliferate under T cell
regulation. Their predominant proteoglycan, which is not heparin,
has a relatively low degree of sulphation (Haig et al 1984), but
its exact nature remains open to question. These cells have been
used for isolation and characterization of mucosal mast
cell-associated GAG.
Primary infection of rats with N. brasiliensis initiates a series
of changes and events at a cellular level (Miller et al 1986), and
among the most noteworthy features is the exponential increase of
mucosal mast cells (Miller and Jarrett 1971). Following intravenous
challenge with homologous worm antigen, extensive mucosal damage
occurs in primed rats, with depletion of mucosal mast cells from
jejunal mucosa, accompanied by the systemic release and decreased
mucosal concentration of RMCP II (Miller et al 1983; King and
Miller 1984).
Since GAG is localized in the same cytoplasmic granules of mature
mast cells as is RMCP II, this Chapter describes an investigation
of some of the properties of mucosal mast cell-derived GAG during
systemic anaphylaxis, and highlights this as yet another example of
the biochemical and functional differences between rodent mucosal
and connective tissue mast cells.
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(4:2). Materials and Methods.
Materials.
Reagents.
'Thrombotect' tubes were purchased from Abbott Laboratories Ltd,
Wokingham, Berkshire, and alkaline phosphatase-conjugated goat
anti-rabbit IgG from Sigma Chemicals Ltd, Poole, Dorset. Plastic,
96-well microtiter plates (Titertek), and rat basophil leukaemia
cells (RBL-1, ATTC No. CRL 1378) were purchased from Flow
Laboratories, Rickmansworth, Herts.
Methods.
This Chapter describes a collaborative study with Dr HAF Miller and
Dr SJ King, who performed all experiments involving the infection
and challenge of rats with worm antigen. They also performed all
RMCP II measurements, histology, cell counts, and cultured the rat
bone marrow cell preparations. The methods used were as follows:
Animals■
19 female outbred Wistar rats were used, 15 of which were immunised
3 and 8 weeks prior to each experiment, by subcutaneous injection
with 6,000 N. brasiliensis larvae. The techniques of parasite
culture, recovery and ennumeration are those described by Nawa and
Miller (1978), and Miller et al (1981). The preparation of whole
worm antigen was as described by Nawa et al (1981), and it was
administered intravenously to groups of fasted (24h) rats in the
following doses:
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Group. No of Animals Dose of Worm Antigen
1. 4 Immune rats challenged with 1000 worm
equivalents (w.e.).
2. 3 Immune rats challenged with 500 w.e.
3. 4 Immune rats challenged with 250 w.e.
4. 4 Immune rats challenged with saline only.
5. 4 Control naive rats challenged with
500 w.e.
Animals were anaesthetised 60min after intravenous challenge, and
bled from the carotid artery.
Preparation of Samples.
Serum.
Blood was collected, allowed to clot, and serum removed after
centrifugation. Sera were stored at -20°C before assay for RMCP II.
Plasma.
Blood was collected into the anticoagulant 'Thrombotect1 (Abbott),
the plasma separated by centrifugation and stored at -70°C before
assay for GAG.
Tissues.
The techniques used were those described by Woodbury and Miller
(1982), which involved the removal of the small intestines of each
animal. The intestines were divided into two equal lengths and each
portion perfused with 10ml of saline plus 10ml of air (Nawa 1979).
Gut perfusates were then stored at -20°C.
A 30cm length of jejunum from 15cm behind the pylorus of each rat
was opened and washed three times in 100ml of phosphate buffered
saline (PBS) at 4°C. The gut segments were washed twice in 0.15M
KC1, blotted to remove exess fluid, and finally weighed. The
-150-
tissues were then minced with scissors in 10ml 0.15M KC1 at 4°C and
homogenized three times for 1 min intervals in a teflon/glass
homogenizer cooled with crushed ice. After centrifugation (300g;
4°C), the homogenate supernatant was removed and clarified by
ultracentrifugation (36,000g; 30min; 4°C) using a Beckman L2 65B
ultracentrifuge. The samples were then freeze-dried and stored at
4°C.
Measurement of RMCP II.
Serum.
The measurement of RMCP II in rat serum was by a competitive
enzyme-linked immunosorbent assay (ELISA) developed by Miller et al
(1983). Basically this involved the incubation of unknown samples
and standards with rabbit anti-RMCP II, in plastic 96-well
microtitre plates coated with RMCP II. After incubation (37°C;
l-2h), the wells were washed three times with a solution of PBS/1%
BSA/0.05% Tween 20, before incubation for lh with alkaline
phosphatase-conjugated goat anti-rabbit IgG (Sigma, Poole, Dorset).
After a further three washes with PBS/BSA/Tween 20, the wells were
incubated with the substrate Na-p-nitro-phenyl phosphate for
20-30min. The plates were finally read in a Titertek Multiscan
Reader (Titertek, Flow Laboratories), and results expressed as ng
RMCP Il/ml of serum.
Tissues.
Levels of RMCP II were measured by radial immunodiffusion as
described by Woodbury and Miller (1982). Samples were added to
radial immunodiffusion plates prepared with 1% agar (as previously
described by Woodbury and Neurath 1978), containing rabbit
anti-RMCP II antibody. The precipitin bands were allowed to develop
in a moist atmosphere at room temperature for 24 hours, when the
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diameters of the bands were measured, and the results expressed as
M g RMCP Il/g wet weight of tissue (Woodbury and Miller 1982).
Histology and Cell Counts.
Samples of jejunum were collected and placed in either Carnoy's
fluid or 4% paraformaldehyde. Tissues were embedded in wax, and
sections were stained either for proteoglycan using Toluidine blue,
pH 0.5 (Enerback 1966), or with Naphthol AS-D chloroacetate to
demonstrate serine esterases (Newlands et al 1984).
Measurement of GAG.
Samples of plasma, gut perfusates and gut homogenates were
pretreated and assayed for GAG according to the method described in
detail in Chapter 2:1. —
Time Course of Both GAG and RMCP II Release following Systemic
Anaphylaxis.
A total of 43 female Wistar rats (200-250g) were used and allocated
randomly to the following groups:
Group. No. Treatment.
1. 5 Immune rats bled 5min after antigen challenge.
2. 10 Immune rats bled 15min after antigen challenge.
3. 9 Immune rats bled 30min after antigen challenge.
4a. 10 Immune control challenged with saline only.
4b. 4 Naive control challenged with saline only.
4c. 5 Naive control challenged with antigen.
Immune rats were bled 5min (Group 1), 15min (Group 2) or 30min
(Group 3) after challenge with 500 w.e., whereas control animals in
Group 4 were bled 30min after challenge with saline or antigen at
500 w.e.
-152-
Samples of plasma and serum were obtained from each animal and
examined for the presence of GAG and RMCP II.
Release of Histamine into Plasma following Systemic Anaphylaxis.
24 female outbred Wistar rats of 200-250g were used and randomly
allocated to groups of 4 as follows:
Group Dose of Worm Antigen (w.e.).
1. Immune rats challenged with 1000 w.e.
2. Immune rats challenged with 500 w.e.
3. Immune rats challenged with saline only.
4. Naive control rats challenged with 1000 w.e.
5. Naive control rats challenged with 500 w.e.
6. Naive control rats challenged with saline only.
The immune rats were challenged 7 days after secondary infection
with 4000 N. brasiliensis, and were bled out under anaesthetic
30min after antigen challenge. Plasma and gut tissue samples were
obtained from each animal and examined for the presence of GAG,
histamine and RMCP II.
Measurement of Histamine.
Samples of plasma were pretreated and assayed for GAG according to
the method of Shore et al (1959), described in detail in Chapter
2:2.
Characterization of GAG.
Cultured Rat Bone Marrow Derived Cells.
Rat bone marrow cells cultured in Iscove's medium with 10% horse
serum, and 30% conditioned medium (Haig et al 1982) were counted
and centrifuged (150g; 15min; 4°C). The supernatant was removed,
(6 * I06)
and cells^washed once in 0.01M phosphate buffer with 0.9% NaCl.
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Centrifugation was then repeated, supernatant removed, and the cell





All subsequent steps to extract GAG from cells, and determination
of its size and degree of sulphation are as described in Chapter 3.
All steps were performed as near to 4°C as possible using an ice
bath, and supernatant fluids retained and assayed for GAG.
Cultured Rat Basophil Leukaemia Cells.
Rat basophil leukaemia cells (Flow Labs Ltd.) cultured in minimum
essential medium with Earless salts and 10% foetal calf serum, were
counted and treated as rat.bone marrow cells above, to extract and
characterize the GAG.
Rat Plasma.
Plasma samples obtained from 4 immune rats challenged with 1000
w.e. were pooled, and assayed to determine GAG content. This
material was then prepared for the Fractogel TSKHW-55(F) column as
described in Chapter 3, to determine the molecular weight range of
GAGs released into rat plasma following systemic anaphylaxis.
Treatment of plasma with chondroitinase ABC is also described in
Chapter 3.
(4:3). Results.
Release of Both GAG and RMCP II from Mucosal Mast Cells following
Systemic Anaphylaxis in the Rat.
The contents of GAG and RMCP II in the samples studied are














































Table_l:Rel aseofGAGndRMCPIIfrommucosalastellsfollowing systemicanaphylaxis. IP=Intestinalperfusates. GH=uthomogenates. Meanvaluesreshownwithstandardd viation.
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RMCP II was present only in the sera of immune rats challenged with
worm antigen (groups 1-3), and in these same groups there was a
10-fold increase in plasma GAG concentration, compared with that of
animals in groups 4 and 5. Figure 1 shows that the patterns of
release of GAG and RMCP II were similar, and neither was dose
dependent. Nevertheless, there was a highly significant correlation
between the concentrations of RMCP II released into serum, and GAG
released into plasma (y=2,110 + 17x, r=0.93, p< 0.001), which may
suggest that they have a common origin. This is illustrated in
Figure 2.
RMCP II was present in the intestinal perfusates of animals only in
groups 1-3, in which there was a concomitant, highly significant
depletion of RMCP II from samples of gut tissue, and a decrease in
the numbers of mast cells in the intestinal mucosa (Figure 3).
The redistribution of GAG in the gut during systemic anaphylaxis
did not appear to follow that of RMCP II (Figure 4), since GAG was
present in the gut perfusates and gut homogenates of animals in all
5 groups (Table 1). There was considerable release of GAG into gut
perfusate of naive controls after antigen challenge (17.42, SD=5.0
p g/ml perfusate), and accurate measurement of mucosal GAG was
restricted, due to interference and high background levels of
tissue GAG in these samples.
To further examine the theory that proteoglycan and serine
esterases were depleted at the same time from discharging mucosal
mast cells, two methods were used to stain these cells:
a. Toluidine blue, which detects mucopolysaccharides contained
in tissues,
and Id. naphthol AS-D chloroacetate which demonstrates the presence
of specific esterases in tissue sections.
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0 250 500 750 1000
Dose of worm antigen (w.e.)
Figure 1: The contents of GAG in plasma (• •) and RMCP II (• •)
in serum (mean ±SEM), of immune rats are shown against
the intravenous dose of worm antigen. Naive control rats
challenged with 500 w.e. of antigen released some GAG(o),












RMCP II pg/ml serum.
Figure 2. Regression analysis of the concentrations of RMCP II in
serum against GAG in plasma (y= 2,110 + 17x, r= 0.93,
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Dose of worm antigen (w.e.).
1000
Figure 3. The concentrations of RMCP II (mean± SEM) in intestinal
perfusates (• •) and jejunal mucosa (» •) are shown
against the dose of worm antigen, with the number of
mucosal mast cells (MMC) per villus crypt unit (VCU)
detected with Toluidine blue (mean ± SEM). RMCP II
concentrations in perfusates (^) and homogenates (a), and
the number of MMC per VCU in naive control rats



















0 250 500 750 1000
Dose of worm antigen (w.e.)
Figure 4. The concentrations of GAG in gut homogenate (o o) and
gut perfusate (o o), and RMCP II in gut homogenate
(• •) and gut perfusate (• •) (mean ± SEM), are
plotted against the dose of worm antigen. GAG was present
in both gut perfusate (♦) and gut homogenate (•) of naive
control rats challenged with 500 w.e., but RMCP II was
present only in gut homogenate (o).
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Staining with both naphthol AS-D chloroacetate and Toluidine blue
indicated mast cell depletion from the mucosa (Figure 5). There was
a highly significant relationship between the numbers of mast cells
detected with these 2 methods (y=-2.3 + l.lx, r=0.98, p< 0.001)
(Figure 5), suggesting a common origin for proteoglycan and RMCP II
release.
Time Course of GAG and RMCP II Release following Systemic
Anaphylaxis.
The content of GAG and RMCP II in the samples studied are
summarized in Table 2.
The release of GAG into plasma and RMCP II into the sera of immune
rats occurred with different time courses (Figure 6). The levels of
RMCP II released into serum increased steadily, approaching a
plateau 30min after worm antigen challenge; GAG was released more
slowly (Figure 6). Neither GAG nor RMCP II was completely released
by 30min after antigen challenge, and clearly a longer experimental
period would have been required to allow for total release. There
was no RMCP II, and very little GAG (< 0.15ug/ml), detected in the
sera of naive rats given saline or antigen 30min after challenge.
Release of Histamine into Plasma following Systemic Anaphylaxis.
The content of histamine, GAG and RMCP II in the samples studied
are summarized in Table 3.
Immune rats challenged with antigen (groups 1 and 2) were found to
have increased levels of histamine as well as GAG and RMCP II in
plasma (Figure 7a), when compared with control groups challenged







Figure 5. Regression analysis demonstrating a highly significant
correlation between the numbers of MMC enumerated after
staining with Toluidine blue and with naphthol AS-D
chloroacetate (y= -2.3 + l.lx, r= 0.98, p < 0.001).
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Group. GAG in Plasma pg/ml. RMCP II in Serum jug/ml.
1. 0.94 + 0.32 207 + 93.0
2. 84.1 ±53.5 375.5 ± 139.8
3. 281.85 ±127.4 439.4 ± 70.1
4a. 0.28 ± 0.14 0
4b. 0,06 ± 0.03 0
4c. 0.14 ± 0.04 0
Table 2.: Time course of GAG and RMCP II release following systemic
anaphylaxis.
















Time interval after challenge 'with
antigen (min).
Figure 6. The contents of GAG in plasma (•—•) and RMCP II in
serum (• •) (mean+SEM) are plotted against time
interval after challenge with 500 w.e. of worm antigen.
Naive rats challenged with 500 w.e. did not have
detectable levels of serum RMCP II, 30min after
challenge with either saline or 500 w.e., and plasma























































Figure 7. The plasma concentrations of GAG (•—•), RMCP II (• •)
and histamine (a a) (mean + SEM) are plotted against
the dose of worm antigen for a. immune rats, and b. naive
rats.
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The release of these substances into plasma (Figure 7a), and
depletion of RMCP II from gut tissue (Figure 8), increased with the
dose of antigen administered.
Since histamine release into plasma followed the same pattern as
GAG and RMCP II following systemic anaphylaxis, a common origin for
all 3 was likely, the mucosal mast cell being the most obvious
source.
Characterization of GAG.
Cultured rat bone marrow derived cells.
The GAG content of supernatant fluids after centrifugation was low,
not exceeding 435 ng/ml.
a. Molecular Weight of GAG'.
The elution profile obtained from the Fractogel TSKHW-55(F) column
illustrates the molecular size distribution of GAG in the sample,
125
compared with the internal marker, I-heparin. Figure 9 shows two
elution profiles of two separate preparations of these cells, and
on each occasion most of the material released was of similar size.
Figure 9a had a small peak representing material of ^ 500,000
molecular weight, but the major GAG peak occurred at 40,000. This
was repeated, (Figure 9b) and a single peak of 40,000 molecular
weight was obtained. The smaller, second peak of radioactivity
125
detected in later fractions was unbound I.
b. Degree of sulphation of GAG.
The elution profile from the Polybrene column (Figure 10) shows
that GAG released from these cells is less sulphated than the
125
I-heparin marker. Two small peaks were present in fractions
eluted at low salt concentrations, but most of the GAG was
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Dose of worm antigen (w.e.)
Figure 8. The concentrations of RMCP II in plasma of immune (• •)
and naive (• •) rats, and the concentrations of RMCP II
in the jejunal mucosa of immune (o o) and naive (o o)
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Fraction number.
Figure 9. Two elution profiles from Fractogel TSKHW-55(F), of GAG
extracted from cultured rat bone marrow derived mast
cells on separate occasions. Similar patterns were
obtained, with most of the material eluting at a position
equivalent to 40,000 molecular weight. (•—• = sample
125


















Figure 10. An elution profile from Polybrene-Sepharose with 0-2M
NaCl gradient (o o) of GAG extracted from rat bone
125
marrow derived mast cells (» »),and I-heparin
(• *)• Cell derived material eluted at lower NaCl











Figure 11. Elution profile from Fractogel TSKHW-55 (F) of GAG
extracted from -rat basophilic leukaemia cells (• m)
125
and I-heparin tracer. The material eluted had a wide




Figure 12. Gel filtration of plasma obtained from immune rats
125
challenged with 1000 w.e. (• •) and I-heparin
tracer (• ®) on Fractogel TSKHW-55(F). Most of the
plasma-derived material was of 40,000 molecular weight.
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* Fraction number.
Figure 13. Plasma obtained from immune rats challenged with 1000
w.e. was treated with chondroitinase ABC (• «), and
125
gel filtered on Fractogel TSKHW-55(F), with I-heparin
tracer (• •). Most of the plasma GAG was digested by
chondroitinase ABC, leaving a residual peak of molecular
weight 22,000.
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displaced from the column when the concentration gradient reached
0.8M NaCl. The unbound radioactivity detected in fractions 4-12 was
, 125
free I.
Cultured rat basophil leukaemia cells.
A wide range of high molecular weight GAG, which was not heparin,
was released from these cells (Figure 11). Material representing
intact proteoglycan of >" 500,000 molecular weight, as well as
individual side chains of at least 20,000 molecular weight, were
detected.
Rat plasma.
Of the GAGs released into plasma during systemic anaphylaxis, the
majority had a molecular weight of 40,000 (Figure 12), similar to
that released from the cultured bone marrow cells. There were also
two smaller peaks present, representing minor components of < 2000
and 500,000.
Treatment with chondroitinase ABC,
Figure 13 shows the elution profile of the same sample as that in
Figure 12, after digestion with chondroitinase ABC. The material
detected was reduced in concentration and the only high molecular
weight material remaining eluted as a sharp peak of 22,000.
(4:4). Discussion.
The findings of this study confirm those of previous reports (King
and Miller 1984), in that:
a. RMCP II was present in large amounts in the intestinal lumen of
N. brasiliensis primed rats undergoing systemic shock.
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b. RMCP II was secreted systemically in primed rats in a dose-
(Figures 1 and 7), and time- (Figure 6) dependent manner (Figure 5)
following intravenous challenge with whole worm antigen.
c. Systemic release of RMCP II was associated with the concomitant
reduction of mucosal RMCP II concentration (Figures 3 and 8).
d. These changes were paralleled by depletion of mucosal mast cells
from jejunal mucosa, as indicated by either (i) Toluidine blue
stain, which detects mucopolysaccharides contained in tissues, or
(ii) naphthol AS-D chloroacetate stain, which demonstrates the
presence of specific esterases in tissue sections. In the presence
of diazonium salt, enzymatic hydrolysis of ester linkages liberates
free naphthol compounds which react to form highly coloured
deposits at sites of enzyme activity, (Figure 3).
In addition to this, the release of GAG into plasma during this
same reaction (Figures 1 and 7) was highly correlated with the
release into serum of RMCP II (Figure 2), although the changes in
mucosal levels of GAG did not correlate with mucosal RMCP II
concentrations. The analysis of mucosal samples was however
complicated by high background levels of tissue GAG and other
factors likely to interfere with the assay. Nevertheless, since gut
tissue was the only source of RMCP II, with the exception of lung
tissue of N. brasiliensis-primed rats, which at most contains 300p g
RMCP Il/g wet weight (Miller et al 1986), and since GAG release
into plasma is so closely correlated with RMCP II release into
serum, a common origin of these two products seems likely, with the
mucosal mast cell being the most obvious source.
The systemic release of RMCP II in N.brasiliensis-primed-rats
occurs immediately after challenge, with 207p g RMCP Il/ml present
in serum after only 5 minutes. This increased to 439p g/ml after
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30minutes, and further increases seemed likely, if the experimental
period had been extended. Previous studies (King and Miller 1984)
have shown serum RMCP II levels to increase to 755p g/ml 60min after
worm antigen challenge, and the first challenge experiment of this
study (in which animals were killed 60min after intravenous
injection with whole worm antigen) confirmed these findings; mean
serum RMCP II levels of up to 770y g/ml were detected (Table 1).
Mean GAG levels in plasma of challenged-immune rats increased to
282p g/ml after 30min (Table 2), and had not apparently reached a
plateau (Figure 6). However, the plasma GAG levels detected in rats
killed 60min after antigen challenge were in fact greatly reduced
(Table 1); this was probably due to rapid clearance of GAG from the
plasma in these animals. Moreover, the GAG levels detected in
control animals after 60min (Table 1, groups 4 and 5) was increased
ten fold, compared to animals killed after only 30min (Table 2,
group 4); the longer time interval obviously allowing for greater
spontaneous release of GAG into the plasma of these animals under
the experimental conditions used. Thus to optimise the magnitude of
the responses due to systemic anaphylaxis, a 30min time interval
after antigen challenge was chosen.
The exponential increase in the mucosal mast cell number of immune
rats is paralleled by increased histamine content of the jejunal
mucosa. Enerback (1985) reported histamine levels in immune rat
jejunal tissue (mean 20.4p g histamine/g wet weight tissue)
increased 5 fold, compared with uninfected control rats (mean 4.5p g
histamine/g wet weight tissue).
Histamine was released into plasma with similar dose-dependence as
the release of GAG and RMCP II into the plasma of immune rats
following intravenous challenge with whole worm antigen challenge
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(Figure 7a), but no such pattern of release was detected in
uninfected control animals (Figure 7b). Furthermore, there was
concomitant depletion of RMCP II from gut tissue (Figure 8), and
these data collectively provide strong circumstantial evidence that
the measured histamine, as well as GAG and RMCP II, is derived from
the mucosal mast cell, all being released during systemic
anaphylaxis.
One of the most obvious differences between mucosal mast cells and
connective tissue mast cells is the distinctive dye-binding
properties of their granules as follows:
a. Staining with alcian blue and MgCl^ (Scott and Dorling 1965)
shows that mucosal mast cell granules contain lower electrolyte
concentrations, and therefore less sulphated GAG than those of
connective tissue mast cell granules (Miller and Walshaw 1972).
b. Spectroscopic studies of in situ complexes formed by GAG
reacting with Toluidine blue, show spectra not typical of heparin,
but of a less sulphated polysaccharide (Tas and Berndsen 1977)
contained in mucosal mast cells.
c. Unlike rat connective tissue mast cells, mucosal mast cells do
not exhibit the strongly fluorescent complexes characteristic of
Berberine binding to heparin (Wingren and Enerback 1983).
These findings collectively provide strong evidence that the
granules of mucosal mast cells do not contain heparin, but a GAG of
a lower sulphate content.
Rat bone marrow derived mast cells (homologous with rat mucosal
mast cells: Haig et al 1982; Haig et al 1983; McMenamin et al 1987)
were found to contain GAG with single polysaccharide chains, the
majority of which had molecular weights of the order 40,000 (Figure
9), while those of heparin are usually 7,000 - 25,000 (Robinson et
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al 1978). The material of 500,000 molecular weight detected
(Figure 9a) was probably proteoglycan in which individual GAG side
chains had not yet been cleaved from the protein core.
A clearer indication that the GAG released from these cells is not
heparin is provided by the observation that it was less sulphated
than heparin, based on its Polybrene-binding affinity. All the GAG
in the sample was eluted at a lower NaCl concentration than
heparin, and was therefore of lower sulphate content (Figure 10).
Similarly cultured rat basophilic leukaemia cells (homologous with
rat mucosal mast cells: Seldin et al 1985), were found to contain
non-heparin proteoglycan (Figure 11), although much of the material
existed largely in macromolecular form. This confirmed previous
reports of the nature of GAG contained in these cells (Razin et al
1982; Seldin et al 1985).
The GAG released into plasma during systemic anaphylaxis in the rat
and the material contained in the cultured bone marrow derived mast
cells, were both of 40,000 molecular weight (Figure 12). This is
consistent with the mucosal mast cell origin of the increased GAG
levels in plasma of infected rats challenged with whole worm
antigen. Much of this material was degraded by digestion with
chondroitinase ABC, and therefore had a chondroitin sulphate-like
(rather than heparin-like) backbone, although some GAG resisted
this treatment (Figure 13). Subsequent experiments using GAG
extracted from cultured bone marrow derived mast cells have
confirmed this observation, whereby chondroitinase ABC digests much
of the GAG, but some undegraded material remains after this
treatment. This material was likely to be heparan sulphate, but
further analysis and enzyme degradation studies will be necessary
to confirm this. However this does provide further evidence for the
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mucosal origin of GAG released into plasma due to systemic
anaphylaxis.
The findings of the studies of this Chapter have served to confirm
and extend previous work on the properties and nature of GAG
contained in mucosal mast cells, and highlight their involvement in
the reactions occurring during systemic anaphylaxis in the rat.
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Chapter 5.
Basophil Counts in Atopic and Non-Atopic Individuals
(5:1). Introduction.
The involvement of basophils in allergic disease has been
recognized for many years, based on
a. their presence in tissue infiltrates occurring in various
inflammatory and allergic states (Mitchell and Askenase 1983),
b. the observation that the basophil is the only blood cell to
contain histamine (Sampson and Archer 1967),
c. this histamine is released in response to antigenic challenge
(Lichtenstein and Osier 1964).
However, studies of their, actual role and significance in allergic
disease have mostly been concerned with tissue infiltrates, nasal
fluids and sputum, due to their low numbers and difficulties in
quantitation in whole blood (Mitchell and Askenase 1983; Denburg et
al 1985; Hastie et al 1979; Okuda et al 1978; Kimura et al 1975).
Paul Ehrlich first described the basophil in 1879, and noted
basophilocytosis in patients with the blood disorder chronic
myelogenous leukaemia (CML). Many other workers have since
confirmed his observation, and it is generally accepted that the
greatest elevations of basophils occur in this disease (Forkner
1938; Doan and Reinhart 1941; James et al 1955; Juhlin 1963a;
Juhlin 1963b). Basophil levels, dramatically increased in
myeloproliferative disorders, particularly CML, may number more
0
than 90,000 x 10 /l (Youman et al 1973), and can account for over
90% of the circulating leucocytes (Austen et al 1974).
Increased numbers of circulating basophil progenitors and basophils
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have recently been reported in the blood of atopic patients
(Denburg et al 1985): however the authors used conventional
microscopic methods for cell counting, which are relatively
insensitive and the emphasis of this study was in fact on
basophilic progenitors. Therefore the numbers of circulating mature
basophils in atopic and non-atopic individuals were determined to
confirm and strengthen these findings, by using a flow cytometer -
the Technicon H-6000 automated leucocyte differential analyser
(Technicon, New York, USA), a modern automated method of cell
counting which is extremely accurate. This method is based on
preferential cellular staining (Saunders et al 1971; Ansley and
Ornstein 1971), according to which leucocytes are classified by the
characteristic properties exhibited by cell-specific constituents,
when treated with cytochemical stains. After lysis of red blood
cells, a photodetector classifies each differentially stained white
blood cell by its absorbance, and/or its forward scatter
characteristics.
In addition, sequential blood samples were taken from a number of
both atopic and non-atopic individuals, to detect possible
variations of individual basphil counts over a period of time.
(5:2) Patients, Materials and Methods.
Patients.
Control Individuals.
35 healthy adult volunteers (24 female; 11 male) of a similar age
range (21 - 53; mean = 29.7) to the atopic population, were
non-atopic controls. All had negative skin tests and total IgE
levels of < 200 kU/1.
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Atopic Individuals.
A total of 55 atopic individuals were studied; 50 were either in¬
patients or out-patients at the University Department of
Dermatology, and 5 were atopic volunteers. Of the 50 patients
studied, all had severe atopic dermatitis; 16 also had asthma,
rhinitis and food allergy, 16 had asthma and rhinitis, 2 had asthma
and IgE-mediated food allergy, 4 had rhinitis and food allergy, and
7 had eczema alone. Of the 5 atopic volunteers, two had asthma and
rhinitis and three exhibited no allergic symptoms. The atopic
patients and volunteers were of both sexes (28 female; 27 male),
aged 17 to 54 (mean age = 29.6) and all produced a positive skin
test (5mm wheal) and RAST score for at least one common allergen;
this is generally accepted as the best working definition of atopy
(Pepys 1979; Platts-Mills 1'982). Total serum IgE levels ranged from
125 to 70,000 kU/1 (Geometric mean = 4229.3 kU/1).
Materials.
Reagents.
RAST and IgE RIA kits for specific and total IgE determination were
purchased from Pharmacia Ltd, Uppsala, Sweden. Baso acid (Product
No T21-0629), Tween 20 (Product No T21-0309), baso dye (Product No
T01-0628), and baso diluent
(Product No T01-0555) were all purchased from Technicon, New York,
USA.
Baso Acid.




This consisted of 0.9% NaCl,
0.143% alcian blue,
0.07% cetylpyridinium chloride (CPC),
0.7% lanthanum chloride, all w/v.
Baso Diluent.
This consisted of 0.9% (w/v) NaCl, with 0.1% (w/v) disodium EDTA.
These reagents were stable for up to one week at 4°C.
Methods.
Determination of Total and Specific IgE.
Serum samples from patient and control populations were obtained
for the measurement of total and specific IgE levels. These
measurements were performed by Mr HAF MacFarlane, using the
following methods.
Total IgE.
Total IgE levels in serum samples were determined by double
antibody radioimmunoassay (IgE RIA kit; Pharmacia Ltd). This test
involved the incubation of 50p 1 of test serum or dilutions of the
test serum in IgE-free diluent (0 units/ml standard; Pharmacia),
125
with 50y 1 of I- labelled human IgE and 50u 1 of rabbit anti-human
IgE in polystyrene tubes. This was incubated at 22°C for 3h, when a
second antibody was added (2ml of sheep anti-rabbit IgG coupled to
Sepharose gel), and then incubated for a further 30 minutes at
22°C.
Bound radioactivity, which was indirectly proportional to the
concentration of IgE in the serum samples was measured using a NE
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1600 y -counter. Standard serum containing 0, 2, 5, 15, 100, 400
and 1000 units of IgE/ml was used for the standard curve. All test
and standard samples were assayed in duplicate, and mean counts
were used in all calculations. The values of the samples were read
from a graph of concentration of standard (log) vs % counts bound
(linear).
Allergen—Specific IgE.
Measurement of the levels of allergen specific IgE in serum samples
was by the Radio Allergosorbant Test (RAST; Pharmacia Ltd). Sera
were incubated with a paper disc to which a particular allergen had
been covalently coupled. 50p 1 of the test serum or dilutions of the
test serum in RAST buffer (Pharmacia) were incubated with an
allergen disc for 3h at 22°C; any allergen-specific IgE in the
serum sample would at this stage bind to the paper disc. After
incubation, 2ml of 0.9% NaCl containing 1.0% Tween 20 (w/v) was
added to each tube and left for 10 minutes. This washing solution
was then removed from the paper discs by suction, and the washing
process repeated twice. The paper discs were finally dried using a
125
Pasteur pipette attached to a vacuum line. 50p 1 of I-labelled
anti-human IgE was added, and incubated for 24h at 22°C. The paper
counted
discs were washed as before, and ^in a y -counter. The amount of
radioactivity was directly proportional to the amount of
allergen-specific IgE on the paper disc.










B. 3.5 - 17.5 3
Strong Positive.
C. 0.7 - 3.5 2
Moderate.




The results for each of the standard sera were used to plot a
standard curve, from which- the test results were read. Test samples
with values of > 12 pru/ml were diluted and reassayed.
Determination of Cell Counts.
These measurements were performed by Dr TL Allen and Mr F
Mackenzie, using the following methods.
Whole blood samples (5ml) were taken into EDTA (0.025M) vacutainer
tubes, and diluted with an air segmented stream of baso diluent, to
which baso dye was then added. The use of CPC caused red blood cell
lysis, eliminated undesired precipitates, and prevented the
clumping of red cell membranes. Lanthanum chloride selectively
inhibited the staining of nucleic acids. Baso acid was added in two
steps to avoid precipitation, and only basophils were stained. The
analytical stream then entered a sheath-stream flow cell where the
forward-scattering signal of each cell was measured at two
non-overlapping wavelengths. The optical measurements were then
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converted into electrical pulses by photodiodes and applied to the
logic circuits for cell classification and quantification. As each
blood sample passed through the machine, 20,000 white cells were
individually characterised by means of their light absorbance and




Absolute numbers of circulating blood basophils of both atopic and
non-atopic populations are shown in Figure 1, with the median
values given for both populations. Using the Mann-Whitney U test,
the atopic population had significantly greater numbers of
» 6
circulating basophils (median= 70x10 /l), than the healthy controls
0
(median= 50x10 /l), (p=0.0005). There was a correlation between the
number of total leucocytes and the number of basophils in the
non-atopic individuals (r=0.51; p= 0.0014), but not in the atopic
population (r=0.081; p=NS). However there was no correlation of
basophil counts with age, total IgE levels, or clinical symptoms in
either population.
Eosinophil Counts.
Absolute numbers of eosinophils of both atopic and non-atopic
populations are shown in Figure 2, with the median values given for
both populations. Using the Mann-Whitney U test, the atopic
population had significantly greater numbers of circulating
eosinophils (median= 520xl06/l), compared with the non-atopic
controls (median= 140x10^/1), (p< 0.001). The number of eosinophils
and basophils correlated in both the atopic (p< 0.02), and














Figure 1. Numbers of circulating basophils were overall
significantly greater in the atopic population (median =
g
70 x 10 /l), than in the non-atopic group studied (median














Figure 2. Numbers of circulating eosinophils were overall
significantly greater in the atopic population (median =
0
520 x 10 /l), than in the non-atopic group studied












Figure 3. Basophil counts were obtained from five atopic (• •)
and four non-atopic (• •) individuals at the same time























Figure 5. Basophil counts were obtained from four atopic dermatitis
patients who also had seasonal rhinitis due to grass
pollen. Samples were taken over a time interval of six
months.
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Daily Variation of Basophil Counts.
Basophil counts were obtained from five atopic and four non-atopic
individuals at the same time on either four or five consecutive
days. There was no significant day to day variation in either group
(Figure 3).
Monthly Variation of Basophil Counts.
Basophil counts were obtained from 6 atopic and 5 non-atopic
individuals at various intervals over periods of up to 20 months
(Figure 4). Again there was no significant variation in the
basophil counts within individuals in either group.
Seasonal Variation of Basophil Counts.
Four patients from the atopic group, known to have seasonal
rhinitis due to grass pollen, were studied at various intervals
over a period of six months (Figure 5), and no obvious pattern of
seasonal variation was detected.
Circulating levels of basophils showed little variation within
individuals on both a short term and long term basis.
(5:4). Discussion.
The observation that mature circulating basophil levels are
elevated in atopic individuals, using this new accurate method for
cell counting, confirms the findings of Denburg et al (1985), who
used a less accurate and less sensitive conventional microscopic
method. This typically involves the examination of 500 leucocytes
on a Romanovsky stained blood film, and since basophils occur
relatively infrequently, gives rise to a large inherent statistical
error. Other errors may arise from inadequate sample mixing, poorly
spread peripheral blood film, or inaccurate identification of
basophils.
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The Technicon H-6000 differential leucocyte count is based on a
count of approximately 20,000 cells (depending on total white cell
count), and thus has much greater precision, and a very marked
reduction in the co-efficient of variation of replicate analyses
(CV). The variance inherent in these two basophil counting
techniques was examined by Winkel (1976), who showed that visual
basophil counts had a CV of 141%, whereas Technicon H-6000 basophil
counts had a CV of 13.1%.
Some consideration has to be given to the accuracy of basophil
counts in general terms. The most obvious major problem is that
there is no quality control material with an accurately assigned
absolute basophil count available. It follows therefore that
whatever method of basophil "counting is chosen, it is not possible
to calibrate the method using a reference preparation. Bearing this
in mind, the method chosen for basophil counting must be based on
sound scientific principles, and must at the very least be precise.
In this respect therefore, the Technicon H-6000 analyser is by far
the most superior method for the enumeration of basophils in whole
blood.
The increased absolute number of basophils in the atopic group
correlated with the percentage of basophils in each differential
leucocyte count (r = 0.83; p< 0.005), but did not correlate with the
total leucocyte count (r = 0.081; p = NS). Thus the increased
number of basophils is not merely due to an increase of total
leucocytes in this group, as in the non-atopic population, where
basophil counts paralleled the total leucocyte counts (r = 0.61;
p< 0.002).
Increased levels of circulating eosinophils were detected in
individuals in the atopic group (Figure 2). The observation that
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basophil and eosinophil counts correlate in both groups studied
(control group p< 0.005; atopic group p< 0.002), is in keeping with
previous reports where their levels in peripheral blood have been
found to fluctuate in parallel, in response to a variety of
antigenic and hormonal stimuli (Dvorak et al 1974a; Ogilvie et al
1980; Rothwell 1975; Rothwell and Love 1975). It is well recognized
that eosinophil counts are also raised in atopy (Weller 1984), and
their role is thought to complement that of basophils, involving
the production of various chemotactic factors during inflammatory
reactions (Weller and Goetzl 1979). Furthermore, they may function
synergistically in certain states, for example, in immune reactions
to parasites (Brown et al 1982). It is not surprising therefore to
find that basophilia occurring in certain clinical conditions is
accompanied by raised levels of circulating eosinophils.
Although the half life of the basophil is 2-5 days (Mitchell and
Askenase 1983), it is believed to spend only about 12 hours in
circulation (Gleich et al 1986). The observation that actual
numbers in the circulation of specific individuals varies
relatively little (Figures 3-5), indicates that this routine
production and destruction of basophils is closely regulated.
Hirsch and Kalbfleisch (1976) reported fluctuating levels of
circulating basophils in a number of individuals with hay fever,
again using traditional visual methods for cell counting. These
individuals, who had been carefully selected as clinically
sensitive only to ragweed allergen, showed a significant elevation
of basophils during the symptomatic period of the ragweed season.
The apparent lack of seasonal variation of basophil counts observed
in the present study (Figure 5) may have been due to the multiple
allergies of the patients, obscuring any seasonal effect on the
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production of basophils. However, the variation of basophil counts
in the individuals of this study was very slight, and seemed to be
independent of allergic state, day of the week, or month of the
year, and the conflict of results with those of Hirsch and
Kalbfleisch (1976) may equally result from the use of the Technicon
H-6000 and increased accuracy of cell counting.
Factors controlling production of basophils in the bone marrow have
not been well established, although their similarity to mast cells,
which also have a myeloid origin, may provide some clues. Factors
regulating ma^t cell production and maturation are thought to be
T-cell derived (Morley et al 1984). For example, interleukin 3
causes maturation of tissue mast cell precursors, and lymphokines
are well established as. regulators of the allergic response; the
source of both are T-helper lymphocytes. Lymphocytes are also known
to regulate delayed hypersensitivity reactions, in which basophil
accumulation may occur (Denburg et al 1980), and thus similar
factors may regulate the production of basophils.
Although certain functions have been identified for the basophil in
vitro (Lichtenstein et al 1986), and in vivo, such as host defence
and resistance to parasites (none of which were relevant to the
individuals involved in this study), the overall functional
integrity of basophils has yet to be evaluated. Equally, the role
of the basophil in IgE-mediated hypersensitivity, and therefore
atopy, still remains to be defined, but the observation that there
are increased circulating basophil levels in atopic individuals,




Allergen-Induced Release of GAG and
Histamine from Human Basophils.
(6:1). Introduction.
Anaphylactic type hypersensitivity reactions are initiated when an
appropriate antigen binds to and cross-links IgE molecules on the
surface of mast cells or basophils. This results in the
non-cytotoxic release of preformed mediators stored in the cellular
secretory granules (Schwartz and Austen 1984). When released, these
preformed secretory components, which include histamine,
heparin-like proteoglycan, chemotactic peptides and a range of
V
enzymes, elicit the acute reactions characteristic of immediate
hypersensitivity. Mast cells are the major source of tissue
histamine (Riley and West 1953), and basophils of humoral histamine
(Graham et al 1955), the amine being stored in the granules in
association with the acidic groups of heparin-related GAGs and/or
proteins by means of ionic bonds (Uvnas et al 1970).
The development in recent years, of several different methods for
the measurement of total and allergen-specific serum IgE, was an
important improvement in the diagnosis of allergic states.
However, these parameters provide little information as to the
precise mechanisms of allergic reactions: immediate
hypersensitivity reactions in man or in experimental animals do not
depend directly upon circulating IgE antibodies, but upon the
release of the mediators from IgE-sensitized mast cells and
basophils. Thus, in vitro methods of diagnosis should reflect the
end stage of the reaction, ie. the degranulation of the cells
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involved. The diagnosis of allergies based on cellular reactivity
has been the subject of research for many years (Shelley and Juhlin
1961; Klopstock et al 1962; Hirsch and Zastrow 1972) and it is
therefore not surprising that the measurement of histamine release
from basophils is well established and has been extensively used
for in vitro studies of human allergy (Siraganian and Hook 1976b).
However, GAG release from basophils has not been previously studied
in this way. The studies outlined in this Chapter have used the
competitive binding assay for GAG and standard histamine assay
(both of which are described in Chapter 2) to study further and
compare the properties of antigen mediated release of these
compounds from human basophils in vitro.
/ \ V
(6:2) Patients, Materials and Methods.
Patients■
Atopic Individuals.
Fourteen atopic subjects were studied in total, 10 patients with
atopic dermatitis and 4 atopic volunteers. Patients studied were
either in-patients or out-patients at the University Department of
Dermatology, Royal Infirmary of Edinburgh, and were of both sexes
(5 female; 9 male) and aged 19-46 years (mean age = 31 years). Of
the atopic dermatitis patients, 9 also had asthma, 7 had rhinitis
and 5 had known food allergy. One of the atopic volunteers had
asthma and perennial rhinitis, one had had asthma as a child, and 2
exhibited no allergic symptoms. All produced a RAST score of 4 for
house dust mite allergen (D.pteronyssinus specific IgE range,
34-1750 RAST units: 1 unit approximately equivalent to 1KU total
IgE/1), and had total IgE in the range of 483 - 67,200 KU/1.
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Control Individuals.
Eight healthy adult volunteers (6 female; 2 male) of a similar age
range (23-34 years; mean age 28 years) to the atopic population,
were non-atopic controls. All had negative skin test results, total
IgE levels of < 200 KU/1, negative skin test results, and a RAST
score of 0 for house dust mite allergen.
Materials.
Reagents.
Freeze dried preparations of D.pteronyssinus were purchased from
Pharmacia, Uppsala, Sweden, and reconstituted in 0.9% (w/v) saline
solution to obtain stock solutions of lOp g/ml of allergen, which
was further diluted using Tris ACM buffer for release experiments.
Buffers.
Tris ACM buffer.
This consisted of Tris A buffer (described in Chapter 2),
supplemented with 0.6mM CaCl^ and ImM MgCl^.
Methods.
Preparation of leucocytes.
Leucocytes were prepared essentially as described by Siraganian and
Hook (1976b), and is described in detail in Chapter 3. The
leucocyte-rich cell pellet was finally resuspended in Tris ACM
buffer. This method produced cell fractions of 3.4 - 5.9% purity
with little loss of total basophil numbers.
Release experiments.
These were performed using 1.5 ml of cell suspension, with 150p 1 of
allergen diluted in Tris ACM buffer. After 60min at 37°C, samples
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were centrifuged (110 x g; 15min; 4°C) and supernatants assayed in
duplicate for both GAG and histamine.
Ca++ Requirement.
To determine the Ca++ requirement for antigen induced release, 40
ml of whole blood from four atopic individuals were sampled into
dextran/ dextrose/ EDTA as before, and at the same time a further
40 ml sampled into dextran/ dextrose/ EGTA (12.5mM). All samples
were left to sediment for 90 minutes, and leucocytes prepared as
before. Release experiments were performed in the absence and
* ++ ++
presence of 0.6 mM Ca and ImM Mg , using D.pteronyssinus at a
concentration previously found to cause release of both GAG and
histamine. —
V
Determination of Total Histamine Content of Cell Preparations.
To determine the total histamine content of the cell preparations
used, basophil enriched fractions were prepared as before from
atopic individuals, and treated with 12% perchloric acid to obtain
complete cell lysis. After centrifugation, supernatants were
assayed for histamine.
Determination of Basophil Counts.
Whole blood and cellular suspensions were stained, and the number
of basophils in each sample was determined by the methods described
in Chapter 5.
Assay of Histamine.
The extraction and assay of histamine was performed by the manual
fluorometric method described in Chapter 2:2.
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Assay of GAGs.
Highly sulphated GAGs were measured in each sample by the method
described in Chapter 2:1. Interference in the assay from membrane
components of concentrated cell lysates precluded determination of
total cell GAG for each individual studied. Results were therefore
expressed as a percentage of spontaneous or background release,
when no allergen was present (background = 100%). Since a
comparison with histamine was to be made, its release was expressed
in the same way.
Statistical Analysis.




The Ca++ requirement for allergen-induced release of GAG and
histamine from cells of 4 atopic individuals is shown in Table 1.
In the presence of EDTA, which sequestrates both Ca++ and Mg++,
release of both GAG and histamine was very low; with EGTA, which
removed existing stores of Ca++ but not Mg++, release was only
slightly increased. Maximum release occurred in the presence of
both Ca++ and Mg++ added at concentrations of 0.6mM and ImM
respectively.
Total Histamine Content.
The mean total histamine content of cellular preparations was 60.3
(range = 42.0-75.2; SEM=32.0) ng/ml, which was comparable to the
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Conditions. 0.6mM Ca++
25mM EDTA 25mM EGTA l.OmM Mg++
Histamine Released
ng/ml (mean ± SEM) 13.7 ± 1.42 19.7 ± 0.93 37.0 ± 2.19
GAG Released
ng/ml (mean ± • SEM) 267,7 ± 43.2 294,0 ± 60.3 803.7 ± 80.
Table 1: Dependence of Release on Divalent Cations.
Cell fractions were obtained from four atopic individuals
in the presence of EDTA (0.025M, to remove existing stores
of Ca++ and Mg++), or EGTA (12.5mM, to deplete stores of
Ca++ only). To show the Ca++ requirement for release, cell
fractions were supplemented with Ca++ (0.6mM) and Mg++
(ImM). Values are expressed as mean and SEM.
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maximum histamine values obtained with D.pteronyssinus-induced
release (mean=42.5; range=10.5-95.0; SEM=11.37ng/ml).
Dose Response of Allergen-induced Release of GAG and Histamine from
Basophils.
D.pteronyssinus was added to cell suspensions at five different
dilutions and dose response relationships were observed between the
concentration of allergen and the release of histamine and GAG in
atopic subjects. However the dose response peaks of histamine and
GAG release were apparently dissociated in all cases; this is
illustrated in Figure 1. This individual was studied twice, with a
six month interval between tests, and the release patterns obtained
were similar on each occasion. There was however wide individual
variation in allergen induced release patterns. Levels of release
at each concentration of D.pteronyssinus were therefore expressed
as % of spontaneous or background release for each individual
(background = 100%) to indicate magnitude of response. Mean values
of allergen-induced histamine and GAG release for both groups
studied are shown in Figure 2. Mean background histamine release
was 11.08 (SEM=1.82) ng/ml for the atopic individuals, and
allergen-stimulated release increased with dose to 372.4 (SEM
99.5)% of this level at a D.pteronyssinus concentration of 10y g/ml.
By contrast, maximum release of GAG occurred on average at 0.1 y g/
ml D. pteronyssinus, and amounted to 227 (SEM=63)% of the mean
background GAG release of 463 (SEM=63) ng/ml. GAG release above
background was significant at the p< 0.001 to p< 0.05 level for the
atopic group.
Although there was no allergen-induced release of histamine from
cells of non-atopic individuals (background release = 9.2ng/ml, SEM
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Concentration of D.pteronyssinus pg/ml
Figure 1: Release of GAG and Histamine in an Atopic Individual.
Release of GAG and histamine were measured from cells
challenged with five concentrations of allergen. Each
point represents the mean of 2 determinations. This
illustrates the pattern of release from one of the atopic
patients studied. Results obtained at each allergen
concentration were calculated in relation to spontaneous
or background release (spontaneous release of GAG =


























































Concentration of D. pteronyssinus (jg/ml


















Concentration of D.pteronyssinus pg/ml
°no 1CT310-2C)1 1 10
allergen
Figure 2: Release of GAG and Histamine in Atopic and N0N—Atopic
Individuals.
Release levels are shown as mean values with SEM for each
allergen concentration within each population. Release of
GAG was significantly raised above background for both
populations at each allergen concentration (p< 0.01 to
p< 0.05, and p< 0.001 to p< 0.05 for atopic and non-atopic
groups respectively). Mean basophil concentration for
0
non-atopic individuals was 59 (SD=38)xlO /l, and 67
0
(SD=24)xlO /I for the atopic group. Release of histamine
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Time interval after allergen challenge (mins)
Figure 3: Time Course of GAG and Histamine Release in Atopic
Individuals.
Aliquots of cell suspension were removed at various time
intervals after addition of allergen, and levels of GAG
( ) and histamine ( ) release were measured. Release
was calculated as % of background for each individual,
(mean background GAG release = 447.5 (SEM=61.3)ng/ml, and
mean background histamine release = 18 (SEM=5.48)ng/ml)
using these values as 100%, and plotted with mean and SEM
for each time interval.
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= 2.18ng/ml), some release of GAG above background of 526.3 (SEM =
66.9) ng/ml was observed with these cells; this was significant at
the level p< 0.01 to p< 0.05, and reached a maximum of 148% above
_3
background at a D.pteronyssinus concentration of 10 p g/ml.
0
The basophil concentrations were 67 (SEM=6.4) x 10 /I for the
0
atopic subjects, and 59 (SEM=13.4) x 10 /I for the non-atopic
controls.
Time Course of GAG and Histamine Release.
Leucocytes from 6 atopic individuals were challenged with
D.pteronyssinus allergen concentrations previously found to cause
release of both GAG and histamine for each individual. Aliquots of
cell suspension were removed 5,10,15,30,60 and 90min after allergen
challenge. Each aliquot was centrifuged as before and assayed for
both GAG and histamine. GAG release was slow and required 60min
incubation with allergen to complete, whereas maximum histamine
release occurred within 15min of allergen challenge (Figure- 3).
Results are expressed as % background release to show magnitude of
response obtained; mean background release of histamine was 18.0
(SEM=5.48) ng/ml, and mean background release of GAG was 447.5
(SEM=61.3) ng/ml.
(6:4). Discussion
The study of the role of the basophil in allergic disease to date
has been hindered by their small numbers in whole blood, and the
limited number of tests of basophil function. Of the tests
available, the release of histamine from the secretory granules is
most widely applied (Siraganian and Hook 1976b). Since histamine is
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known to be associated with heparin-like molecules in cytoplasmic
granules (Galli and Dvorak 1979), the GAG assay described in
Chapter 2:1 was used to evaluate the characteristics of its release
from basophils in the allergic response.
Since GAG was previously found to be exclusively contained in the
basophil fraction of whole blood (Chapter 3), and this is also the
case for histamine (Graham et al 1955), it may be concluded that
although whole blood or leucocyte preparations were used in the
experiments of this Chapter, release of these compounds indicated
the response of the basophils, and no other cell type.
Release of GAG and histamine were similarly inhibited by Ca++ and
Mg++ chelation with EDTA, and sequestration of Ca++ alone with
EGTA; release of both mediators thus exhibited a common Ca++
++ *
requirement. Mg alone did not support release. It is generally
assumed that since histamine and GAG are contained in the same
granules within cells, they will be released together during
degranulation. However, this is the first study in which
allergen-induced GAG release from basophils has been examined in
detail, and the evidence suggests that they are released at
different stages of the degranulation process, possibly by
different mechanisms. Optimum release of histamine from cells of
atopic individuals occurred within 15min of allergenic challenge,
whereas GAG release from the same cells occurred at a slower rate,
requiring at least 60min to complete. Histamine is already known to
have different time courses of release, depending on the stimulus
initiating the degranulation process (Lichtenstein and Osier 1964;
Siraganian and Hook 1977), and there have been previous reports of
various other mediators being released at different rates
(Theohardies et al 1982), which has been explained by the possible
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existence of different sites of mediator storage (Tamir et al
1982). Alternatively, the different time courses of GAG and
histamine release may be explained by the theory of Uvnas (1978),
which postulates the formation of a "pore" when fusion between the
secretory granule membrane and plasma membrane occurs at
degranulation. This pore might then act as a dialysing membrane
across which ion exchange mechanisms are thought to result in the
release of small molecules such as histamine. Release of the
macromolecular GAGs would be slower and occur at a later stage of
the degranulation process.
Release of both GAG and histamine from basophils of atopic
individuals could be stimulated by D.pteronyssinus allergen.
However a wide range of allergen-induced release patterns were
obtained, and optimum release of histamine and GAG occurred at
different allergen concentrations for each individual. Although
release of GAG occurred more slowly than that of histamine, the
allergenic stimulus required to elicit maximum release of GAG was
less. Again this points to the existence of a complex release
mechanism, possibly involving more than one compartment.
A smaller but significant amount of GAG release was also detected
in the non-atopic group. This occurred independently of histamine
release and was probably due to a non-immunological response. A
large number of factors are known to cause degranulation of mast
cells and basophils, including various chemicals such as aspirin
(Asad et al 1984), various components of complement (Siraganian and
Hook 1976), lectins (Foreman et al 1977), physical stimuli such as
cold (Soter et al 1976), and spontaneous release has been reported
from cultured human colonic mucosa (Elakim et al 1986). The
D.pteronyssinus preparation used in release experiments may contain
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some agent capable of promoting a small amount of non-IgE mediated
release of GAG from basophils of non-atopic individuals.
It has long been recognized that GAG is released from basophils on
degranulation, but in the absence of a sufficiently sensitive assay
this process has not been examined in detail. Further investigation
is needed to elucidate the exact mechanisms involved, but the
preliminary findings of this Chapter indicate that the properties
of the Ca++-dependent release of GAG from human basophils is
different from that of histamine in several respects, and may
occur, at least in part, by a different mechanism.
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Chapter 7.
Human Mast Cells in Nasal Turbinates
of Atopic and Non-Atopic Individuals.
(7:1). Introduction.
Studies of human mast cells frequently utilise nasal tissue for a
number of reasons.
a. Mast cells are abundant in the nasal mucosa and are easily
recognized in toluidine blue stained biopsy sections. They occur
frequently in the sub-epithelial layer, occasionally between
epithelial cells, and surrounding blood vessels in the deeper
layers of the lamina propria (Wihl 1979).
b. Nasal tissue is easily 'obtained, and biopsies can be taken
without anaesthesia.
c. Nasal secretions contain granule-derived mediators, and reflect
the extent of degranulation of the mast cells; repeated samples
of fresh tissue, secretions and smears are easily obtained, and
intact mucous membranes are easy to inspect.
The frequency of mast cells in the nose is thought to aid in the
defence against harmful airborne agents, thus the nose filters,
warms and moisturises inspired air, as well as functioning as an
olfactory sense organ. However, many airborne agents are inhalant
allergens, such as grass and weed pollens and house dust mite
allergen; these provoke IgE-mediated allergic reactions in
sensitized individuals, and r*esult in the symptoms of allergic
rhinitis. These symptoms can also be produced by food, beverages,
non-specific agents in the ambient air, and changes in temperature,
the severity of which are dependent upon the reactivity of the
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nasal mucosa of individuals (Borum 1979).
Release of mediators from mast cells in nasal allergy causes
sneezing, rhinorrhoea, nasal obstuction, mucosal oedema, itching of
the nose, palate and pharynx, and the accumulation of eosinophils
in the tissues.
The importance of the role of histamine in the pathogenesis of such
reactions is well recognized and is reflected in the benefits of
antihistamine therapy (Mygind 1982); these drugs successfully
control itching and sneezing, but often fail to relieve
obstruction, in which case surgery may be required.
In this Chapter, nasal tissue from atopic and non-atopic
individuals was used to study the content of histamine and GAG in
human mast cells as a marker for mast cell involvement in atopic
disease, and as a comparison with the other studies described,
which are mostly concerned with basophils.
(7:2). Patients and Methods.
Patients.
Twenty six patients were studied in total (16 male: 10 female) all
undergoing bilateral inferior turbinectomy for chronic rhinitis. Of
these patients, 15 were non-atopic (aged 13-72 years; mean=41
years) and 11 were atopic (aged 16-64 years; mean=27 years). Atopic
history, principal symptoms and differential leucocyte counts were
noted. A diagnosis of atopy was based on standard prick skin tests
to 11 common allergens (a weal of 4mm or greater, present at 15
minutes to one or more allergen signified a positive result), and
measurements of total serum IgE, and IgE specific for 3 common
inhaled allergens (house dust mite, grass pollen and animal
dander). One patient was not skin tested because of severe eczema.
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Methods.
Preparation of Tissue Samples.
On removal, 1 turbinate (right or left by random allocation) was
placed in 10ml 0.9% (w/v) NaCl at 4°C, and within 3-5 minutes all
bone was removed and tissue coarsely chopped into 2-3mm fragments,
followed by light centrifugation for 5 minutes to separate solid
tissue fragments and supernatant fluid. The supernatant fluid
samples containing free GAG and histamine, and the nasal tissue
containing the cellular mediators were then stored separately at
-20°C for subsequent GAG and histamine estimation. Prior to
biochemical analysis, 0.9% NaCl was added to the nasal tissue
fragments to standardize weight/volume ratios in all samples, which
were then homogenized at 20p000 rpm for 50 seconds.
Determination of Total and Specific IgE.
These measurements were made using the methods described in Chapter
5.
Assay of Histamine.
The extraction and assay of histamine was performed by the manual
fluorometric method described in Chapter 2:2.
Assay of GAG.
Highly sulphated GAGs were measured in each sample by the method
described in Chapter 2:1.
Assay of Protein.
The protein content of the homogenized tissue specimens was
measured by Mr D Pratt, MRC/SNBTS Blood Components Assay Group,
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Edinburgh, using a dye binding method (BioRad Protein Assay,
England) with bovine serum albumin as the standard.
Mast Cell Counts.
The second turbinate removed from each patient during surgery was
used for microscopic examination of tissues, and to obtain mast
cell counts. These measurements were performed by Dr DM Salter,
Department of Pathology, University of Edinburgh, who also provided
the electron micrographs. Three transverse blocks were taken and
fixed in Carnoy's solution and 3y m paraffin sections were stained
with 1% toluidine blue. Cell counts were performed with an eyepiece
2
graticule (0.23mm ) at a magnification of x 250. Ten sites were
randomly selected from each~of the 3 blocks. At these 10 sites the
edge of the graticule was Orientated at the epithelial surface and
3 contiguous areas perpendicular to the surface counted. Counts
2 2
were expressed as number of cells per mm , a total area of 6.9 mm
having been counted. Additional counts were made on serial sections
of turbinates fixed in 4% neutral buffered formaldehyde. These were
stained with either 1% toluidine blue or with polyclonal anti-IgE
(Dakopatts Ltd, Denmark) using a standard peroxidase (PAP)
technique. In a few atopic and non-atopic subjects, electron
microscopy was performed to assess the degree of degranulation of
the mast cells.
Statistical Analysis.
Statistical analysis was performed using the Student's t-test on
biochemical data, and the Wilcoxon rank sum test on the mast cell
counts. Correlation coefficients were used to establish the
relationship, if any, between the variables measured.
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Histamine and protein values are expressed as mean ± standard
deviation. Total IgE and GAG levels failed to show a normal
distribution and these data were log transformed prior to analysis,
and geometric means derived.
(7:3). Results.
Clinical Details and Symptoms.
The clinical symptoms of the patients studied are shown in Table 1.
As expected, nasal obstruction was the commonest symptom (24
patients). Rhinorrhoea and sneezing were more common to the atopic
group, and facial pain to the non-atopic group.
The total serum IgE levels were significantly raised in the atopic
group (geometric mean 200KU/1), when compared with those of the
non-atopics (geometric mean 19KU/1), (p< 0.001). RAST scores
correlated with skin test results in all but one patient.
Histamine, GAG and Protein Content of Nasal Tissue and Supernatant
Fluid.
Histamine, GAG and protein concentrations of both groups are
summarised in Table 2.
Protein Content
Protein concentrations in the tissue homogenates did not differ
between the two groups.
Histamine Content.
There was no significant difference between atopics and non-atopics
in either free or cellular histamine levels (Figure la), or in the
ratio of free to cellular histamine (Table 2). Histamine levels did
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Tablel: Clinical Symptoms.
Non—atopic Individuals. Atopic Individuals.




Facial paip 13 5
Anosmia 10 4
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Table 2: Histamine, GAG and Protein Content of Nasal Tissue and
Supernatant Fluids.
Non-atopic Individuals. Atopic Individuals.
^Histamine Free (ng/ml) 32.6 ± 11.8 28.9 + 13.1 NS
Cellular (ng/ml) 211.0 ± 81.0 162.0 ± 81 NS
Free/cell ratio 0.17 ± 0.07 0.2 ± 0.1 NS
+GAG Free (ng/ml) 1073 1792 NS
Cellular (y g/ml) 116 54 p< 0.02
Free/cell ratio - 0.0092 0.033 p< 0.05
*Protein Cellular (mg/ml) 10.1 ± 6.7 9.3 ± 7.5 NS
* = mean ± Standard Deviation.





























Figure 1: Concentration of Histamine and GAG in Nasal Tissue and
Supernatant Fluids.
The histamine content (Figure la) and GAG content
(Figure lb) in tissue homogenate and extracellular fluid
(ECF) samples of atopic (n = 11) and non-atopic (n = 15)












igure 2: Log Transformed levels of Cellular GAG in Atopic and
Non-Atopic Individuals.




Figure 3: Parallelism Studies of Nasal Mast Cell—Derived GAG
Dilution curves of supernatant fluid (SF) and tissue
homogenate (TH) samples in the standard GAG assay






Figure 4: Electron Micrographs of Adjacent Mast Cells in the Nasal
Turbinate of an Atopic Individual.
These electrom micrographs illustrate
a. Fully granulated mast cell.
b. Partially granulated mast cell.
c. Degranulated mast cell.
(Lead citrate and uranyl acetate, magnification= x 4200).
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not correlate with total serum IgE, nor was there any association
with total number of positive skin tests.
GAG Content.
Wide distributions of 'free' (210 - 20,050 ng/ml) and cellular (33
- 777 g/ml) GAG were observed. Mean 'free' GAG in the atopic group
did not significantly differ from that of the non-atopic group, but
the mean cellular GAG in the atopics was significantly less than in
the non-atopics, as was the mean ratio of 'free' to cellular GAG
(Table 2 and Figure lb). There was no correlation of GAG levels
with nasal histamine or serum IgE, nor any sex difference. Three
non-atopic individuals had very high levels of cellular GAG (Figure
2), but no other distinctive features could be identified in these
patients. As with histamine levels, the number of allergens to
which each individual was sensitive did not influence the GAG
levels in the atopic group.
Nature of GAG in Nasal Tissue and Supernatant Fluid.
When serial dilutions of supernatant fluid and tissue homogenate
samples were assayed, the resulting curves were not parallel with
the heparan sulphate standard (Figure 3a). This was then repeated
using the heparin assay described in Chapter 2:1 (that is, in the
presence of 50% DMS0), the material was readily assayed and
produced a curve parallel with the heparin standard (Figure 3b).
The GAG contained in the nasal tissue and fluid was therefore
heparin-like rather than heparan sulphate-like material.
Mast Cell Counts.
The results of mast cell counting on specimens fixed in Carnoy's
showed a significant difference (p< 0.01), between a mean of 4.4 (SD
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2 2
= 5.05)/mm in atopics, and 20.8 (SD = 17.2)/mm in non atopics.
Supplementary studies using anti-IgE or toluidine blue on 4%
formaldehyde-fixed tissue did not, however, confirm the presence of
a larger number of mast cells in the non-atopics. Electron
micrographs of tissues indicated that mast cell degranulation is
extremely variable, even among adjacent mast cells, in both the
atopic and non-atopic groups. Figures 4a, 4b and 4c illustrate the
varying degrees of degranulation in adjacent mast cells in the
nasal tissue of an atopic individual.
(7:4). Discussion.
Allergic rhinitis affects up to 20% of the population, but as with
most allergic reactions,-- the precise mechanisms of nasal
hypersensitivity are poorly understood. Mast cells are thought to
play an important role in these reactions, and to support this,
increased mast cell numbers have been detected in nasal smears from
patients with rhinitis (Mygind and Thomsen 1973). Furthermore,
nasal provocation tests with pharmacological agents such as
histamine and/or metacholine induce the symptoms of allergic
rhinitis, sneezing and marked vasodilation probably via both and
receptors in the nasal mucosa (Secher et al 1982). Nasal
provocation tests which administer antigen to the nose thereby
causing mediator release, are also indicative of allergic rhinitis.
The concentration of histamine in nasal fluids has previously been
shown to be extremely variable, and unrelated to an individual's
atopic status (Drake-Lee and McLaughlan 1982; Drake-Lee et al 1984;
Drake-Lee J 984). Histamine levels in normal nasal mucosa varied
over a similar range to that reported in nasal polyps. In this
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study however a variable biological assay was used for the
detection of histamine in small turbinate biopsies (Baxter and Rose
1953), and subsequent studies have relied on the collection of
nasal washings or epithelial curettings and have produced
conflicting results (Hamaguchi et al 1983; Eggleston et al 1978;
Naclerio et al 1983; Otsuka and Okuda 1981). A study of the release
of mast cell granule-derived GAG in human nasal tissue has not
previously been reported.
The results obtained from the 26 patients examined confirmed the
previous reports of variable histamine levels in fluids and tissues
of the nose. The results indicate that in chronic rhinitis there
are significant basal levels of 'free' histamine (range 14-65
ng/ml), the corresponding" plasma value being < 10 ng/ml. The
histamine levels in the'' tissue homogenate samples were much
greater, with a range of 81-405 ng/ml. There were no significant
differences in either 'free' or residual cellular histamine levels
between the atopic and non-atopic groups, perhaps due to the
masking of differences by the rapid metabolism of released
histamine by histaminase (Schwartz and Austen 1984) outside the
secretory granule. Any release of histamine from the mast cells
into supernatant fluid would therefore not be detected, due to its
very short half life.
The GAG contained in, and released from the human mast cells
studied resembled heparin rather than the heparan sulphate-like GAG
in the basophils. Parallelism studies using doubling dilutions of
both supernatant fluid and tissue homogenate samples in the GAG
assay revealed that the material contained in these samples was
more sulphated than the heparan sulphate standard (Figure 3a).
Subsequent analysis of these samples using the assay specific for
-224-
heparin produced dilution curves parallel with the heparin standard
in both supernatant fluids and tissue homogenates (Figure 3b). The
involvement of basophils in allergic rhinitis has previously been
reported (Hastie et al 1979; Okuda et al 1978; Okuda and Otsuka
1977), and circulating basophils are thought to migrate to the
nasal mucosal surface (Okuda et al 1979). Any basophil-derived GAG
contained in these samples would not be detected in the heparin
assay. Nevertheless, basophils have previously been shown (Chapter
3) to contain no heparin-like material. As no source of heparin
other than mast cells has been identified, it may therefore be
concluded that the material detected in supernatant fluid samples
originated from the mast cells of the nasal mucosa.
A wide range of 'free' GAG "levels was also detected in both atopic
and non-atopic groups, but these did not correlate with 'free'
histamine levels. This is consistent with the findings of Chapter
6, whereby the release of GAG and histamine from basophils appear
to be dissociated and vary widely in both atopic and non-atopic
individuals. Overall, 'free' GAG levels were greater in the atopic
group, but this difference failed to reach statistical
significance. However, residual cellular GAG levels were
significantly greater in the non-atopic individuals; the mast cell
counts on Carnoy's fixed specimens suggested that this might simply
reflect a larger number of granulated mast cells in the tissue of
non-atopic individuals. However, further counts using different
staining procedures on 4% neutral buffered formaldehyde-fixed
specimens gave nasal mast cell numbers in atopic individuals
similar to or slightly greater than those of non-atopics. This may
indicate the possible existence of different subpopulations of mast
cells within nasal tissues, which are selectively demonstrated by
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the methods used. A recent report by Shanahan et al (1987) showed
that histochemically distinct mast cell subpopulations which can be
identified by different fixation and staining procedures exist in
human lung tissue. The findings presented here suggest that a
similar heterogeneity may also exist in mast cells of the nasal
mucosa. Furthermore, functional heterogeneity of human mast cells
from different anatomical sites in vivo has recently been reported
(Tharp et al 1987). It is possible that GAG in mast cells of atopic
individuals exists in a more 'releasable' form than in those of
non-atopic individuals, and therefore cellular stores of GAG in
atopics may have been depleted prior to surgery. Alternatively,
cellular stores of GAG in atopic individuals may have been depleted
due to allergenic stimulation. Nasal mucosa of non-atopic
individuals appeared to contain a higher proportion of granulated
mast cells demonstrated by Carnoy1s fixation which may contain
excess stores of less 'releasable1 or ' non-releasable' GAGs. These
data are consistent with those obtained from the studies on
basophils (Chapter 6), and collectively point to the possible
existence of more than one storage pool for secretory granule
mediators in both mast cells and basophils.
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Chapter 8.
Plasma GAG Levels in Health and Disease.
(8:1). Introduction.
The studies outlined in this thesis so far have indicated that GAGs
found in human plasma have similar biochemical characteristics to
those contained in the circulating basophils. The highly sulphated
GAGs contained in human tissue mast cells do not appear in plasma
at detectable levels. Plasma GAG may therefore, at least in part,
be basophil-derived (Chapter 3). The studies outlined in this
Chapter have examined further the relationship between plasma GAG
and circulating basophils and its physiological importance in the
pathogenesis of type 1 hypersensitivity reactions.
In order to assess plasma GAG levels in health and disease,
circulating levels of plasma GAG were measured in atopic and
non-atopic individuals and related to their individual basophil
counts. Sequential blood samples were also taken from a number of
both atopic and non-atopic individuals, to detect variations of
basophil counts with time. In addition, a group of patients with
various related myeloproliferative diseases including chronic
myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), acute
myeloblastic leukaemia (AML), and acute lymphoblastic leukaemia
(ALL), in which circulating basophils (Parwaresch 1976) and
histamine (Jacquiliat 1975) are known to be elevated, were studied
to provide a population for comparison.
Plasma GAG levels were measured in a group of patients prone to
anaphylactic and anaphylactoid reactions, which are particularly
difficult to study in humans, due to their rapid nature and serious
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consequences. Severe systemic reactions of this kind are
occasionally experienced by patients under certain clinical
conditions where they can be closely monitored: such as following
the transfusion of blood or blood products, including intravenous
immunoglobulin. Adverse reactions associated with the
administration of intravenous immunoglobulin have been attributed
to a number of factors, including the presence of aggregates of IgG
in the preparations (Barundun et al 1962; Barundun et al 1979),
vasoactive peptides (Alving et al 1980), endotoxins (Hanson et al
1979), anti IgA antibodies (Vyas et al 1969; Burks et al 1986), and
the physiological effects of the immunoglobulin (Barundun et al
1962). A decrease in the proportion of aggregated immunoglobulin in
the products available from-various manufacturers following changes
in preparative procedures,* has been associated with a decrease in
the incidence of adverse reactions (Eibl et al 1984; Pirofsky
1984). However, the precise mechanisms of these adverse reactions
remain poorly understood.
The possibility of basophil involvement in these reactions, as
measured by plasma GAG and histamine, was therefore assessed by
studying:
a. a group of 15 patients before and after platelet transfusion.
b. a group of 18 patients with primary disorders of immunoglobulin
production, during a blind crossover evaluation of a new
preparation of immunoglobulin for intravenous use.
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(8:2). Patients, Materials and Methods.
Patients.
Control Individuals.
35 healthy adult volunteers, described in Chapter 5, were
non-atopic controls.
Atopic Individuals.
55 atopic individuals, described in Chapter 5, were studied in
total.
Leukaemia Patients.
A total of 34 patients were studied at various stages of therapy;
17 patients aged 20 - 58 years (mean age = 45.7 years) had
Philadelphia chromosome pos'itive CML in chronic phase, 9 aged 49 -
82 years (mean age = 63.9 years) had CLL, 5 aged 39 - 45 years
(mean age 42.3 years) had AML, and 3 aged 48 - 67 (mean age = 55.3
years) had ALL.
Patients Receiving Blood and Blood Products.
Platelet Transfusions.
Plasma samples were collected from 15 patients receiving platelet
transfusions.
Intravenous Immunoglobulin Preparations.
A total of 18 patients (15 male; 3 female) aged 18 months to 20
years (median age = 10 years 10 months), who were attending an
immunoglobulin replacement clinic of the Royal Childrens Hospital,
Melbourne, Australia, were studied. All had been receiving
intravenous immunoglobulin replacement therapy every four weeks at
a dose of 300 to 450 mg/kg per infusion. The median duration of
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intravenous therapy prior to enrolment was 3 to 5 years (range = 1
month to 10 years). None of the patients had acute infections at
the time of study. Ten patients had experienced frequent adverse
reactions to the intravenous immunoglobulin preparation used as
standard therapy, frequent reactions being defined as infusion-
related symptoms necessitating slowing or interruption of the
infusion on at least three occasions during the six month period
preceding the study. This study was performed in collaboration with
Dr DM Robertson and Dr CS Hosking, who carried out the clinical
parts of the study, and collected the samples for assay.
Materials.
Intravenous Immunoglobulin.Preparations.
The two intravenous immunoglobulin preparations were prepared by
the Commonwealth Serum Laboratories (CSL), Parkville, Australia,
and were supplied as 6% (w/v) solutions. Both were prepared from
pooled volunteer blood donor plasma by ethanol fractionation.
"Standard" CSL normal human immunoglobulin for intravenous use was
briefly exposed to pH 4.0, followed by adjustment to pH 6.4. The
preparation did not contain maltose and had been used continuously
for previous therapy for all 18 patients. A modified preparation
("low pH" immunoglobulin for intravenous use) was maintained at pH
4.0 and contained 10% maltose.
The "standard" CSL immnnunoglobulin preparation for intravenous use
contained approximately 18% aggregated IgG, whereas the aggregate




Whole blood samples were taken into trisodium citrate (3.12% w/v),
and plasma obtained as described in Chapter 2:1.
Basophil Counts.
Whole blood samples were collected into EDTA (0.025M) vacutainer
tubes and cell counts determined as described in Chapter 5.
Assay of GAG
Samples were prepared and assayed for GAG by the method described
in Chapter 2:1.
Assay of Histamine.
Samples were prepared and assayed for histamine by the method
decribed in Chapter 2:2.
Sequential Studies of Plasma GAG.
Daily Variation of Plasma GAG.
Duplicate plasma samples were obtained from 2 atopic and 2
non-atopic individuals at the same time on 5 consecutive days, and
assayed for GAG.
Diurnal Variation of Plasma GAG.
Plasma samples were prepared in duplicate from 5 atopic and 3
non-atopic individuals at intervals of 3h over a period of 24h, and
assayed for GAG.
Platelet Transfusions.
Three samples were collected from each patient; one just before the
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transfusion, and two further samples, lh and 24h after the
transfusion. Patients were closely monitored for any adverse
reaction to the platelet transfusion.
Intravenous Immunoglobulin.
This study was a blind crossover trial, with each patient receiving
one intravenous infusion of the standard immunoglobulin and one
infusion of the low pH immunoglobulin. Nine patient pairs were
assigned by random allocation, with one patient in each pair
receiving the standard product and one the low pH product at the
initial infusion. The order was reversed for each patient pair for
the second infusion given four weeks later. No medications were
given during the 48h prior to each infusion.
All infusions were given at the same rate of 0.75ml/min/20kg
patient body weight for the first 30min, and subsequently at
1.5ml/min/20kg patient body weight. Each patient received their
usual dose of immunoglobulin and the same volume of immunoglobulin
was prescribed for each treatment. Samples were taken immediately
prior to each infusion and lh after commencement of the infusion.
Further samples were taken at 2h and 3h if the infusion had not
been completed at these times. Samples were collected by aspiration
through intravenous cannula, also used for administration. Samples
were stored at -70°C, coded prior to testing, and assayed without
knowledge of the ocurrence of reactions or the type of
immunoglobulin received.
Statistical Analysis.
Significance tests on all plasma GAG levels were analysed by
Student's t-test on log transformed data, except for the
-232-
intravenous immunoglobulin study which used the McNemar test for
significance of changes with correction for continuity, the
Wilcoxon matched pairs signed ranks test and the Fisher exact test.
(8:3). Results.
Plasma GAG Levels.
Atopic and Non-atopic Individuals.
Levels of plasma GAG did not differ significantly between atopic
(range = 210-905; mean = 432.2; SEM = 29.8 ng/ml) and non-atopic
(range = 205-1005; mean = 418.1; SEM= 28.2 ng/ml) groups (p =
0.32), (Figure 1). Plasma GAG did not correlate with basophil
counts in either atopic (r = 0.09) or non-atopic (r = 0.19) groups.
Leukaemia Patients.
Plasma GAG was significantly raised above normal in patients with
CML (range = 615-5,350; mean = 1993.5; SEM = 303.3 ng/ml),
(p< 0.001), (Figure 2); circulating basophil counts (range =
20-5,480; mean = 1405.3; SEM = 403 x 10^/1), (Figure 3), and
eosinophil counts (range = 60-4,380; mean = 919.4; SEM = 240.4 x
0
10 /1), (Figure 4) were also raised in these patients. Moreover,
basophil and eosinophil counts correlated in this group (p< 0.005).
A strong correlation (r = 0.80, p< 0.001; regression equation y =
2.06 + 0.35 x) was observed between plasma GAG and absolute
basophil counts in the group of leukaemic patients as a whole,
suggesting that increased GAG levels in plasma can directly reflect
elevated absolute basophil numbers.
Daily Variation of Plasma GAG.









Figure 1: Plasma GAG Content of Atopic and Non-Atopic Individuals.
Levels of plasma GAG did not significantly differ between







Figure 2: Plasma GAG Content of Patients with Various Related
Myeloproliferative Disorders.
Plasma GAG was significantly raised above normal in









Figure 3: Circulating Basophil Counts in Patients with Various
Related Myeloproliferative Disorders.
Circulating basophil counts were significantly raised












CML CLL AML ALL
Figure 4: Circulating Eosinophil Counts in Patients with Various
Related Myeloproliferative Disorders.
Eosinophil counts were significantly raised above normal
in patients with CML (p < 0.005). Mean values are
indicated.
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obvious pattern and with no apparent differences between the atopic
and non-atopic individuals (Figure 5). There was no correlation
between the variation of plasma GAG and basophil counts in either
group.
Diurnal Variation.
A wide variation of plasma GAG levels occurred both within and
between each population studied (Figures 6a and 6b). Again no
obvious pattern of fluctuation was observed.
Plasma GAG Levels in Patients Receiving Blood and Blood Products.
Platelet Transfusions.
There was no obvious pattern of fluctuating plasma GAG levels in
any of the patients studied during the course of uneventful
platelet transfusions (Figure 7); none of the patients exhibited
any adverse reactions during treatment.
Intravenous Immunoglobulin Study.
Plasma Histamine Content.
Plasma histamine concentrations in all samples taken before and
during infusion with either immunoglobulin preparation were below
the lower limit of detection of the assay, which was 5 ng/ml.
Plasma GAG Content.
The median plasma GAG contents prior to and during infusions are
shown in Table 1. There were no significant changes in GAG
concentrations during treatment with either type of immunoglobulin,
nor were there any significant differences between the two
treatment groups at any of the sampling times (Wilcoxon matched
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Figure 5: Daily Fluctuations of Plasma GAG Concentrations.
Plasma GAG levels fluctuated considerably from day too
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Figure 6: Diurnal Variation of Plasma GAG Concentration.
A wide variation of plasma GAG levels occurred both
within and between atopic (Figure 6a), and non-atopic
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Figure 7: Plasma GAG concentrations of Patients at Various Stages
of Platelet Transfusion.
No obvious pattern of fluctuation of plasma GAG levels
occurred durin the course of transfusion; none of the




Pre-infusion. lhour. 2hours. 3hours.
Standard
Immunoglobulin. 890 985 805 755
(range) < 200-3800 < 200-4800 -385-14,600 500-4000
Low pH
Immunoglobulin 1290 775 1020
(range) . < 200-3950 < 200-2100 < 200-2420
Table 1. Plasma GAG levels before and during infusion with standard
(aggregate-containing) and low pH immunoglobulin
preparations.
Values shown are medians. No samples were taken at 3 hours
in the low molecular weight immunoglobulin group, since
all infusions were completed by this time.
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(8:4). Discussion.
The glycosaminoglycans circulating in human plasma have been shown
in previous Chapters to be indistinguishable from those contained
in human basophils (Chapter 2:1 and Chapter 3). Moreover, this GAG
has been found to be exclusively contained in the basophil fraction
of whole blood (Chapter 3), and plasma GAG may therefore originate
at least in part from circulating basophils; the relationship
between plasma GAG and individual basophil counts in various groups
was therefore studied. Plasma GAG levels varied considerably within
atopic and non-atopic groups, and unlike basophil counts (Chapter
5) plasma GAG did not differ significantly between these two
populations (Figure 1). Basophil counts were considerably raised
above normal in many of -"the leukaemic patients studied, and
previous reports that the greatest elevations of basophils occur in
CML (Forkner 1938; Doan and Reinhart 1941; James et al 1955; Juhlin
1963b) were confirmed (Figure 3). The increasing basophilia
associated with CML may indicate the development of blast
transformation (Edzinli et al 1970; Theologides 1972; Jacquillat et
al 1975) , and these basophils do show a number of inherent
biochemical and functional defects (Lett-Brown and Juneja 1985).
The raised eosinophil counts in these individuals (Figure 4) are
consistent with the findings of Chapter 5, in which circulating
basophil and eosinophil levels of both atopic and non-atopic
individuals are closely correlated. Histamine levels are known to
be elevated in CML (Jacquiliat 1975), and plasma GAG levels were
also found to be significantly elevated in this group (Figure 2).
At these concentrations, plasma GAG was closely correlated with the
absolute basophil count (r = 0.08, p< 0.001; regression equation y =
2.06 + 0.35x). Such a close relationship would suggest that the
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increased plasma GAG levels directly reflected elevated absolute
numbers of basophils, rather than GAG release from another cell, or
immunologically mediated basophil activation with granule release,
for which no obvious precipitating factors were observed. Although
the levels of plasma GAG detected were much lower than levels
observed in patients with GAG-associated bleeding tendencies
(Dawes, personal communication), sequential plasma GAG measurements
on CML patients to monitor any increase during the accelerated
phase, with complementary coagulation studies to determine any
physiological effect may be of interest in patients with untreated
CML. Although 'basophil counts were higher in atopic than non-atopic
groups, differences were atopic groups, differences were not
sufficiently marked to infl-uence GAG levels in plasma.
The levels of plasma GAG i-n both atopic and non-atopic individuals
fluctuated with time (Figures 5 and 6); no obvious pattern of
variation or external factors responsible for such fluctuations
could be identified in either group. This probably reflects release
of granule-associated GAG from basophils and its metabolism in
vivo.
None of the patients receiving platelet transfusions experienced
adverse reactions. Plasma GAG levels did fluctuate pre- and
post-transfusion in many cases (Figure 7), but were not apparently
influenced by the treatment administered; rather, they probably
reflect the variation described above (Figures 5 and 6).
By contrast, adverse reactions were frequently associated with the
infusion of intravenous immunoglobulin. In the blind crossover
study described, a strong association was shown between adverse
reactions during the infusion, and the presence of high molecular
weight IgG in the immunoglobulin preparation (Robertson et al;
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submitted for publication). Plasma histamine and GAG levels did not
change significantly during infusions with either immunoglobulin
preparation, or with the occurrence of adverse reactions during
infusion. Although the apparent lack of histamine release could
simply be due to the rapid metabolism of any released histamine by
histaminase in plasma, it is consistent with previous reports that
antihistamines and sodium chromoglycate are not useful as treatment
or prophylaxis of adverse reactions (Pirofsky 1984). Moreover, the
failure to detect any significant change in plasma GAG also appears
to indicate that basophil release is unlikely to occur during these
reactions. In this study, it was shown that although conversion of
occurred in plasma from patients receiving the aggregate-
containing preparations, there was no quantitative correlation with
either the incidence or severity of reactions. Plasma granulocyte
elastase concentrations also increased during infusion of the
aggregate-containing immunoglobulin, and patients experiencing
reactions tended to have higher plasma granulocyte elastase
concentrations. This was not however statistically significant, and
was independent of the degree of conversion. It may reflect in
vivo stimulation of polymorphonuclear leucocytes (PMN), by the
binding of aggregated IgG to receptors on neutrophils. None of
the parameters measured were indicative of incidence or severity of
reactions experienced by patients.
The finding that hypogammaglobulinaemic patients capable of
producing some immunoglobulin are more likely to experience adverse
reactions suggests that investigations directed towards the
detection of anti-isotypic antibody, or even perhaps idiotype-anti
-idiotype reactions (Cunningham-Rundles 1982), may be more useful
in further elucidating the mechanisms of adverse reactions




Release of histamine from basophils has served as an excellent in
vitro assay of immediate hypersensitivity for many years, but
knowledge of the actual participation of these cells in such
reactions has to date been limited. The measurement of GAGs has
added to the existing knowledge of human basophils in both health
and disease.
The major findings of the studies outlined in this thesis are
summarized as follows:
a. Highly sulphated GAGs were detected in plasma and the basophil
fraction of human whole "blood. The nature of plasma GAG was
indistinguishable from that of basophil-derived GAG. Plasma GAG may
therefore originate at least in part from circulating basophils.
Approximately 70% of the highly sulphated GAGs in basophils was
heparan sulphate and 30% was highly sulphated chondroitin sulphate,
probably chondroitin sulphate E.
b. These GAGs are released from basophils of atopic individuals
following Ca^+- and dose-dependent allergenic stimulation with D.
pteronyssinus. There was also some release from basophils of
non-atopic individuals, which probably occurred by a
non-immunological mechanism. Allergen-induced release of histamine
occurred only from basophils of atopic individuals, and differed
markedly from the release of GAG both in time course, and allergen
concentration required for optimum release.
c. The major GAGs contained in rat mucosal mast cells and cultured
rat basophilic leukaemia cells had similar biochemical properties
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to those of human basophils: these were released together with
histamine and RMCP II protease (both also mucosal mast
cell-derived) during systemic anaphylaxis of Nippostrongylus
brasiliensis-primed rats challenged intravenously with worm
antigen.
d. Circulating basophil numbers in atopic individuals were
significantly elevated above those of non-atopic individuals, as
were eosinophil counts, which paralleled those of basophils in both
populations. Individual basophil counts did not fluctuate over
short or long periods of time in either atopic or non-atopic
individuals.
e. GAG contained in mast cells of nasal mucosa was heparin, and was
present in significantly greater concentrations in non-atopic than
atopic individuals.
f. Plasma GAG levels did not differ significantly between atopic
and non-atopic populations, but individual GAG levels fluctuated
considerably. However, in a group of patients with CML with very
high basophil counts, plasma GAG levels were raised and there was
significant correlation of plasma GAG and circulating basophil
numbers.
g. There was no significant increase in plasma GAG levels in
patients following uneventful platelet transfusions. No significant
increase of plasma GAG or histamine levels was seen in patients
receiving intravenous immunoglobulin, although raised levels of
granulocyte elastase and complement breakdown products were
observed in many patients experiencing adverse reactions. This was
a good indication that basophils were not involved in the
mechanisms of adverse reactions to infusions of intravenous
immunoglobulin preparations.
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The release of GAG but not histamine from the secretory granules of
basophils from non-atopic individuals after exposure to a D.
pteronyssinus preparation raises the possibility that more than one
type of storage pool exists for different mediators in these cells.
This is supported by the findings from the studies of nasal tissue
mast cells. Cellular stores of GAG were present in significantly
greater concentrations in non-atopic individuals than in atopic
individuals, whereas cell numbers and both cellular and
extracellular histamine concentrations remained constant in both
populations.
The degranulation of basophils during type 1 hypersensitivity
reactions involves the crosslinking of adjacent IgE receptors on
the cell surface, and results in the release of both stored and
newly synthesized mediators from the cytoplasmic secretory
granules. Since histamine is closely associated with GAGs in these
organelles, it has generally been assumed that they will be
released together, and by the same mechanism, during degranulation.
Evidence presented here points to the existence of a complex
process, in which release of GAG and histamine occurs at different
rates, and possibly by different mechanisms.
It has been confirmed that human nasal tissue mast cell GAG is
largely heparin, whereas basophils contain the less sulphated GAGs
also present in plasma. Previous studies in patients have defined
these GAGs as chondroitin sulphates, but evidence presented here
suggests that of the highly sulphated GAGs in normal human
basophils, approximately 70% was heparan sulphate and 30% was
highly sulphated chondroitin sulphate, probably chondroitin
sulphate E.
The release of mediators from mast cells and basophils appears to
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play a central role in immediate hypersensitivity reactions, and
clearly all of these mediators could have clinical importance in
the manifestations of allergic diseases. However, the exact role of
the secretory granule-derived GAG, when released, is unclear. The
most obvious physiological function (other than packaging of the
granule mediators) for mast cell-derived heparin is as an
anticoagulant at local sites of inflammation. In addition, heparin
has many other functions described in Chapter (2:1); these include
the inhibition of cell migration and growth, binding to and
altering the activity of eosinophil-derived major basic protein
(Gleich 1977), and possibly inhibiting complement activation at
several steps along the cascade (Weiler et al 1970). Basophils do
not contain heparin, but rather possess less sulphated
proteoglycans, heparan sulphate and ' oversulphated' chondroitin
sulphate E. Heparan sulphate does have anticoagulant activity,
though approximately twenty times less than that of heparin, and
the anticoagulant activity of chondroitin sulphate E has not yet
been determined. The anticoagulant effect of GAGs released from
basophils may be less important than that of mast cells, since
basophils are not so directly involved at local sites of
inflammation in type 1 hypersensitivity reactions. Furthermore, if
basophil-derived proteoglycan had anticoagulant activity as potent
as that of heparin, general systemic coagulation problems could
result in many individuals.
The involvement of mast cells and basophils in human anaphylaxis is
thought to be of considerable importance, but direct evidence of
their role in such reactions is difficult to obtain. The importance
of basophils in type 1 hypersensitivity reactions has been
highlighted by the finding that basophils were significantly
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elevated above normal in a large group of atopic individuals. With
the use of the Nippostrongylus-primed rat model, the mechanisms of
anaphylaxis could be studied in greater detail. Knowledge of mast
cell involvement during anaphylaxis from studies on rat mucosal
mast cell-derived RMCP II, has been supplemented with histamine and
GAG measurement at the same time and from the same cells. From
these studies, it was clear that generalized systemic release of
mediators occurs during anaphylaxis. It was also confirmed that
unlike connective tissue mast cells, rodent mucosal mast cells did
not contain heparin, but less sulphated GAGs of similar biochemical
nature to those contained in human basophils, contributing to the
evidence for mast cell heterogeneity.
The measurement of highly sulphated GAG and its release during the
degranulation process has 'proved valuable in the study of normal
human basophils and their involvement in type 1 anaphylactic
hypersensitivity reactions. Although the exact role of the basophil
in allergic disease and type 1 hypersensitivity reactions remains
unclear, the information presented in this thesis underlines that




One of the major findings of this study was the characterization of
the highly sulphated GAGs derived from human basophils as heparan
sulphate and oversulphated chondroitin sulphate. However, these
experiments used extracts of GAG from relatively crude basophil-
enriched fractions of whole blood, and should be repeated using
more highly purified GAG extracts. GAGs from a basophil-enriched
fraction obtained by density gradient centrifugation as described
in Chapter 3 should initially be purified on Polybrene-Sepharose
and then subjected to specific enzymic and chemical degradation
procedures. Finally, identification of the resulting disaccharides
would permit clear delineation of the GAG structure.
The GAG content and composition of human basophils must be studied
further in a physiological context, to determine whether the ratio
of heparan sulphate/oversulphated chondroitin sulphate remains
constant within or between individuals, or if it varies with time,
sex, age or atopic status. This would also answer one of the
important questions remaining unresolved from this work, that of
the possible variation of GAGs in basophils of specific
individuals.
Until fairly recently, in vitro systems for the study of human mast
cells have not been available; therefore, much of the understanding
of normal mast cell function has been derived from rodent models.
Within the past several years however, techniques have been
developed which permit in vitro investigation of suspensions of
human mast cells derived from different anatomical sites, and it
has been found that a significant similarity exists between human
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and rodent mast cells (Gruber et al 1986; Tharp et al 1987;
Schulman et al 1982; Fox et al 1985). The study and
characterization of GAG in human mast cells from these different
anatomical sites may contribute to the understanding of human mast
cell heterogeneity, and their possible function in a given tissue.
This would involve the extraction of GAGs from mast cells of the
various tissue types, which could then be analysed in terms of
their chemical composition and biological characteristics.
The mechanisms involved in the release of histamine from human mast
cells and basophils has been the subject of much research in the
field of allefgy in recent years; the study of GAG release from
these cells has however, received very little attention as adequate
methods for its measurement were not available. The results
described here indicate that GAG may be released from basophils by
more than one mechanism. This is an important area which requires
further investigation.
It is known from these studies that considerable quantities of GAG
are released from basophils in response to allergenic stimulation,
but despite exhaustive attempts, the exact percentage of total cell
GAG released could not be determined. Methods other than those
tested should therefore be sought for the measurement of total cell
GAG. The determination of total cell GAG content would also be
useful in the study of the exact intracellular location of the GAG
contained in basophils and mast cells, and the pattern of its
release following activation of the cell. For example, how much
cellular GAG, if any, is contained outside the secretory granule,
how much is contained in the matrix of the secretory granule, how
much is bound to the secretory granule membrane, and exactly how
much cellular GAG is released during degranulation of the cells.
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Such studies may also indicate whether more than one pool of
mediator storage exists in these cells.
Experiments where degranulation is prevented, in the presence of
allergen stimulus would be useful to delineate the properties of
GAG release further, and to determine whether degranulation of the
cell is necessary for its release, or whether GAG is passively
secreted without degranulation.
GAGs are metabolized in the liver, and the degradation products
excreted by the kidneys. It will therefore also be useful to study
GAG derived from mast cells and basophils in the plasma of patients
with hepatic and renal dysfunction.
In Vivo Studies Using an Animal Model.
The knowledge gained frbm the biochemical studies on the
Nippostrongylus brasiliensis-infected rat animal model should be
used to study further the different cell types in vivo, and their
response during systemic anaphylaxis. As rat connective tissue and
mucosal mast cells contain different GAGs, analysis of those
released will furnish information on
a. Contribution of each type of cell in response to different
stimuli.
b. Characteristics of release in relation to protease markers of
mast cell type.
c. Mast cell release during antigenic priming.
In addition, when rat basophil GAGs can be characterized, this will
permit analysis of basophil involvement in anaphylaxis.
Since the major beneficial function of the basophil/mast cell/IgE
system is likely to be the protection of the host against parasitic
infections, the study of these cells in patients with helminthic
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disease should also be informative and add to existing knowledge of
the function of basophils.
Clinical Studies.
It has been assumed for many years, that basophils as well as mast
cells are important in the reactions of type 1 hypersensitivity.
The study of basophils in such reactions should be continued with
clinical studies of both allergy and anaphylaxis. Differences
between the basophils and mast cells of patients susceptible to
these reactions and those of healthy individuals should be sought
and highlighted. The study of basophils in common allergic disease
such as asthma and allergic rhinitis is relatively easy to arrange,
since this is such a common problem and samples are readily
obtained. By contrast, systemic anaphylaxis in humans where
basophils would be expected to play a major role is extremely
difficult to study, since these reactions are rare, acute and
usually unexpected. The most appropriate models for the controlled
study of systemic anaphylaxis in humans are likely to be:
a. Hymenoptera venoms (from bee and wasp stings). These reactions
may occur during hyposensitization therapy, where patients receive
small doses of the venom, which are increased during the course of
treatment. Patients are finally challenged with a full dose of the
venom, and at this stage anaphylactic reactions may also well
occur. Smith et al (1980) previously used this model in the course
of a controlled study to evaluate immunotherapy for insect
hypersensitivity.
b. Following injection of a drug such as (i) penicillin, for
example in patients attending Genito-Urinary Medicine Clinics who
frequently receive parenteral antibiotic treatment, or (ii) a
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muscle relaxant eg, suxamethonium) or anaesthetic (eg, thiopentone
sodium) used preoperatively.
c. Following infusion of blood or blood products, although the
resulting reactions are more likely to involve many other factors
including complement activation. The mechanisms of these reactions
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The Presence in Blood of Both Glycosaminoglycan and Mucosal Mast Cell
Protease following Systemic Anaphylaxis in the Rat
Stephen J. Kinga, Karen Reillyb, Joan Dawesb, Hugh R.P. Millera
" Department of Pathology, Moredun Research Institute, and b MRC/SNBTS Blood Components Assay Group, Edinburgh, UK
Abstract. The appearance in blood of rat mast cell protease II (RMCPII) and glycosaminoglycan (GAG)
was examined in normal and Nippostrongylus brasiliensis-primed rats challenged intravenously with worm an¬
tigen. Systemic release of these two products occurred only in immune recipients of antigen; substantial levels
of RMCPII were also present in the intestinal perfusates of these same rats and there was depletion of both
RMCPII and mucosal mast cells (MMC) from the intestinal mucosa. Depletion of MMC was evident after
staining for proteoglycan or for serine esterase and the mast cell counts with both histochemical techniques
were highly correlated. Taken together, the results suggest that MMC are likely to be the principal source of
secreted GAG and RMCPII.
During the immune expulsion of the gastrointesti¬
nal nematode Nippostrongylus brasiliensis from the
rat, there is discharge of granule contents of mucosal
mast cells (MMC), and depletion of proteoglycan
from these cells [1]. Following intravenous challenge
of primed rats with N. brasiliensis worm antigen, ex¬
tensive mucosal damage ensues which is accompan¬
ied by the systemic and enteric release of a specific
neutral proteinase: rat mast cell protease II (RMCPII)
[2] derived from MMC, and depletion of MMC from
the jejunal mucosa [3]. The present study was under¬
taken to analyse body fluids for the presence of
MMC-derived proteoglycan during systemic anaphy¬
laxis in the rat.
15 female outbred Wistar rats, immunised 3 and 8
weeks earlier by subcutaneous injection with 6,000 N.
brasiliensis larvae [4], were allocated randomly to 3
groups of 4 rats and 1 group of 3 rats and were chal¬
lenged intravenously with 1,000, 500 or 250 worm
equivalents (w.e.) of adult whole worm antigen or sa¬
line. Worm antigen was prepared as described previ¬
ously [5], A further group of 4 naive rats was chal¬
lenged with 500 w.e. intravenously. 1 h after intrave¬
nous challenge, animals were anaesthetised with ether
and bled out. Blood was collected into the anticoagu¬
lant 'Thrombotecf (Abbott) and the plasma was sepa¬
rated by centrifugation and stored at -70 °C. Serum,
small intestinal perfusates and samples of jejunum
were collected and the concentrations of RMCPII in
these samples were measured by radial immunodiffu¬
sion [2, 3]. Additionally, adjacent segments of jeju¬
num were placed in either Carnoy's fluid or 4% para¬
formaldehyde prepared with phosphate-buffered sa¬
line. Tissues were embedded in wax and sections were
stained with either Toluidine blue [6] or with naphthol
AS-D chloroacetate to demonstrate serine esterases
[7]. Plasma, gut perfusates and gut homogenates were
analysed for the presence of glycosaminoglycan
(GAG) by a modification of the competitive heparin
binding assay previously described [8], in which poly-
brene-Sepharose was substituted for protamine-Se-
pharose as the binding reagent and the radioactive
tracer and standard were heparan sulphate rather
than heparin.
RMCPII was present only in the sera of immune
rats challenged with worm antigen (fig. 1) and in these
same rats there was a 10-fold increase in the concen¬
tration of GAG in plasma when compared with im¬
mune recipients of saline or naive rats given antigen
(fig. 1). Although the release of RMCPII and GAG
into the blood was, in this experiment, independent of
the dose of antigen, there was a highly significant
correlation between the concentrations of RMCPII
and GAG (y = 2,110+ 17 x, r = 0.93, p < 0.001; fig. 2),
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Fig. 1. a Total recoveries of RMCPII (mean ± SEM) in intesti¬
nal perfusates (•) and concentration of enzyme in jejunal mucosa
(gg/g wet weight tissue, ■) of immune rats given worm antigen or
saline (dose = 0). The number ofmucosal mast cells (MMC) per vil¬
lus crypt unit (VCU) detected with Toluidine blue (mean ±SEM,
O) are also shown. Individual symbols showing the concentrations
of RMCPII in perfusates (♦) and gut homogenates (□) and the
number ofMMC (O) in naive rats challenged with 500 w.e. of anti¬
gen are also plotted, b The concentrations of RMCPII in serum
(mean + SEM •) and glycosaminoglycan (GAG) in plasma (mean
± SEM ■) are plotted against the dose of worm antigen. Values
from immune rats injected with saline are plotted at the zero dose
and in naive rats given antigen the values are plotted at 500 w.e. for
RMCPII (O) and for GAG (□).
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Fig. 3. Regression analysis demonstrating a highly significant
correlation between the numbers of MMC enumerated after stain¬
ing with Toluidine blue and with naphthol AS-D chloroacetate
(y = -2.3 + 1.1 x, r = 0.98, p < 0.001).
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Fig. 2. Regression analysis of the concentrations of RMCPII in
serum against GAG in plasma (y = 2,110+17 x, r = 0.93,










which would suggest that they may have been released
from the same source.
Intestinal perfusates from primed, challenged rats
contained 1,144-2,085 jj.g RMCPII (fig. 1), whereas
perfusates from controls were devoid of this enzyme
(fig. 1). There was a concomitant, highly significant
(p < 0.001) depletion of RMCPII and MMC from the
mucosa of primed, challenged rats when compared
with control values (fig. 1). Analysis of gut perfusates
and homogenates showed GAG to be present within
each sample. No decrease from jejunum or increase
within the perfusate was detected. The analysis of
these tissues is, however, likely to be complicated by
endogenous GAG other than that contained in the
mast cells.
Mast cell depletion from the mucosa was detected
both with Toluidine blue (pH 0.5) and with naphthol
AS-D chloroacetate; the correlation between the num¬
bers ofmast cells detected with these two methods was
highly significant (y = -2.3 + 1.1 x,r = 0.98, p < 0.001;
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fig. 3), suggesting that proteoglycan and serine ester¬
ases were depleted concomitantly from discharging
MMC.
The results of this study are consistent with data
from previous experiments [2] except that shock was
severe with the lowest dose of worm antigen and was
not augmented by further increasing the challenge
dose. There was, as previously described [2], substan¬
tial secretion of RMCPII into the gut lumen and a
concomitant fall in the mucosal concentration of this
enzyme. These changes were paralleled by a reduction
in the number ofMMC detected with either Toluidine
blue or naphthol AS-D chloroacetate. Whilst we were
unable to detect changes in mucosal levels of GAG,
probably for technical reasons associated with a high
background of tissue GAG, there was a tenfold in¬
crease in the concentration of GAG in plasma which
was highly correlated with the release, into serum, of
RMCPII. Although the distribution of RMCPII in
tissues other than the gut have not yet been published,
our own studies have shown that, apart from the lung
in which RMCPII is increased after infection with N.
brasiliensis and which, at most, contains 300 /j.g
RMCPII/g wet weight, most other organs contain
little or none of this enzyme [9]. Clearly, therefore, the
major source of secreted RMCPII is the enteric mu¬
cosa, and it would seem likely that GAG present in
plasma is also released from this site with MMC being
the most obvious source of these two products.
More conclusive evidence ofthe mucosal mast cell as
the source ofsecreted GAGmust await further analysis.
However, it is relevant to note that MMC granule prote¬
oglycan is, like that from the murine mast cell cultured
from bonemarrow [ 10], non-heparin proteoglycan [11],
and that the latter cell releases chondroitin sulphate E in
response to immunological stimuli [ 12], By contrast the
heparin present in rat peritoneal mast cells remains
within the granule matrix, apparently complexed with
the insoluble chymase (RMCPI) [13]. If, as the present
study suggests, granule products of MMC are highly
soluble, this is yet another example of the biochemical
and functional differences between MMC and connec¬
tive tissuemast cells.
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